Impaired awareness of hypoglycemia in type 1 diabetes. The role of lactate by Rooijackers, H.M.M.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/196836
 
 
 
Please be advised that this information was generated on 2019-06-02 and may be subject to
change.
Impaired awareness 
of hypoglycemia
in type 1 diabetes
The role of lactate
Hanne M.M. Rooijackers
Impaired awareness of hypoglycemia
in type 1 diabetes
The role of lactate
Hanne Margaretha Maria Rooijackers
Colofon
The research presented in this thesis was performed at the Department 
of Internal Medicine, Radboud university medical center, Nijmegen, the 
Netherlands.  Financial support for the research described in this thesis 
was provided by the Dutch Diabetes Research Foundation, the European 
Foundation for the Study of Diabetes and by an unrestricted grant from Sanofi.
© Hanne Rooijackers, 2018. All rights reserved. No part of this thesis may be 
reproduced, stored in a retrieval system or transmitted in any form or by any 
means without the prior written permission of the author. 
 
Cover design: Hanne Snel Illustraties, www.hannesnel.com 
Layout:  Guus Gijben/proefschrift-aio.nl 
Printed by: proefschrift-aio.nl
ISBN:  978-94-92801-54-8
Impaired awareness of hypoglycemia
in type 1 diabetes
The role of lactate
Proefschrift
ter verkrijging van de graad van doctor
aan de Radboud Universiteit Nijmegen
op gezag van de rector magnificus prof. dr. J.H.J.M. van Krieken,
volgens besluit van het college van decanen 
in het openbaar te verdedigen op donderdag 22 november 2018 
0m 10.30 uur precies
door
Hanne Margaretha Maria Rooijackers
geboren op 10 november 1988
te Helmond
Promotoren
Prof. dr. C.J.J. Tack
Prof. dr. A. Heerschap
Copromotoren
Dr. B.E. de Galan
Dr. ir. M. van der Graaf
Manuscriptcommissie
Prof. dr. R.E. Brock
Prof. dr. J.B.L. Hoekstra (UvA)
Prof. dr. R.J. McCrimmon (University of Dundee, Verenigd Koninkrijk)


Table of contents
Chapter 1  General introduction and outline of the thesis
Chapter 2   Brain glucose metabolism during hypoglycemia in type 1 
diabetes: insights from functional and metabolic neuroimaging 
studies
   Cellular and Molecular Life Sciences, 2016
Chapter 3   Brain lactate concentration falls in response to hypoglycemia 
in patients with type 1 diabetes and impaired awareness of 
hypoglycemia
   Diabetes, 2016
Chapter 4   Effect of lactate administration on brain lactate levels during 
hypoglycemia in patients with type 1 diabetes with or without 
impaired awareness
   Journal of Cerebral Blood Flow & Metabolism, 2018
Chapter 5   Effect of exercise-induced lactate elevation on brain lactate 
levels during hypoglycemia in patients with type 1 diabetes 
and impaired awareness of hypoglycemia 
   Diabetes, 2017
Chapter 6   A single bout of high-intensity interval training reduces awareness 
of subsequent hypoglycemia in patients with type 1 diabetes
   Diabetes, 2017
Chapter 7   Proinflammatory effects of hypoglycemia in humans with or 
without diabetes 
   Diabetes, 2017
Chapter 8  Summary and discussion
Chapter 9 Nederlandse samenvatting
Appendices Dankwoord
   List of publications
   Curriculum Vitae
9
31
71
85
109
125
147
173
187
196
202
204
8
91
General introduction and outline of 
the thesis
Chapter 1
10
Introduction
Introduction
Diabetes mellitus is a highly prevalent condition that is characterized by 
chronically elevated blood glucose levels (hyperglycemia). Fueled by unfavorable 
life style changes, the number of adults with diabetes mellitus has globally 
quadrupled from 108 million in 1980 to 422 million in 2014, and is projected to 
increase by at least 50% in the next 20 years (1). Diabetes is generally classified 
into two main types: type 1 and type 2 diabetes. In the Netherlands, there were 
over one million people living with diabetes in 2015 (2), with type 1 diabetes 
accounting for approximately 10% of cases (3). Although type 1 diabetes is not 
related to life style, its incidence and prevalence are also increasing (4; 5). Since 
the present thesis focuses on patients with type 1 diabetes, type 2 diabetes will 
not be discussed in further detail here. 
Type 1 diabetes typically develops in childhood or early adulthood, but may present 
at any age. It is an autoimmune disease characterized by near-complete destruction 
of the insulin producing pancreatic beta-cells and results in an absolute insulin 
deficiency (6; 7). In healthy individuals, insulin is rapidly released into the circulation 
in response to a meal, and promotes the uptake of glucose from the circulation 
into the liver, skeletal muscle and adipose tissue, while simultaneously suppressing 
glucose production by the liver (8). These actions result in stable blood glucose 
levels in healthy people. In people with type 1 diabetes, insulin deficiency leads to 
hyperglycemia and necessitates the use of insulin replacement therapy. However, 
therapeutic insulin is a relatively poor replacement of endogenous insulin, in part 
due to a slower onset of action and a more prolonged glucose-lowering effect (9). In 
addition, injection of identical insulin doses may result in different glucose responses 
within the same individual at different times, because of variability in insulin 
absorption and metabolic effects (10). As a consequence, glucose fluctuations and – 
on average – chronic hyperglycemia remain part of everyday life in these patients. 
Chronic hyperglycemia, even when mild, increases the risk for microvascular 
complications, including retinopathy, nephropathy and neuropathy (11). Chronic 
hyperglycemia is also a risk factor for atherosclerotic disease of the large vessels, 
so-called macrovascular complications, causing cardiac, cerebral and peripheral 
vascular disease. Despite major medical advances over the past 20 years, the 
estimated life expectancy for people with type 1 diabetes at the age of 20 is 
still approximately 12 years less compared with the general population without 
diabetes. The largest percentage of the estimated loss in life expectancy is due to 
cardiovascular complications (12).
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There is ample evidence that intensive insulin treatment aimed at maintaining 
near-normal blood glucose levels substantially reduces the risk of microvascular 
and macrovascular complications in patients with type 1 diabetes (13-15). 
Guidelines therefore recommend tight, near-normal glycemic control to prevent 
or delay these complications (16), but this comes at a price, i.e. an increased risk 
for low blood glucose levels (hypoglycemia) (17). As a consequence, the glycemic 
goal in a patient with diabetes is almost by definition a compromise between 
preventing complications associated with hyperglycemia and minimizing 
the problems associated with iatrogenic hypoglycemia (18). In other words, 
iatrogenic hypoglycemia is the main barrier in the glycemic management of 
type 1 diabetes (19).
Hypoglycemia and glucose counterregulation
Insulin-induced hypoglycemia in people with diabetes is called non-severe if the 
individual is able to self-treat such an event, usually by ingesting carbohydrates. 
Severe hypoglycemia is defined as an event that requires the help from another 
person for recovery (20). Patients with type 1 diabetes experience on average 
two non-severe episodes per week and one severe, potentially hazardous event, 
every year (21; 22). Although the rate and severity of hypoglycemia varies greatly 
between persons (21), this means that people with type 1 diabetes are exposed 
to many thousands of hypoglycemic episodes over a lifetime of diabetes. 
The maintenance of adequate plasma glucose levels is particularly important 
for the brain, because the brain relies on a continuous supply of glucose as 
its primary energy source. To this extent, a hierarchically coordinated system 
of physiological mechanisms, commonly referred to as counterregulatory 
responses, exists in healthy, non-diabetic individuals, that effectively prevents 
hypoglycemia in virtually all circumstances (23) (figure 1). The initial response to 
a decrease in plasma glucose levels within the physiological range is suppression 
of endogenous insulin secretion. When plasma glucose levels fall just below the 
physiological range (<3.9 mmol/L), the second response is an increase in glucagon 
secretion by pancreatic alpha-cells, which stimulates hepatic glycogenolysis 
and gluconeogenesis. The third response of the system occurs at similar plasma 
levels, but only becomes critical when glucagon secretion is insufficient, and 
concerns the release of adrenaline by the adrenal medulla (23). Adrenaline 
stimulates glycogenolysis and gluconeogenesis, mobilizes gluconeogenic 
substrates and limits peripheral glucose uptake. Growth hormone and cortisol 
are released at slightly lower plasma glucose levels and are aimed at preventing 
prolonged hypoglycemia, but are not essential for the acute response (24). 
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When counterregulatory hormones fail to prevent hypoglycemia and plasma 
glucose levels drop below ~3.2 mmol/L, this further increases sympathoadrenal 
responses and induces autonomic warning symptoms, such as hunger, 
palpitations and sweating, aimed at initiating an appropriate behavioral 
response: the ingestion of carbohydrates (23). The most worrisome symptoms 
of hypoglycemia for patients (25) occur at even lower plasma glucose levels and 
result from glucose deprivation in the brain. These so-called neuroglycopenic 
symptoms range from difficulty in concentrating to alterations in consciousness 
and eventually seizures or coma, which requires third-party assistance for 
recovery. Hypoglycemia is detected by both peripheral and cerebral glucose 
sensing neurons, with the most important sensors located in the central 
nervous system (CNS) (26). A fall in cerebral glucose levels is generally sensed 
as a result of a change in energy status (ATP/ADP and AMP/ATP ratios) in 
specific hypothalamic neurons (27). Counterregulatory responses (including 
neuroendocrine, autonomic and behavioral responses) are also predominantly 
initiated and coordinated by the CNS. 
Defective counterregulation and impaired awareness of 
hypoglycemia
In patients with type 1 diabetes, the normal counterregulatory responses to 
hypoglycemia are impaired (23) (figure 1). First, the loss of insulin secreting 
capacity disrupts the insulin response to declining plasma glucose levels, and 
insulin levels remain elevated due to the use of exogenous insulin therapy. 
Second, within a few years after diagnosis, patients fail to generate an 
adequate glucagon response to hypoglycemia, presumably because of the loss 
of the paracrine interaction between alfa- and beta-cells (28), but islet-selective 
loss of sympathetic nerves may also contribute (29). In the absence of the 
glucagon response, patients depend predominantly on adrenaline for glucose 
counterregulation. Unfortunately, the adrenaline response also becomes 
attenuated and is activated at lower glucose levels in most patients with longer 
diabetes duration (30). Failure of this third line defense against hypoglycemia 
causes defective glucose counterregulation and markedly increases the risk of 
severe hypoglycemia (23).
A defective adrenaline response is a marker for an attenuated sympathoadrenal 
(or autonomic) response (23), and is associated with, but not necessarily the 
cause of, defects in the emergence of autonomic symptoms of hypoglycemia 
(31; 32). A diminished ability to perceive the onset of acute hypoglycemia is 
known as the clinical syndrome of impaired awareness of hypoglycemia (IAH). 
13
1
This syndrome includes reduced symptom intensity and an altered symptom 
profile, as well as failure to interpret hypoglycemic symptoms correctly. IAH 
occurs in up to one third of patients with type 1 diabetes and increases the risk 
of severe hypoglycemia by a factor 6 or more (33; 34). In the past, the term 
‘hypoglycemia unawareness’ has often been used, but IAH is preferred, because 
very few patients are completely unaware of hypoglycemia, meaning that they 
have a total loss of symptoms of hypoglycemia under all circumstances. 
Figure 1. Physiology of glucose counterregulation. A simplified illustration of the mechanisms 
that normally prevent or rapidly correct hypoglycemia, and defects in these mechanisms in 
type 1 diabetes. NA, noradrenaline, Ach, acetylcholine. Figure adapted from (23).
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Pathophysiology of IAH
Antecedent hypoglycemia
For many years, IAH was thought to result from peripheral autonomic neuropathy. 
Although these conditions may coexist in patients with longstanding type 1 
diabetes, most people with IAH have no signs of (severe) autonomic neuropathy 
(35-37). Instead, IAH is probably a functional disorder, rather than the result of a 
structural (e.g. neuropathic) defect. 
Currently, it has been firmly established that hypoglycemia itself initiates 
a process of habituation that attenuates counterregulatory hormone and 
symptomatic responses to hypoglycemia occurring in the subsequent 24-48 
hours (38; 39). Reduced counterregulatory responses in the context of therapeutic 
hyperinsulinemia increase the likelihood of subsequent hypoglycemia, creating 
a vicious cycle of recurrent hypoglycemia and progressive deterioration of 
counterregulatory defenses. This has led to the concept of ‘hypoglycemia-
associated autonomic failure’ (HAAF) in diabetes that postulates that recent 
antecedent (i.e. previous periods of) hypoglycemia causes both defective 
glucose counterregulation and IAH (39). A schematic representation of this 
concept is given in figure 2. 
Semantically, HAAF may not be the best term, since there is adaptation rather 
than complete failure of the counterregulatory system. Indeed, meticulous 
avoidance of hypoglycemia at least partly restores the counterregulatory deficits 
induced by recurrent hypoglycemia (31; 40). In addition, not only antecedent 
hypoglycemia, but other situations where the autonomic nervous system is 
activated, such as antecedent low- and moderate-intensity exercise (41; 42), 
are also able to attenuate the sympathoadrenal response to hypoglycemia, 
as is sleep (43). The effects of more intensive exercise types, such as the more 
and more popular high-intensity interval training (HIIT), on awareness of 
hypoglycemia have not yet been investigated. 
Since hypoglycemia plays such a pivotal role in the development of impaired 
awareness, clinical risk factors for IAH relate primarily to prior exposure to 
hypoglycemia, and include increased duration of diabetes, absent endogenous 
insulin secretion, a history of recurrent (severe) hypoglycemia, counterregulatory 
failure, and strict glycemic control (44-46). While many people with type 1 
diabetes experience recurrent hypoglycemia, less than half of them develop 
IAH. The reason for the inter-individual susceptibility to develop IAH is unknown, 
but may involve genetic factors (46). 
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Figure 2. Schematic diagram of the concept of hypoglycemia-associated autonomic failure 
in type 1 diabetes. The mechanisms contributing to the development of IAH and impaired 
counterregulation, including the potential role of adaptations in brain metabolism. Figure 
adapted from (19).
The role of the brain
Although the role of antecedent hypoglycemia in the development of IAH is 
undisputed, the mechanisms by which hypoglycemia reduces responses to a 
subsequent episode of hypoglycemia are still poorly understood and warrant 
further investigation. There is agreement that the cause should reside in the 
brain (19), given its dependence on glucose and its critical role in hypoglycemia 
sensing and in coordinating responses to restore euglycemia. 
Most hypotheses regarding IAH involve adaptations in brain fuel transport, 
cerebral blood flow or metabolism (19; 24), and both global changes and local 
adaptations in specific brain regions essential for glucose sensing have been 
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suggested to play a role. A full discussion of these theories and the methods 
to study cerebral metabolism will be provided in Chapter 2 of this thesis. 
Importantly, previous studies from our study group have shown that brain 
metabolism is relatively preserved during hypoglycemia, hence does not 
decrease. Remarkably, brain metabolism during hypoglycemia was maintained 
at a higher level in patients with type 1 diabetes than in non-diabetic individuals, 
despite a similar fall in brain glucose levels (2; 3). This suggests that metabolism 
of a non-glucose, alternative fuel is involved. We posit that this alternative fuel 
is lactate. 
The role of lactate
Lactate or lactic acid is a hydroxycarboxylic acid that exists in two isomers: 
L-lactate and D-lactate, the former being the dominant isoform in humans. 
At a physiological pH, lactic acid is more than 99% dissociated into lactate 
anions and protons (47). Lactate is continuously produced by most tissues in 
the body, with the highest production in skeletal muscle and adipose tissue 
(48; 49). It is predominantly derived from glucose via the glycolytic pathway 
after its conversion into pyruvate, and a small amount of lactate is derived 
from alanine. The enzyme lactate dehydrogenase catalyzes the formation and 
removal of lactate through a reversible oxidation-reduction (redox) reaction. 
After conversion to pyruvate, lactate may proceed to the oxidative pathway in 
various tissues or to the gluconeogenesis route in the liver (49).
 
Under resting conditions, plasma lactate concentrations vary between 0.5 and 
1.5 mmol/L. Lactate accumulation and acidosis occur when the production of 
lactate exceeds its clearance, as can be seen in septic shock, during seizures or 
due to regional ischemia (50). Plasma lactate levels also markedly increase in 
response to high-intensity work-outs, with lactate values rising up to 12-20mM 
during the first minutes following ‘all-out’ maximal exercise bouts. Although 
lactate was traditionally considered a harmful waste product of glycolysis that 
accumulated as a result of hypoxia, this dogma has dramatically changed since 
the early 1970s. It is now widely accepted that lactate is produced all the time 
in fully oxygenated tissue and is not just a noxious waste product of glycolytic 
metabolism (47; 51). In fact, lactate is considered a crucial intermediary in 
numerous metabolic processes, an important metabolic regulator, and a mobile 
fuel for aerobic metabolism that can be rapidly exchanged between cells and 
tissues (47), including the brain (52).
17
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Under resting conditions, lactate is present in the brain at tissue levels of 
approximately  0.5mM and in cerebrospinal fluid at about 1-2.0 mM. It can be 
measured non-invasively by proton magnetic resonance spectroscopy (1H-MRS) 
(53), a technique that is further explained in Chapter 2. Lactate is a valuable 
energy source for the brain during euglycemia (54; 55) and may spare cerebral 
glucose utilization, especially when plasma lactate levels are elevated (54). 
Administration of lactate may improve neuroenergetics in patients suffering 
from traumatic brain injury (56), has neuroprotective effects during severe 
hypoglycemia in rodents (57) and is able to suppress counterregulatory hormone 
responses to and symptoms of hypoglycemia in humans (58; 59). More recently, 
it has been reported that patients with IAH have increased capacity for brain 
lactate transport during hypoglycemia (60; 61). One could then hypothesize 
that increased use of lactate by the brain during hypoglycemia may prevent 
cognitive dysfunction in patients with IAH, since the brain is no longer deprived 
of fuel. At the same time this maintenance of brain metabolism may interfere 
with the brain’s ability to detect hypoglycemia, thus explaining the clinical 
picture of IAH. Alternatively, lactate may affect awareness of hypoglycemia by 
acting as a signaling molecular or metabolic regulator, instead of, or in addition 
to being a metabolic substrate (62).  
Real life experience with IAH
Clinical consequences of impaired awareness of hypoglycemia
The morbidity associated with IAH is mostly related to the increased risk of 
severe hypoglycemia, with all its accompanying physical, psychological and 
social consequences. 
Hypoglycemia accounts for 7 to as much as 10% of deaths in young adults with 
type 1 diabetes. Most of these deaths are not directly related to brain death, 
but rather due to trauma (e.g. hypoglycemia while driving) and cardiovascular 
effects, such as fatal arrhythmia (63). Severe hypoglycemia has also been 
associated with increased mortality from cardiovascular events, particularly 
in patients with type 2 diabetes (64; 65). Evidence for an association between 
severe hypoglycemia and cardiovascular disease is less consistent in type 1 
diabetes. A recent prospective cohort study found that neither exposure to 
severe hypoglycemia, nor the presence of IAH increased all-cause or 
cardiovascular mortality in patients with type 1 diabetes (66).   
18
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Patients are often concerned that recurrent severe hypoglycemia may lead 
to persistent cognitive decline, obviously because cognitive functioning is 
extremely sensitive to acute changes in plasma glucose levels. Most studies in 
adults with type 1 diabetes have reported the absence of such an association 
(67), although a recent study did detect subtle deficits in cognitive function in 
patients with IAH that may reflect impaired functioning of the hippocampus, a 
brain region that is most vulnerable to damage from hypoglycemia (68). 
Regarding psychological consequences, severe hypoglycemia has a negative 
impact on patients’ well-being at various dimensions and is associated with 
increased fear of hypoglycemia and diabetes-related distress, reduced diabetes-
related self-efficacy, and a reduction in quality of life (69; 70). Patients with IAH 
report imposed and self-imposed changes to their lives following the onset 
of IAH that include having to leave employment, reducing physical activity, 
spending more time being supervised by others, and extensively planning 
time spent away from home (71). Clearly, the effects of IAH extend beyond the 
person with the condition, as IAH is also a significant burden for family members 
of patients, who have to assist in detecting and treating hypoglycemia and are 
often concerned about the safety of the person with IAH (72). In addition to 
the psychological consequences, severe hypoglycemia represents a substantial 
economic burden, not only due to direct costs for medical treatment, but also 
because of indirect cost such as those related to absence from work resulting in 
lost productivity (73). 
Interestingly, a substantial part of patients with IAH is not appropriately concerned 
about their condition (74). These patients are generally more worried about being 
high than low and place excessive emphasis on avoiding hyperglycemia and its 
associated complications. In contrast, they underestimate the consequences of 
hypoglycemia, despite previous severe, potentially life threatening, episodes. It 
is true that most young people with type 1 diabetes recover uneventfully from 
even severe acute hypoglycemia, but there is much controversy about the long-
term effects of hypoglycemia. Increasing our knowledge of long-term effects of 
hypoglycemia is crucial for patients and care providers in order to provide a more 
balanced view on potentially harmful effects of hypoglycemia. 
Several studies have shown that acute hypoglycemia induces pro-inflammatory 
effects such as an increase in circulating leukocyte numbers, and an elevation 
of plasma proatherothrombotic and proinflammatory factors (75-77). The 
systemic inflammatory response thus induced by hypoglycemia may provide 
19
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a mechanistic link between hypoglycemia and long-term cardiovascular 
complications. However, the mechanisms by which hypoglycemia increases 
circulating proinflammatory cytokines and leukocytes have not been 
investigated. In addition, it is unknown whether repeated hypoglycemia or IAH 
affects inflammatory responses to hypoglycemia or whether hypoglycemia 
alters the function of inflammatory cells.
Treatment of IAH
Although it has been demonstrated that IAH can be reversed, at least in part, by 
meticulous avoidance of further hypoglycemia for several weeks to months (31; 
40), achieving this in clinical practice is extremely difficult, hard to sustain, and 
frequently accompanied by deterioration of glycemic control (78). Strategies 
used to reduce the incidence of hypoglycemia include (temporary) relaxation 
of glycemic control, structured educational approaches with or without 
behavioral interventions, technological interventions such as continuous 
subcutaneous insulin infusion (CSII), continuous glucose monitoring (CGM) and 
sensor-augmented insulin pumps with low-glucose suspend features. Despite 
the application of such treatment strategies, a substantial number of patients 
continues to experience disabling hypoglycemia (79). In some of these cases, 
islet cell transplantation has been used as a last-resort therapeutic option 
(80). Clearly, islet cell transplantation, or ideally, beta-cell replacement, has 
important limitations, including limited availability of donors, costs and severe 
side effects of immune suppression.
So far, treatment of IAH has focused primarily on avoidance of hypoglycemia, and 
although a few studies have taken a more mechanistic approach and investigated 
pharmacological treatments that improve counterregulatory responses, none of 
these are currently clinically  used (81-83). Novel, targeted treatment strategies 
for IAH are urgently needed. To identify such new treatment options, more 
detailed knowledge regarding the underlying mechanisms of IAH is needed. 
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Outline of the thesis
As discussed earlier, recurrent hypoglycemia causes the syndrome of impaired 
awareness of hypoglycemia (IAH) in one out of three patients with type 1 
diabetes, and results in a high risk for severe hypoglycemia. Hence, IAH 
contributes to substantial morbidity and mortality. Despite extensive studies, 
the underlying mechanisms by which recurrent hypoglycemia causes IAH 
are insufficiently clarified, but adaptations in the brain’s handling of energy 
substrates are most likely involved. The central hypothesis in our studies is that 
the brain of patients with IAH has adapted to recurrent hypoglycemia and is 
better able to use alternative fuels when glucose supply is low. The overall aim of 
this thesis is to investigate the role of lactate as a non-glucose alternative fuel for 
the brain in the development of IAH.  
Much of the work presented in this thesis has been established in close 
collaboration with the radiology department, using a proton magnetic 
resonance spectroscopy (1H-MRS) method which was optimized for lactate 
detection. 1H-MRS was our technique of choice, since it is non-invasive and 
allows the quantification of brain lactate concentrations in vivo. In a series of 
experiments, described in chapter 3, 4 and 6, we combine 1H-MRS with the 
glucose clamp technique, a method that allows plasma glucose levels to be 
held at specific predetermined targets by using a constant insulin infusion and a 
variable glucose infusion. 
First, the available literature about brain metabolism during and in response 
to hypoglycemia was critically reviewed. Chapter 2 describes the different 
metabolic and functional neuroimaging techniques that can be used to study 
brain metabolism in vivo, summarizes and discusses their most important 
findings in dept, and highlights remaining gaps in the literature. 
In Chapter 3 we attempt to fill the first of these gaps and investigated 
what actually happens with brain lactate levels during hypoglycemia under 
‘physiological conditions’, i.e. when no additional lactate is infused or otherwise 
increased. Brain lactate concentrations were assessed by 1H-MRS during a 
hyperinsulinemic euglycemic-hypoglycemic clamp. Results obtained in patients 
with type 1 diabetes and IAH were compared with results of patients with type 1 
diabetes and normal awareness of hypoglycemia (NAH), and healthy individuals. 
Next, the effects of elevated plasma lactate levels on brain lactate 
concentrations during hypoglycemia were investigated. We examined both 
21
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the effect of exogenous and endogenous plasma lactate elevations with 
1H-MRS. Previous studies have shown that exogenous administration of 
lactate during hypoglycemia suppresses counterregulatory hormone responses 
and hypoglycemic symptoms, presumably because lactate can substitute 
for glucose as a cerebral fuel. Whether elevated plasma lactate levels lead 
to an accumulation of lactate in the brain is subject of debate. In Chapter 4, 
we examined the effects of stable plasma lactate elevations on brain lactate 
concentrations during euglycemia and hypoglycemia. We hypothesized that 
exogenously administered lactate, resulting in high physiological plasma levels, 
sufficient to impair awareness of hypoglycemia in patients with NAH, is taken 
up and used by the brain. Second, to detect and confirm adaptations in brain 
handling in IAH, we compared the effect of lactate administration on brain 
lactate concentrations between patients with NAH and IAH. 
When elevation of endogenous plasma lactate levels, as frequently occurs 
in response to high-intensity (interval) exercise, increases brain lactate, this 
may negatively affect awareness of subsequent hypoglycemia in patients with 
diabetes. In Chapter 5, we used a single bout of high-intensity interval training 
(HIIT) to raise endogenous plasma lactate levels and studied the effect on 
cerebral lactate levels with 1H-MRS during subsequent hypoglycemia in patients 
with type 1 diabetes with and without IAH, and in healthy individuals. 
Following on the results obtained in chapter 5, we set out to investigate the 
clinical consequences of a single bout of HIIT on counterregulatory responses 
to hypoglycemia. We hypothesized that elevated levels of endogenous lactate 
induced by HIIT have similar suppressive effects on awareness of hypoglycemia 
as exogenous lactate infusion. In this context, we performed a randomized 
crossover trial in which patients with NAH, patients with IAH and healthy 
individuals underwent a hypoglycemic clamp, either after a short high-intensity 
interval training or after seated rest, and we measured counterregulatory 
responses to, symptoms of and cognitive functioning during hypoglycemia. The 
results of this study are presented in Chapter 6. 
Hypoglycemia does not only affect the brain, but has broader, systemic effects 
that have gained renewed interest in recent years. Hypoglycemia increases 
circulating pro-inflammatory cytokines and has been suggested to contribute to 
systemic inflammation in patients with diabetes and therefore to cardiovascular 
complications. However, the mechanisms that lead to increased cytokine 
production and the effect of (recurrent) hypoglycemia on the inflammatory 
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function of immune cells have received limited attention. In Chapter 7 we 
provide the results of ex vivo stimulations of peripheral blood mononuclear cells 
obtained during a euglycemic-hypoglycemic clamp in patients with and without 
IAH, and healthy volunteers, to determine whether hypoglycemia altered the 
composition and inflammatory function of immune cells. 
Finally, the results of the presented studies are summarized and put into 
perspective in Chapter 8.
23
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Abstract
Hypoglycemia is the most frequent complication of insulin therapy in patients 
with type 1 diabetes. Since the brain is reliant on circulating glucose as its 
main source of energy, hypoglycemia poses a threat for normal brain function. 
Paradoxically, although hypoglycemia commonly induces immediate decline in 
cognitive function, long-lasting changes in brain structure and cognitive function 
are uncommon in patients with type 1 diabetes. In fact, recurrent hypoglycemia 
initiates a process of habituation that suppresses hormonal responses to and 
impairs awareness of subsequent hypoglycemia, which has been attributed to 
adaptations in the brain. These observations sparked great scientific interest 
into the brain’s handling of glucose during (recurrent) hypoglycemia. Various 
neuroimaging techniques have been employed to study brain (glucose) 
metabolism, including PET, fMRI, MRS and ASL. This review discusses what 
is currently known about cerebral metabolism during hypoglycemia, and 
how findings obtained by functional and metabolic neuroimaging techniques 
contributed to this knowledge.
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Introduction
The brain is one of the most metabolically active organs in the body and it 
consumes energy disproportionate to its size. In humans, the brain represents 
only about 2% of total body weight, yet it accounts for approximately 20% of 
the body’s oxygen use and 25% of the body’s use of glucose. Glucose is the 
primary fuel for the adult brain. In young adults, the ‘resting’ brain consumes 
approximately 110 grams of glucose per day, i.e. 5.5 mg glucose per 100 g of 
brain tissue per minute (1). Since the brain’s energy stores are small, normal 
brain function depends on a continuous supply of glucose from the bloodstream. 
Under normal conditions, the human body takes great effort and is very efficient 
in avoiding hypoglycemia in almost all circumstances to maintain sufficient 
glucose delivery to the brain. 
Type 1 diabetes mellitus is an autoimmune-mediated disease, characterized by 
destruction of most, if not all, of the insulin-producing capacity of pancreatic 
beta-cells. As a consequence, supplemental insulin treatment is required to 
maintain glucose control and decrease the risk of complications resulting 
from hyperglycemia (2). Unfortunately, therapeutic insulin is still poor at 
mimicking the pharmacology of endogenous insulin. As a consequence, people 
with type 1 diabetes – in particular those aiming for strict glycemic control – 
are at continuous risk of hypoglycemia, the average frequency of which has 
been estimated at two non-severe, symptomatic episodes per week (3-5) and 
one severe, potentially hazardous event, per year (4; 6; 7). Although there is 
substantial variation in both the rate and the severity of hypoglycemia, both 
between and within persons (4; 8), this estimation means that the brains of 
people with type 1 diabetes are exposed to many thousands of hypoglycemic 
episodes over a lifetime of diabetes. 
Studying brain metabolism during hypoglycemia may reveal the potential 
harmful effects of (recurrent) hypoglycemia on the brain and may increase our 
understanding of metabolic adaptations that might underlie impairments in 
the defenses against hypoglycemia (9). Modern neuroimaging techniques have 
enabled the study of cerebral metabolism in vivo in a relatively non-invasive 
manner. This review will focus on the effect of hypoglycemia on brain (glucose) 
metabolism, with a particular emphasis on recent findings from functional and 
metabolic neuroimaging studies. Basic mechanisms of brain energy metabolism 
and neuroimaging techniques will be discussed briefly.
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Glucose counterregulation
In healthy, non-diabetic humans, hypoglycemia is unlikely to ever occur due 
to a hierarchically coordinated system that integrates insulin secretion and 
counterregulatory hormone and symptom responses (10; 11). When glucose 
levels in the low-physiological range (e.g. late post-absorptive or fasting 
state) tend to fall, insulin secretion is suppressed to such an extent that true 
hypoglycemia can almost always be prevented. When insulin is given to 
experimentally induce hypoglycemia in people without diabetes, glucose levels 
at or below ~3.8 mmol/L will induce a glucagon response, the secretion of which 
by pancreatic alpha-cells is probably controlled by the neighboring beta-cells 
(10; 11). Such a glucose level also stimulates the secretion of adrenaline, whereas 
slightly lower levels are needed to elicit autonomic warning symptoms, such as 
sweating, palpitations, trembling and feeling hungry (10; 11). These symptoms 
are aimed at initiating a behavioral response (i.e. ingesting carbohydrates). 
Further falls in plasma glucose values result in neuroglycopenic symptoms, 
which range from mild cognitive impairment, such as difficulty in concentrating, 
to overt confusion and even coma or seizures in its most severe form (10; 11).
In patients with type 1 diabetes, hypoglycemia typically results from the interplay 
between therapeutic peripheral hyperinsulinemia and impaired defenses against 
falling plasma glucose levels (10). These impairments first include the inability to 
decrease insulin and to increase glucagon in response to hypoglycemia. The latter 
is not a structural defect, but specific for hypoglycemia and probably secondary 
to loss of control by non-functioning beta-cells (12). In patients with longer 
diabetes duration and more frequent exposure to hypoglycemia, adrenaline 
responses to hypoglycemia become attenuated, in part due to a shift of these 
responses to lower glucose values (13). The defective adrenaline responses are 
associated with, although not necessarily the cause of, similar defects in the 
emergence of autonomic symptom responses (14; 15). Disappearance of these 
symptoms interferes with the ability to timely and accurately perceive, interpret 
and respond to falling plasma glucose levels. This inability is known as the clinical 
syndrome of impaired awareness of hypoglycemia and increases the risk of 
particularly severe hypoglycemia, defined as those events requiring assistance 
from another person (16), by a factor of six or more (17; 18). Both the attenuated 
adrenaline response and impaired awareness of hypoglycemia are usually 
the result of (recurrent) antecedent hypoglycemia rather than of autonomic 
neuropathy, for which the term ‘hypoglycemia-associated autonomic failure’ 
(HAAF) has been introduced (19). HAAF can be effectively treated by several 
weeks to months of scrupulous avoidance of hypoglycemia (15; 20; 21), although 
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it appears that the symptomatic component responds earlier and better than 
the hormonal component (15). The underlying mechanism(s) explaining the 
attenuating effect of prior hypoglycemia on responses to subsequent events 
have not been fully elucidated. However, there is agreement that alterations in 
the brain play a pivotal role.
Morbidity associated with hypoglycemia
The glucose level at which cognitive function declines is subject to substantial 
variation; in some people cognitive dysfunction already occurs at plasma 
glucose levels between 3.0 and 4.0 mmol/L, whereas others continue to function 
well at levels below 2.5 mmol/L (8; 22). Almost all domains of cognitive function 
are potentially at risk during acute hypoglycemia, with complex tasks (e.g. car 
driving) being affected earlier than simple tasks (23; 24). Prolonged and/or 
profoundly severe hypoglycemia may eventually cause neuronal death (25; 26). 
The cerebral cortex and hippocampus are the most vulnerable regions in the 
brain to be injured by severe hypoglycemia, while the brain stem and cerebellum 
are most resistant (27). However, although persistent vegetative states or brain 
death resulting from hypoglycemia have been described (28-30), most patients 
with type 1 diabetes recover uneventfully from even severe hypoglycemia 
complicated by seizures or coma, especially when they are young and in good 
clinical condition. In addition, evidence for an association between multiple 
episodes of severe hypoglycemia and long-term cognitive decline in people 
with type 1 diabetes is lacking (31; 32). Finally, although 4 to 10% of all deaths 
in patients with type 1 diabetes have been attributed to hypoglycemia, most of 
these deaths are thought to be either accidental (e.g. in traffic) or cardiovascular 
(e.g. arrhythmia) rather than the direct consequence of brain death (33; 34). 
It should be noted that both the developing brain of young children with type 
1 diabetes (35; 36) and the brain of the elderly, in particular in patients with 
type 2 diabetes (37; 38), seem more susceptible to harm from hypoglycemia. 
Children with type 1 diabetes performed worse on cognitive tests when they 
had a history of severe hypoglycemia below the age of 5 years, compared to 
patients without such a history and non-diabetic controls (35). In prospective 
cohorts of people with type 2 diabetes , a history of severe hypoglycemia has 
been associated with cognitive decline and frank dementia (38), as well as with 
greater risks of cardiovascular events and death (39; 40). On the cellular level, 
there are now indications that glucose deprivation may accelerate apoptosis of 
neurons, which could underlie neuronal cell death and predispose for cognitive 
decline (41). It has also been speculated that the acute, physiological changes 
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in hematological and hemodynamic parameters induced by hypoglycemia may 
be particularly damaging when the vasculature has already been injured (42; 
43), possibly explaining the discrepancy between type 1 and type 2 diabetes 
(31; 44). Another factor explaining this discrepancy may lie in the concept of 
hypoglycemic preconditioning. Rodents exposed to recurrent hypoglycemic 
events of moderate severity were less likely to develop neuronal damage or 
cognitive impairments or die during subsequent severe hypoglycemia than 
age-matched littermates who were not pre-exposed to hypoglycemia (45; 46). 
These data may help to explain recent observations that patients with type 1 
diabetes and impaired awareness of hypoglycemia, as a reflection of recurrent 
hypoglycemia, appeared not at greater risk of dying than patients with intact 
awareness (47).
The role of the brain in glucose counterregulation
The brain is not just at the receiving end of hypoglycemia, but it plays an important 
role in both the detection of hypoglycemia and in the subsequent initiation 
and coordination of counterregulatory responses to restore euglycemia, as 
described above. This system maintains glucose homeostasis through a classic 
sensory-motor integrative pathway in which a decrease in plasma glucose levels 
is detected by an extended network of glucose sensing neurons located within 
the brain and the periphery (48). Specialized glucose-sensing cells are located in 
the hepatic portal/mesenteric vein, gut, carotid body and oral cavity. In the brain, 
glucose-sensing neurons are found at a number of locations, but particularly in 
the ventromedial nucleus of the hypothalamus (VMH) and areas that originate 
from the hindbrain. Integrative networks receive projections from these sensing 
neurons and subsequently assimilate their input with signals from other brain 
regions, such as information about circadian rhythm and arousal state. This 
information is relayed to motor neurons, which generate an output that drives 
the counterregulatory response and subsequently restores plasma glucose 
levels. Conversely, glucose sensing may influence other neural processes that 
have no role in glucose counterregulatory function (49).
Although the VMH is only one of a number of regions involved in the detection 
of hypoglycemia, it is thought to be the most important. The VMH serves as 
the central rely station for signals from many other regions and plays a crucial 
role in the coordination of the counterregulatory responses to falling glucose 
levels. Animal studies have shown that both destruction of the VMH and 
local perfusion of the VMH with glucose, disrupt counterregulatory hormone 
responses to systemic hypoglycemia (50; 51). Conversely, local glucopenia in 
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the VMH stimulates these responses in the absence of hypoglycemia (52). In 
analogy, glucose counterregulation was also found defective in a patient with 
lesions from sarcoidosis in the hypothalamus, presumably due to destruction of 
the glucose-sensing neurons in the VMH (53). 
The mechanism of glucose-sensing by the brain, in particular in the VMH, has 
not been fully clarified. Two main types of glucose-sensing neurons have been 
identified: glucose-excited neurons, whose activity increases as glucose levels 
rise, and glucose-inhibited neurons, which become more active as glucose levels 
fall and less active when they rise (54). These neurons ‘sense’ a fall in glucose 
probably as a result of alterations in ATP/ADP and AMP/ATP ratios, respectively, 
following a reduction in glucose metabolism. This could explain why fuelling the 
VMH with an alternative source of energy, such as lactate, suppresses glucose 
counterregulation (55; 56). The subsequent intracellular actions that may 
ultimately lead to a counterregulatory response probably involve activation of 
AMP-activated protein kinase, formation of nitric oxide and release of glutamate 
in glucose-inhibited neurons. Other potential mediators involved in these 
responses include (a decrease in) gamma-aminobutyric acid (GABA) release 
from glucose-excited neurons, noradrenaline, serotonin and corticotrophin-
releasing hormone (57). For further reading on this subject, we refer to recent 
reviews by McCrimmon (54) and Chan and Sherwin (57). 
Cerebral glucose delivery, uptake and metabolism 
Glucose is transported across the blood-brain barrier into extracellular fluid 
(ECF) by facilitated diffusion, mediated via glucose transporter protein 1 (GLUT1)
(58). The predominant transporters involved in subsequent glucose uptake from 
the ECF in neurons and in astrocytes are GLUT3 and GLUT1, respectively (59), 
both insulin-independent glucose transporters. Once intracellular, glucose is 
phosphorylated by hexokinase as the initial step of glucose metabolism. The 
glucose-6-phosphate (Glc-6-P) thus produced can enter several metabolic 
pathways in the brain (60).
In 1945, Kety and Schmidt developed the first method to quantitatively assess 
brain glucose uptake in humans in vivo and to derive data on its subsequent 
metabolism (61). This highly invasive technique required the use of arterial and 
internal jugular vein catheterizations to determine arteriovenous concentration 
differences for glucose, which together with measurement of global cerebral 
blood flow (CBF) were then used to calculate the global cerebral metabolic rate 
of glucose (61-64). In humans, the Kety-Schmidt method was used to show that 
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brain glucose uptake falls during hypoglycemia and that this coincides with the 
appearance of counterregulatory hormone responses and autonomic warning 
symptoms (65; 66). However, whether these data can be used to reliably assess 
brain glucose metabolism is a matter of debate. Indeed, the calculations rely 
solely on the disappearance rate of glucose from the circulation. Therefore, this 
technique cannot discriminate between specific metabolic steps and ignores 
the potential contribution of other metabolites. Moreover, the highly invasive 
nature of the Kety-Schmidt technique is a considerable limitation for research 
in humans. 
The past forty years have shown rapid advances in modern metabolic and 
functional neuroimaging techniques to study brain (glucose) metabolism 
vis-à-vis CBF during hypoglycemia, including positron emission tomography 
(PET), functional magnetic resonance imaging (fMRI) and magnetic resonance 
spectroscopy (MRS). It is important to note that the distribution of CBF and 
the cerebral metabolic rate of glucose (CMRglc) are closely linked to local brain 
activity. Brain activation causes proportionate increases in both local CBF 
and CMRglc. These processes are being referred to as neurovascular coupling 
or neurometabolic coupling, respectively, and hypothesized to be mediated 
by neurotransmitter release and vasoactive metabolic products (67). Many 
functional neuroimaging techniques, including fMRI, rely on neurovascular 
coupling. The principles of the various imaging techniques will be briefly 
discussed (Fig.1). 
PET
Positron emission tomography can be used to measure emissions from a 
variety of radioactively labeled tracers in the brain to quantify CBF, glucose 
uptake and phosphorylation, oxygen consumption and brain receptors for 
major neurotransmitters (by binding to the radioligand), depending on the 
type of radiotracer used (68). 15O-labeled water PET, for example, has been 
commonly applied to quantify regional CBF (69; 70). For the study of brain 
glucose metabolism, [18F]fluoro-2-deoxy-D-glucose (FDG) is the most widely 
used tracer. FDG is taken up by the brain in a similar manner as glucose, but 
unlike native glucose, once phosphorylated (FDG-6-P), it cannot be metabolized 
further, resulting in accumulation of the tracer in the cell. Under steady-state 
conditions, in which total influx of metabolites into a pathway equals the 
outflow, the rate of tracer accumulation in the brain can be used to estimate 
global and regional rates of glucose transport and metabolism (58). PET has 
been particularly valuable in studying the effect of hypoglycemia on CBF, brain 
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Fig. 1 A simplified illustration of the multiple metabolic pathways of glucose in the brain and 
the metabolic signals used in different neuroimaging techniques. The initial step of glucose 
metabolism is phosphorylation of glucose to glucose-6-phosphate (Glc-6-P) by hexokinase. Glc-
6-P can enter several metabolic pathways in the brain. It can be metabolized to produce energy 
via glycolysis or the TCA cycle. Glycolytic and TCA cycle intermediates are also used for the 
synthesis of amino acids and neurotransmitters. In addition, Glc-6-P is a precursor for glycogen. 
Lastly, metabolism of Glc-6-P via the pentose phosphate pathway (PPP) provides pentose for 
nucleotide synthesis and NADPH, required for reductive reactions, such as lipid synthesis and 
for protection against oxidative stress. Arteriovenous concentration differences (AV dif) can be 
used to estimate global cerebral metabolic rate from the disappearance of metabolites from 
the circulation. PET (depicted in orange) uses radiolabeled glucose analogues (such as FDG), 
which are trapped early in metabolism (for example fluorodeoxyglucose-6-phosphate/FDG-
6-P), to estimate rates of glucose uptake and metabolism. 31P MRS (depicted in blue) provides 
information about ATP production and thus brain energy metabolism. 13C-MRS (depicted in 
green) is useful for estimating TCA cycle fluxes and CMRglc, derived from 
13C label incorporation 
into specific metabolites (Glu, Gln). Both ALS and BOLD fMRI provide estimates of CBF. 
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glucose uptake and cerebral metabolic rate in humans with and without type 
1 diabetes (71-74). However, this technique cannot be used to study glucose 
metabolism downstream of its conversion to glucose-6-phosphate (75). Also, 
animal studies suggest that the lumped constant, a correction factor that 
relates the metabolic rate of FDG to that of native glucose (76), may increase 
during hypoglycemia (77; 78). The tracer [11C]3-O-methyl-D-glucose (3-OMG) 
may provide more robust information about cerebral glucose uptake at varying 
glucose concentrations, as it is not phosphorylated (79), but its relative short 
half-life time (~20 minutes) and complex preparation limits the use of this 
compound in a clinical setting (80). 
fMRI
Functional magnetic resonance imaging is primarily used to study regional 
neuronal activation (patterns) by the detection of changes in oxygen demand by 
the brain (81), based on the concept of neurovascular coupling described above. 
Blood oxygenation level dependent (BOLD) contrast is one of the primary 
contrast mechanisms for fMRI, which exploits the differences in magnetic 
properties between deoxygenated and oxygenated hemoglobin (82). Regional 
brain activation increases local oxygen demands, but because the consequent 
increase in CBF exceeds these demands, the balance between deoxygenated 
and oxygenated hemoglobin changes towards the latter. This change in 
hemoglobin oxygenation can be probed and detected, so that a brain map of 
regions with increased or decreased activation can be constructed (81). fMRI 
has been especially useful in detecting brain activation patterns in response to 
specific cognitive tasks or visual stimulation. Hypoglycemia has been reported 
to reduce regional BOLD activation in response to these tasks, but less so in 
patients with type 1 diabetes (83) than in non-diabetic subjects (84; 85). These 
reductions in BOLD responses are commonly attributed to decreased neuronal 
activity, yet the potential impact of hypoglycemia on (global or regional) CBF, 
neurovascular coupling or oxidative metabolism, remains to be determined. 
ASL
Arterial spin labeling (ASL) is an MRI method that provides non-invasive 
quantification of global and regional CBF. ASL does not require an exogenous 
contrast agent, but uses magnetically labeled arterial blood water as a diffusible 
tracer. Arterial blood water is first labeled magnetically using radiofrequency 
(RF) pulses. Subsequently, this labeled arterial blood flows into the brain where 
it exchanges with tissue water, after which an image is taken. The experiment 
is then repeated without labeling the arterial blood to create a control image. 
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The signal difference between control and labeled images reflects local CBF (86; 
87). While the signal to noise (SNR) ratio in BOLD fMRI is higher, ASL measures 
brain perfusion more directly, enables quantification of CBF, and is suitable 
for studying variations in CBF over a longer period of time due to stable noise 
characteristics (88). ASL thus allows the detection of changes in CBF during 
hypoglycemia and is, in contrast to fMRI, less dependent on other metabolic 
parameters, such as oxygenation or glucose concentrations that might change 
during hypoglycemia. A high magnetic field (e.g. 3 Tesla) is usually recommended 
to improve SNR when performing ASL. 
MRS
MRS is a non-invasive technique, closely related to MRI. Both techniques make 
use of the spin properties of certain nuclei when brought into a magnetic field. 
For MRI, the proton nucleus is used to construct a highly detailed anatomical 
image based on the different water concentrations in various tissues. For 
MRS, these spin properties are used to determine the concentration of specific 
metabolites in the tissue examined. These concentrations are derived from the 
peaks in a spectrum (89). MRS is feasible on any nucleus possessing a magnetic 
moment, but is most frequently performed on the high natural abundant 
and MR sensitive proton nucleus (1H), providing steady-state information on 
concentrations of proton-containing brain metabolites at a single time point 
(90). However, because water contains most of the proton nuclei, the water 
signal needs to be suppressed to allow reliable measurements of metabolite 
concentrations. As a consequence, the sensitivity of MRS is manifold lower 
than that of MRI, even at high magnetic fields. Nevertheless, since nearly all 
metabolites contain protons, 1H-MRS is a powerful technique to identify and 
quantify a large number of metabolites relevant for glucose metabolism (e.g. 
lactate, glutamate, glutamine) at in vivo concentrations typically above 0.5 mM. 
The use of carbon-13 (13C) in MRS is specifically relevant for the study of 
brain glucose metabolism. Carbon exists in the human body in two isotopes, 
of which carbon-12 (12C) is dominant with a natural abundance of 98.9%. 12C 
does not possess a net nuclear spin and consequently cannot be detected by 
MRS. In contrast, 13C does possess a magnetic moment, but has a very low 
natural abundance of 1.1%. However, the intravenous infusion of 13C-enriched 
substrates, such as [1-13C]glucose, [3-13C]lactate or [3-13C]acetate, offers the 
possibility to study fluxes of these substrates in the brain through important 
metabolic pathways (Fig. 2). 
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Fig. 2 Time series of 13C-MR spectra, aquired from a ~125 mL voxel, placed in the occipital 
cortex. Spectra are averaged over 20 minutes, after administration of [1-13C]glucose during 
a hypoglycemic clamp in one healthy subject. Once the infused [1-13C]glucose is taken up by 
the brain and incorporated into various glucose metabolites, an increase in signal over time is 
observed. Numbers indicate the position of the 13C label, as explained in more detail in Fig. 3. 
Asp; aspartate; Gln, glutamine; Glu, glutamate; Lac, lactate (from: (143), with permission from 
Elsevier).  
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Fig. 3 One-compartment metabolic model describing the incorporation of 13C label from 
(infused) [1-13C]glucose into the TCA cycle and its metabolites. When taken up by the brain, 
the 13C-label is first incorporated into the C3 position of pyruvate and subsequently into the C3 
position of lactate. Once the 13C-label continues through the TCA cycle, it is incorporated into 
the C4 position of αKG, glutamate and glutamine. In the second turn of the cycle, the label is 
equally distributed over the C2 and C3 positions of these metabolites. The TCA cycle flux can 
be estimated using a metabolic model where the time courses of the uptake of the 13C-label 
in glutamate and glutamine in the different carbon positions, measured with 13C-MRS, are 
used as input. Filled circles represent the carbon position that is labeled with  13C, white circles 
represent unlabeled carbons. αKG, α-ketoglutarate; BBB, blood-brain-barrier; Glc, glucose; 
Gln, glutamine; Glu, glutamate; Lac, lactate; LDH, lactate dehydrogenase.; Pyr, pyruvate; 
Vgln, exchange rate between glutamate and glutamine; VTCA, TCA cycle rate; Vx, exchange rate 
between α-ketoglutarate and glutamate. 
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For the study of brain glucose metabolism, it is important to note that [1-13C]
glucose is taken up and metabolized by the brain similar to native (i.e. unlabeled) 
glucose. Following transport across the blood-brain barrier and phosphorylation 
by hexokinase, glucose is the main substrate for the production of energy (by 
formation of ATP) via glycolysis and the tricarboxylic acid (TCA) cycle (82). As 
such, 13C-MRS allows the fate of the 13C-labeled glucose to be followed as it flows 
into glycolysis. The 13C-label is transferred from glucose on the C-1 position to 
pyruvate on the C-3 position during glycolysis and, subsequently, passes through 
all metabolites of the TCA cycle. In this process, the 13C-label is incorporated 
into the MRS-detectable metabolites glutamate, glutamine and aspartate, all 
at specific carbon positions. Because these positions change during the second 
time the isotope flows in the TCA cycle (Fig. 3), the time-course of 13C-label 
incorporation into these metabolites can be used as input for a metabolic model 
to calculate the TCA cycle flux and CMRglc (91). However, although the fates 
of individual carbon atoms can be tracked in the TCA cycle, cerebral 13C-MRS 
provides no information about the loss of label in diffusible metabolites, such 
as glutamine and lactate which may exchange between brain and blood plasma 
(82; 92). 
13C-MRS has been proven to be a valuable imaging technique to study brain 
(glucose) metabolism via specific pathways in humans in vivo, under various 
conditions, including hyperglycemia (93) and hypoglycemia (94). In addition, 
13C labeled compounds other than glucose, such as 13C-acetate and 13C-lactate, 
can be used to provide a more complete picture of the very complex metabolic 
processes in the brain. Indeed, 13C-acetate, which is metabolized almost 
exclusively in astroglia (95), has been used to distinguish astroglial and neuronal 
metabolism more directly, and to study transport and metabolism of non-
glucose fuels during hypoglycemia (96; 97). 
Phosphorus-31 (31P) is another naturally abundant nucleus with a relatively high 
sensitivity for MRS. 31P-MRS of the brain can be used to detect metabolites that 
play a key role in brain energy metabolism and provides information on flux through 
the creatine kinase reaction (e.g. ATP, phosphocreatine, inorganic phosphate), 
intracellular pH and magnesium concentrations (98). Thus far, this technique has 
been seldom used to study brain metabolism during hypoglycemia (99).
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Cerebral nutrient transport capacity and hypoglycemia
Glucose uptake
As mentioned above, glucose uptake into the brain occurs through facilitated 
transport independent of insulin. As a consequence, there is a linear relationship 
between plasma glucose concentrations and brain glucose content over a range 
of plasma glucose values up to ~30 mmol/L (100-103). This linear relationship 
also extends well into the hypoglycemic range, although data below plasma 
levels of ~2.5mmol/L are missing in humans (Fig.4)(104). To explain HAAF, it has 
been hypothesized that chronic or repeated hypoglycemia increases glucose 
transport capacity over the blood-brain barrier to compensate for the fall in 
glucose availability to the brain during subsequent hypoglycemia. Indeed, several 
animal studies have shown that days to weeks of chronic hypoglycemia cause 
upregulation of brain glucose transporters, including both GLUT-3 on neuronal 
membranes (105; 106), and GLUT-1 on the vascular endothelium at the blood-
brain barrier (107; 108). In accordance, Boyle and co-workers applied the Kety 
and Schmidt technique to show preservation of brain glucose transport rather 
than a fall during hypoglycemia in healthy volunteers after prior exposure to 
hypoglycemia, whereas it fell when such exposure had not taken place (65). The 
Fig. 4 Linear relationship between plasma and brain glucose levels under normo- and 
hypoglycemic conditions in healthy subjects (open squares) and patients with type 1 
diabetes(closed circles). Brain glucose levels were measured with 13C-MRS. The plasma versus 
brain glucose relation was fitted with linear regression analysis to determine reversible 
Michaelis-Menten kinetics to show the best fit of the data with 95% confidence intervals. 
R2=0.59. P<0.001. Assuming continuation of this linear relationship between plasma and brain 
glucose levels, brain glucose approaches zero at a plasma glucose level of approximately 1.2 
mmol/L (from: (104), with permission from the American Diabetes Association). 
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investigators went on to report similar findings of preserved glucose transport 
in patients with type 1 diabetes and near-normal glycosylated hemoglobin 
(HbA1c), possibly reflecting high hypoglycemic burden, as they also had reduced 
awareness of hypoglycemia (66). 
In mice and in rats, very low plasma glucose values, typically well below 2.0 
mmol/L, have been found to proportionally increase brain glucose uptake as a 
function of increased cerebral perfusion (102; 109). Various neuroimaging studies 
investigating glucose transport over the blood-brain barrier in humans have 
produced conflicting results. A 1H-MRS study performed under hyperglycemic 
conditions showed greater brain glucose concentrations in patients with type 
1 diabetes and impaired awareness of hypoglycemia than in people without 
diabetes (110). However, a similar study found no evidence of altered brain 
glucose transport in healthy volunteers subjected to antecedent repeated 
hypoglycemia, despite clearly attenuated hormone responses to hypoglycemia 
(111). In accordance, global blood-to-brain glucose transport, as measured with 
[1-11C]-glucose PET, remained unaltered in healthy volunteers after exposure to 
24 hours of moderate hypoglycemia, albeit interspaced with transient glucose 
normalizations during meals (112). Finally, a 3-OMG-PET study also showed 
no differences in global brain glucose transport during hypoglycemia between 
patients with normal and those with impaired awareness of hypoglycemia (72). 
Monocarboxylic acid (MCA) uptake
Although glucose is its principal source of energy, the brain may resort to 
alternative non-glucose fuel substrates under glucopenic conditions. These 
alternative substrates include foremost ketones, and lactate, which enter 
the TCA cycle after conversion to pyruvate or acetyl coenzyme A, and can be 
metabolized in a similar way as glucose to sustain brain metabolism, and spare 
glucose.
Ketones such as beta-hydroxybutyrate and acetoacetate are synthesized 
in the liver from fatty acids during prolonged fasting, starvation and severe 
carbohydrate restriction. Under such conditions, up to 60% of brain energy 
requirements may be derived from ketone metabolism (113), whereas ketogenic 
diets can more or less restore brain energy metabolism and prevent epileptic 
seizures in patients with GLUT1 deficiency who are unable to transport glucose 
into the brain (114; 115). However, because insulin suppresses the production 
of ketones, the brain is usually unable to use this source of energy during 
insulin-induced hypoglycemia (116). PET studies with the use of both ketone 
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and glucose tracers may help to unravel the complex interaction between the 
metabolism of ketones and glucose by the brain under different circumstances, 
including hypoglycemia (113).
In recent years, it has gradually been recognized that lactate plays an 
important role in the energy metabolism in the brain, particularly during 
hypoglycemia since both hypoglycemia and insulin increase plasma levels of 
lactate, at least in healthy subjects (94; 117; 118). Under basal, euglycemic, 
conditions, the contribution of systemic lactate to cerebral energy metabolism 
is approximately 8-10%. However, the proportional contribution of lactate has 
been reported to increase during strenuous exercise, when plasma lactate levels 
rise substantially (119; 120). The role of lactate in specific areas of the brain 
includes its involvement in or interference with hypoglycemia detection in the 
VMH as stated above. Lactate has also been found to be a crucial monitored 
variable in the detection of energy imbalance in the caudal hindbrain (121). 
The importance of lactate for the brain was first highlighted when Pellerin and 
Magistretti published their astrocyte-neuron lactate shuttle (ANLS) hypothesis. 
This hypothesis posits that glucose is taken up by and metabolized in astrocytes 
to form lactate, after which lactate is exported to neighboring neurons where it 
is oxidized, especially during activation (122). This concept, which bears analogy 
to the cell-cell lactate shuttle, through which skeletal muscle can transport a 
non-glucose energy source to other organs (123), thus suggests that astrocytes 
play the primary role in brain glucose metabolism. Simpson et al. later came to 
a different conclusion and developed a model that basically adopts the opposite 
view, in which neurons are the principal site of glucose uptake and metabolism, 
and the chief exporter of lactate. This hypothesis was therefore termed the 
neuron-astrocyte lactate shuttle (NALS) (59) and fuelled a heavy debate (124; 
125). The debate on the direction of the lactate shuttle is ongoing with studies 
identifying the neuron as the principal locus of glucose uptake (126), and other 
studies indicating that neurons rather than astrocytes are the primary sites for 
oxidation of exogenous lactate (119; 127). 
Monocarboxylic acid transporters (MCTs) facilitate the uptake of lactate as well 
as that of acetate and ketone bodies into the brain, the expression of which 
may increase following sustained hyperketonemia or recurrent hypoglycemia. A 
recent study in rats demonstrated a two-fold increase in the expression of MCTs 
1 and 2 in the cerebral cortex after the induction of diabetes by streptozotocin. 
After 8 weeks of frequent, prolonged endurance training and concomitant 
exposure to hypoglycemia after and between exercise sessions, the expression of 
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both transporters increased even further (128). Such greater transport capacity 
may explain recent observations in which recurrent exposure to hypoglycemia 
increased the uptake of 13C-labeled lactate into the rat brain under hypoglycemic 
conditions (129). During hypoglycemia, the uptake of both acetate and lactate 
into the human brain, as measured by 13C-MRS during infusion of 13C-labeled 
acetate or lactate, respectively, was found to be considerably greater in patients 
with well-controlled type 1 diabetes than in healthy controls (97; 130). 
Transport and uptake of other substrates
Oral intake of amino acids has been reported to enhance the glucagon response 
to hypoglycemia and to improve some aspects of cognitive function during 
hypoglycemia in non-diabetic and diabetic subjects (131; 132). Amino acids 
might also serve as a non-glucose substrate that could be used by the brain as 
an alternative fuel and to sustain cognitive function during hypoglycemia. Early 
studies showing utilization of amino acids by the rat brain during prolonged 
hypoglycemia and of amino acids contributing to glycogen synthesis in brain 
cell cultures, supported this theory (133; 134). However, data obtained in humans 
using arteriovenous concentration differences found no evidence that greater 
availability of amino acids increased its net brain uptake during hypoglycemia 
(135) or was able to offset energy deficit due to reduced glucose supply (136). 
A few studies have investigated whether the human brain can use lipid substrates 
to support cerebral metabolism and brain function during hypoglycemia. Fatty 
acids can readily cross the blood-brain barrier to be oxidized by the brain, as 
demonstrated by a 13C-MRS study in rats (137). In healthy humans, elevated 
plasma levels of non-esterified fatty acids and glycerol were found to reduce 
hormonal and symptom responses to hypoglycemia, but could not protect 
against the fall in cognitive function (138). Conversely, in a more recent 
study, ingestion of medium-chain triglycerides maintained cognitive function 
during hypoglycemia without affecting adrenergic or symptomatic responses 
to hypoglycemia in intensively treated subjects with type 1 diabetes (139). It 
should be acknowledged, however, that the inferences made with respect to the 
uptake of lipid substrates in the brain were indirect and that no neuroimaging 
studies have been performed that evaluated the effects of these substances on 
cerebral metabolism more directly.
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Brain metabolism during hypoglycemia
Glucose metabolism
Both PET and MRS have been used to investigate the effect of hypoglycemia on 
brain glucose metabolism. PET has been particularly useful in detecting regional 
differences in tracer accumulation in the brain, both during hypoglycemia (71), 
and after restoration to euglycemia (74). However, rather than focusing on 
glucose uptake or metabolism, the close link with neuronal activation is then 
exploited to use the data as input factors for mapping regional brain activity. 
Thus, the observation that CMRglc relatively increased during hypoglycemia 
in patients with type 1 diabetes and normal awareness of hypoglycemia, and 
relatively fell in patients with impaired awareness of hypoglycemia, was 
interpreted as an increase in brain activation and absence of such a response 
(72). When this increased activation would occur in brain areas involved in the 
perception of and the generation of responses to hypoglycemia, the lack of 
increased activation could then underlie loss of hypoglycemic awareness (72; 
140). Support for this hypothesis came from another FDG-PET study (141) and 
a subsequent analysis of these data (73), as tracer uptake in areas that engage 
appetite control and food-seeking behavior was reduced in patients with 
impaired compared to patients with intact awareness of hypoglycemia.
As outlined above, 13C-MRS in combination with infusion of 13C-labeled glucose 
has the unique property that it enables the investigation of cerebral glucose 
metabolism in humans in vivo. Since the SNR is relatively low, most studies 
employing this technique used large doses of isotopically enriched glucose at 
high enrichment percentages. Measurements have consequently generally been 
performed under hyperglycemic conditions with glucose levels up to 17 mmol/L 
and plasma C-13 enrichment values exceeding 60%. Under such conditions, 
Henry et al. (93) reported no differences in the TCA cycle rate between patients 
with type 1 diabetes with impaired awareness of hypoglycemia and healthy 
controls. More recently, an improved sensitivity of the 13C-MRS method (142) 
in combination with an optimized 13C-glucose infusion protocol enabled us to 
study glucose metabolism in the human brain during hypoglycemia at lower 
enrichment values (143). With this optimized technique, no differences were 
observed in cerebral glucose metabolism between hypoglycemia and euglycemia, 
neither in healthy controls (94), nor in patients with type 1 diabetes (144). Under 
hypoglycemic conditions, however, the TCA cycle rate was approximately 45% 
higher in patients than in healthy subjects, and inversely related to HbA1c. 
Appreciating a low HbA1c as a proxy for a high hypoglycemic burden, these data 
suggested a role for prior hypoglycemic exposure in the higher TCA cycle rate in 
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patients with type 1 diabetes. Differences in brain glucose levels did not explain 
the preservation of brain metabolism and the higher TCA cycle rate in the 
patients, which suggested influx of a non-glucose carbohydrate source (104). In 
an animal study by Herzog et al. (129), brain glucose transport capacity during 
hypoglycemia became rate limiting for TCA cycle activity in control animals, but 
not in rats exposed to antecedent recurrent hypoglycemia. Explanations for the 
discrepancy between the human and rodent data include the different species 
and the fact that the hypoglycemic condition was more profound in the animals. 
Indeed, studies in mice suggest that intracellular brain glucose concentrations 
approach depletion at plasma glucose values between 2 and 3 mmol/L (109).
Glycogen metabolism
The brain is able to store glycogen and to use this compound when plasma 
glucose levels are low, although its capacity to do so is very limited compared 
to other tissues such as skeletal muscle and the liver. It was long assumed that 
this presence of glycogen was restricted to astrocytes. However, a recent study 
showed that neurons contain a low but measurable amount of glycogen, the use 
of which was found to protect against hypoxic stress, at least in neuronal cell 
cultures and animal models (145). Both in rodents (146) and in humans (147), 
it was shown that brain glycogen was used during hypoglycemia, and that its 
stores were replenished above baseline levels after restoration of euglycemia, 
a phenomenon termed glycogen supercompensation. It has been speculated 
that this expanded source of glucose within the brain could contribute to the 
development of impaired awareness of hypoglycemia by fuelling the brain or at 
least those areas involved in glucose-sensing during subsequent hypoglycemia 
(146). However, prior exposure to recurrent hypoglycemia neither facilitated 
nor impaired access to glucose from glycogen in the rat brain during subsequent 
hypoglycemia (148). Additionally, brain glycogen content, as measured by 
13C-MRS in conjunction with 13C-glucose administration, was lower rather than 
higher in patients with type 1 diabetes and hypoglycemia unawareness (149). 
Glutamate metabolism
Glutamate is the major excitatory neurotransmitter in the brain, but has 
many other metabolic fates, including the formation of glutamine, GABA and 
glutathione (150). In addition, a new concept has been introduced by Sonnewald 
(151), who proposed that glutamate degradation in astrocytes contributes to 
most of the lactate that is released from the brain under resting conditions, 
offering a novel explanation for the concept of aerobic glycolysis in the resting 
state (151; 152). Lastly, glutamate can be oxidized for the production of energy 
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(150). To this end, glutamate production in the brain is tightly coupled to TCA 
cycle activity (153). Using 1H-MRS, Bischof et al. reported that hypoglycemia 
reduced the cerebral glutamate to creatine ratio in healthy controls, but not 
in patients with type 1 diabetes (154). Similar results were reported by a more 
recent 1H-MRS study, where hypoglycemia reduced brain glutamate levels in 
healthy controls and in patients with type 1 diabetes with normal hypoglycemic 
awareness, but not in patients with impaired awareness  of hypoglycemia 
(155). The authors concluded that the preservation of brain glutamate during 
hypoglycemia in the latter group reflected a metabolic adaptation that 
eliminated the need to oxidize glutamate. They speculated that this adaptation 
could be augmented transport of glucose or of alternative fuels to the brain. 
Metabolism of monocarboxylic acids
As discussed earlier, MRS studies using 13C-labelled acetate and lactate have 
clearly suggested that the capacity to transport MCAs over the blood-brain 
barrier during hypoglycemia is increased in patients with well-controlled 
type 1 diabetes. Indeed, a study during which 13C-acetate was infused under 
hypoglycemic conditions showed more than twofold higher brain acetate 
concentrations in subjects with type 1 diabetes compared to healthy controls. 
This greater acetate availability translated into a fraction of oxidative metabolism 
that resulted from acetate to be similarly increased (97). In accordance, the 
relative contribution of acetate to brain metabolism in rats exposed to recurrent 
antecedent hypoglycemia was also increased during next-day hypoglycemia, 
indicating that brain substrate preferences may change rapidly from glucose 
to alternative substrates if needed (156). To delineate whether this effect was 
a function of diabetes, prior hypoglycemia or both, the investigators repeated 
their 13C-acetate study in patients with type 1 diabetes with normal or impaired 
awareness of hypoglycemia and in healthy controls. They found that absolute 
rates of acetate metabolism during hypoglycemia were only higher in the 
patients with impaired awareness of hypoglycemic, suggesting that changes 
in acetate metabolism are the consequence of prior exposure to hypoglycemia 
rather than of diabetes per se (96).
Lactate uses the same MCT as acetate to cross the blood-brain barrier. Since 
plasma levels of lactate are approximately 10-fold higher than those of 
acetate, and hypoglycemia stimulates the production of lactate (117), it seems 
plausible that lactate is the more likely substrate for brain metabolism when 
glucose levels are low. Studies dating back to the 1990s have shown that 
exogenous administration of lactate attenuates counterregulatory responses 
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to and preserves cognitive function during hypoglycemia, presumably because 
lactate is used as an alternative source of energy by the brain (157-160). In 
agreement, brain lactate concentrations during hypoglycemia, derived from 
the cerebral uptake of 13C-labelled lactate, were several fold higher in patients 
with type 1 diabetes with a history of frequent hypoglycemic episodes than 
in non-diabetic subjects (130) and in rats exposed to recurrent hypoglycemia 
versus those not exposed (129). Surprisingly, the authors found no indication of 
greater lactate oxidation, as reflected by unchanged 13C fractional enrichments 
of brain glutamate and glutamine (130). Data from the rodent study, in which 
lower glucose levels were achieved than in the human study, suggested that 
prior hypoglycemic exposure increased both the uptake and the oxidation of 
glucose by the brain, despite the higher lactate levels (129). However, when the 
animal brain was stimulated during hypoglycemia, animals exposed to recurrent 
hypoglycemia had a partial loss of their functional cortical response, which was 
only normalized after the administration of lactate. This suggests that the higher 
capacity for lactate transport only becomes critical when the brain is activated 
during (deep) hypoglycemia.
Cerebral blood flow and hypoglycemia
There is uncertainty as to whether hypoglycemia affects global CBF and in what 
direction. Previous research in both patients with type 1 diabetes and healthy 
controls has reported either no change in global CBF during hypoglycemia (65; 
66; 136), a modest increase (161-163), or even a slight decrease (71). Differences in 
the plasma glucose levels achieved during hypoglycemia and, more importantly, 
in imaging techniques probably explain many of the discrepancies. Studies that 
investigated the effect of hypoglycemia on regional relative changes in CBF 
seem to have produced more consistent data. Both in healthy controls (161) and 
in patients with type 1 diabetes (164), hypoglycemia was found to increase blood 
flow to the frontal lobes. This relative redistribution of regional CBF was already 
observed under euglycemic conditions in patients with type 1 diabetes, and 
was more pronounced in patients who had experienced frequent hypoglycemia 
(165). Since the frontal lobes are among the most vulnerable brain areas to suffer 
structural damage, this may be an adaptive response to prevent such damage 
by maintaining fuel supply during subsequent hypoglycemia. 
Hypoglycemia has also been found to increase CBF in the thalamus (71; 166; 
167) and hypothalamus (168; 169). Mild or moderate hypoglycemia caused a 
rise in CBF in the hypothalamus in healthy non-diabetic subjects, as assessed 
by fMRI (168) or ASL (169), which preceded the rise in counterregulatory 
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hormone responses seen during hypoglycemia (169). Interestingly, Mangia et 
al. found blunting of this increase in thalamic perfusion during hypoglycemia in 
patients with type 1 diabetes with hypoglycemia unawareness, and a correlation 
between thalamic perfusion and the adrenaline response to hypoglycemia (167). 
In contrast, recurrent hypoglycemia enhanced, rather than decreased, thalamic 
perfusion during subsequent hypoglycemia in healthy controls (170), so that the 
role of this brain region in the adaptation to hypoglycemia remains uncertain.
Discussion 
The scientific field of metabolic and functional neuroimaging techniques for 
the brain has tremendously progressed over the past couple of decades. The 
application of these techniques to hypoglycemia research has considerably 
advanced our understanding of the brain’s responses to hypoglycemia. As 
plasma glucose falls below levels that can be reversed by responses at the 
level of pancreatic islets, i.e. suppression of insulin release and stimulation 
of that of glucagon, the brain’s sensing abilities are activated to allow timely 
detection of hypoglycemia. Data from functional and metabolic neuroimaging 
techniques now suggest that such moderate hypoglycemia neither affects 
the perfusion to nor the uptake of glucose into the brain, at least not globally, 
unless much deeper levels of glucose are achieved (102; 109). In accordance, 
cerebral glucose metabolism appears largely maintained during moderate 
hypoglycemia (94; 129; 144). However, on the regional level, moderate 
hypoglycemia causes redistribution of CBF to various brain areas involved in 
the detection of hypoglycemia, particularly the (hypo)thalamus (71; 166-169), 
where enhanced neuronal activation stimulates glucose uptake and metabolism. 
Such enhanced neuronal activation has also been found to occur in brain areas 
involved in appetitive motivational networks (73), thus linking the detection of 
hypoglycemia to a behavioral response. 
Modern neuroimaging studies have revealed that recurrent hypoglycemia, which 
typically affects people with type 1 diabetes and underlies the clinical syndrome 
of impaired awareness of hypoglycemia, may initiate cerebral adaptations at 
many different levels. First, there is interference with the accurate detection 
of hypoglycemia, probably occurring at the level of the VMH. Brain areas that 
control appetite and induce fear and anxiety may not become activated during 
hypoglycemia. Whether or not locally increased glucose uptake in or reduced 
neuronal activation of the hypothalamic area (or both) form the underlying 
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mechanism remains to be revealed. Importantly, it should be acknowledged 
that neurovascular coupling may be altered as a consequence of diabetes per 
se (171), chronic hyperglycemia (172) or microangiopathy (173), thus limiting the 
interpretation of studies relying on this concept. There is conflicting evidence 
as to whether recurrent hypoglycemia can stimulate brain glucose uptake 
during hypoglycemia (65; 66), although most studies employing neuroimaging 
techniques found no evidence for this suggestion (72; 111; 112). Nevertheless, 
patients with type 1 diabetes, particularly those with impaired awareness of 
hypoglycemia (155), seem better able in maintaining brain (glucose) metabolism 
during hypoglycemia than healthy controls (94; 144; 154; 155), probably as 
a consequence of prior hypoglycemia (144). Since profound hypoglycemia 
will eventually cause brain glucose metabolism to deteriorate (129), such an 
adaptation may shift the threshold for deterioration of the metabolic rate to 
lower plasma glucose levels. 
Several mechanisms have been proposed that could explain the discrepancy 
between hypoglycemia-induced preservation of cerebral glucose metabolism 
and the fall in glucose availability during hypoglycemia. It seems likely that 
influx of a non-glucose energy substrate plays a role. Recent (neuroimaging) 
studies found little evidence to support enhanced blood to brain transport of 
amino acids (135; 136) or lipid substrates transport (138; 139) and ketones are 
unlikely candidates because its production is suppressed by insulin. Also, the 
lower brain glycogen content in patients with type 1 diabetes and impaired 
awareness of hypoglycemia compared to controls (149) argues strongly 
against the glycogen supercompensation hypothesis. Several arguments 
suggest a major role for lactate in preserving brain glucose metabolism during 
hypoglycemia. These include: 1) lactate can be used by the brain and may even 
be preferred over glucose under non-hypoglycemic conditions (174; 175); 2) 
the capacity for lactate transport over the blood-brain barrier is increased in 
patients with impaired awareness of hypoglycemia and in rats after exposure to 
hypoglycemia (97; 129); 3) the use of lactate by glucose-sensing neurons in the 
VMH may interfere with hypoglycemia sensing (54; 56; 57). However, there are 
data that suggest that lactate is not used as major energy source for the brain 
during moderate hypoglycemia, despite greater availability (129; 130). Also, it is 
not yet known whether brain uptake or metabolism of endogenously produced 
lactate is increased during hypoglycemia in patients with type 1 diabetes and 
impaired awareness of hypoglycemia. Finally, it has been suggested that lactate 
may serve as a metabolic regulator or intercellular signaling molecule rather 
than a fuel, modulating brain glucose metabolism, oxygen delivery and CBF 
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(176; 177). Mechanisms by which lactate might exert this effect (178) include 
modulation of prostaglandin action (and thus CBF) (177; 179), adjustment of the 
NADH/NAD+ redox ratio (123), and the regulation of neuronal cAMP formation 
via the lactate receptor G-protein-coupled receptor 81 (GPR81)(180). 
Conclusion
Hypoglycemia is the principal barrier for achieving optimal, let alone normal, 
glycemic control for indefinite periods of time in patients with type 1 diabetes 
and advanced insulin-requiring type 2 diabetes (181). Recurrent hypoglycemia 
forms the basis of HAAF and the clinical syndrome of impaired awareness of 
hypoglycemia by attenuating physiological defenses against subsequent 
hypoglycemia, consequently increasing the risk for severe hypoglycemia. 
Paradoxically, the mechanism(s) underlying these glucose counterregulatory 
impairments may be related to, or even caused by, processes that are seemingly 
aimed at protecting the brain against harm from severe hypoglycemia. The 
progress in metabolic and functional neuroimaging techniques has revealed that 
recurrent hypoglycemia causes cerebral adaptations to occur on many different 
levels. These adaptations include those in the regional delivery (blood flow) and 
transport of glucose to the brain, the handling of glucose by the brain and that 
of non-glucose alternative fuels, as well as activation or de-activation of brain 
areas involved in behavioral responses. It remains to be elucidated whether, 
and if so under which circumstances and in which brain areas, the brain uses 
non-glucose alternative sources of energy, particularly lactate, and whether 
this contributes to the emergence of impaired awareness of hypoglycemia. 
Such information is needed first to foster personalized decision-making with 
respect to glycemic targets, but should eventually lead to treatments that 
eliminate hypoglycemia from the lives of people with type 1 diabetes without 
compromising glucose control. 
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Abstract 
Brain lactate may be involved in the development of impaired awareness of 
hypoglycemia (IAH), a condition that affects approximately 25% of patients 
with type 1 diabetes and increases the risk of severe hypoglycemia. The aim 
of this study was to investigate the effect of acute hypoglycemia on brain 
lactate concentration in patients with IAH as compared with those with normal 
awareness of hypoglycemia (NAH) and healthy control subjects (n = 7 per group). 
After an overnight fast, all subjects underwent a two-step hyperinsulinemic 
euglycemic (5.0 mmol/L)-hypoglycemic (2.8 mmol/L) glucose clamp. Brain 
lactate concentrations were measured continuously with 1H-MRS, using a specific 
lactate detection method. Hypoglycemia generated symptoms in patients with 
NAH and healthy control subjects, but not in patients with IAH. Brain lactate 
fell significantly by ~20% in response to hypoglycemia in patients with type 1 
diabetes with IAH but remained stable in both healthy control subjects and in 
patients with NAH. The fall in brain lactate is compatible with increased brain 
lactate oxidation providing an alternative fuel source during hypoglycemia, 
which may contribute to the impaired detection of hypoglycemia.
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Introduction
Approximately 25% of patients with type 1 diabetes have lost the capacity to 
timely detect hypoglycemia, a condition referred to as impaired awareness of 
hypoglycemia (IAH) (1). IAH increases the risk for severe, potentially hazardous 
hypoglycemia up to sixfold (2) and is usually the end result of a process of 
habituation to recurrent hypoglycemia (1). 
Although the precise mechanisms underlying IAH remain to be revealed, 
there may be a pivotal role for the alteration in the brain’s handling of energy 
substrates other than glucose (3). Indeed, using 13C magnetic resonance 
spectroscopy (MRS), we found that brain metabolism was largely preserved 
during hypoglycemia in both subjects without diabetes and subjects with 
type 1 diabetes, despite a similar fall in brain glucose availability (4-6). These 
observations indicate that metabolism of a non-glucose carbohydrate energy 
source may be involved. 
Several observations suggest that this nonglucose energy source is lactate. 
Lactate is a valuable energy source for the brain during euglycemia (7-9) and 
may be critical to maintaining brain function during severe hypoglycemia (10). 
Administration of lactate during hypoglycemia impairs hypoglycemic symptoms, 
attenuates counterregulatory hormone responses, and preserves cognitive 
function, mirroring the changes seen in subjects with IAH (11; 12). Finally, brain 
lactate transport capacity through monocarboxylic acid transporters was found 
to be increased during hypoglycemia in patients with IAH (13; 14).
The brain of patients with type 1 diabetes and IAH may have been conditioned 
to use lactate under glucopenic conditions to maintain brain function, thereby 
simultaneously impairing hypoglycemia sensing. We therefore hypothesized 
that brain lactate levels would fall during hypoglycemia in people with type 
1 diabetes and IAH. To test this hypothesis, we measured brain lactate under 
hypoglycemic conditions with a dedicated 1H-MRS method optimized for lactate 
detection (15). 
Research Design and Methods
Subjects
We recruited seven patients with type 1 diabetes and IAH, seven patients with 
normal awareness of hypoglycemia (NAH), and seven healthy subjects without 
diabetes. Awareness state was based on the Dutch modified version of the 
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Cox questionnaire, where scores of 0-1 out of 5 indicate normal awareness and 
scores ≥3 impaired awareness (16; 17). Patients were eligible if they had an HbA1c 
<9.0% (75 mmol/mol) and were free from microvascular complications, except 
for background retinopathy. Exclusion criteria were contraindications for MRI 
examinations, a history of brain injury or cardiovascular events, and the use of 
drugs other than insulin interfering with glucose metabolism. The institutional 
review board of the Radboud university medical center approved the study, and 
all subjects gave written informed consent. 
Hyperinsulinemic glucose clamps
All participants presented at 8:00 A.M. after an overnight fast having abstained 
from caffeine, alcohol, and smoking for 24 h and from strenuous exercise for 
three days. Subjects with diabetes were instructed to adjust their basal insulin 
dose the evening before the clamp to prevent nocturnal hypoglycemia and to 
omit their morning prandial insulin dose. The brachial artery of the nondominant 
arm was cannulated under local anesthesia for frequent blood sampling. An 
intravenous catheter was inserted into the antecubital vein of the contralateral 
arm to administer glucose 20% (Baxter, Deerfield, IL) and insulin (insulin 
aspart; Novo Nordisk, Bagsvaerd, Denmark). After cannulation and baseline 
measurements, the subjects were positioned in the MR scanner, and a two-step 
hyperinsulinemic (60 mU/m2/min) euglycemic (5.0 mmol/L)-hypoglycemic (2.8 
mmol/L) glucose clamp was initiated. During the clamp, arterial plasma glucose 
and lactate levels were determined every 5 min (Biosen C-Line, EKF Diagnostics, 
Cardiff, U.K.). Counterregulatory hormone and insulin levels were determined at 
the end of each glycemic phase. Insulin levels were also measured at baseline. 
Subjects completed an 18-item semiquantitative symptom questionnaire just 
prior to initiating the glucose clamp and at the end of the hypoglycemic phase 
in which symptoms were scored from 0 (none) to 6 (severe). 
Analytical methods
Plasma insulin was assessed by an in-house radioimmunoassay (RIA) (18). 
Plasma adrenaline was measured by high performance liquid chromatography 
combined with fluorometric detection (19). 
MRS protocol
MR measurements were performed at 3T (Tim MAGNETOM Trio; Siemens, 
Erlangen, Germany) using a 12-channel receive-only head coil. First, an 
anatomical image was acquired (T1-weighted MPRAGE; 256x256 mm² field 
of view, 256 slices, 1 mm³ isotropic voxels). Subsequently, 1H-MRS data were 
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acquired from a 25 cm3 voxel (Fig. 1A), in data blocks consisting of two consecutive 
acquisitions to determine tissue concentrations of brain lactate and of the 
other major brain metabolites, respectively. Brain lactate concentrations were 
determined using an interleaved J-editing semi-LASER sequence (20) optimized 
for lactate detection (15) (echo time (TE) 144 ms; repetition time (TR) 3,000 ms; 
32 averages; total duration of acquisition (TA) 1.40 min). J-editing was performed 
with MEGA-pulses with a bandwidth of 75 Hz. Spectra with a shorter TE with water 
suppression were acquired to determine the tissue concentrations of other major 
brain metabolites (sLASER, TE 30 ms, TR 3,000 ms, 32 averages; TA 1.40 min). 
Lastly, spectra acquired without water suppression were used for quantification 
of the metabolite concentrations (TE 30 ms; TR 5,000 ms; 8 averages). 
Figure 1: Representative MR data from one healthy subject. A: T1-weighted anatomical image 
with typical location of the voxel  (2.0 x 5.0 x 2.5 cm) for the acquisition of the MRS data B: 
MEGA off, MEGA on, and difference spectra of one subject. J-editing was performed with 
MEGA-pulses centered on the lactate quartet at 4.1 ppm (MEGA on) and subsequently at -3 
ppm (MEGA off). As a consequence, the lactate doublet at 1.3 ppm is inverted in the MEGA off 
spectrum and upright in the MEGA on spectrum. Subtracting the MEGA on spectrum from the 
MEGA off spectrum results in the difference spectrum, which contains only the positive lactate 
doublet, removing the signals from all other metabolites in the spectrum. C: MR spectrum 
recorded with a TE of 30 ms. Glu, glutamate; ml, myo-inisitol; tCre, total creatine; tCho, total 
choline; tNAA, total N-acetylaspartate; Lac, lactate.
Analysis of MRS data
After zero-filling (from 1,024 to 2,048 points) and Fourier Transformation, all 
J-edited spectra from each subject were phase and frequency aligned with the 
first spectrum recorded by maximizing the scalar product between this so-called 
reference spectrum and the other spectra. Difference spectra were apodized 
with a 5 Hz Lorentzian, and moving averaging with a sliding window of three 
scans was performed. In the final difference spectra, the lactate doublet was 
fitted with the AMARES algorithm in jMRUI (21). 
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The spectra acquired with a TE of 30 ms were analyzed with the LCModel software 
to quantify the other major brain metabolites, including total N-acetylaspartate, 
total choline, total creatine, myo-inositol, aspartate, glutamine, glutamate, 
scyllo-inositol and taurine. Only metabolites with a Cramér-Rao lower bound 
<20% were considered to be reliably quantified and included in further analyses 
(22). All metabolite concentrations were calculated taking voxel composition 
(determined by segmenting the T1-weigthed anatomical images using SPM8) 
and differences in T2 relaxation of metabolite spins into account. 
Statistical analysis
Within group differences were compared with two-sided Student t tests. 
Between group differences were analyzed by ANOVA followed by pairwise 
Bonferroni post hoc tests between all groups. All data are expressed as mean 
± SEM unless otherwise indicated. A P value <0.05 was considered statistically 
significant. Statistical analyses were performed with IBM SPSS Statistics 20.
Results
The groups were well matched for relevant parameters (Table 1). Baseline plasma 
glucose values were elevated to a similar extent in both diabetes groups (Fig. 2A). 
During the clamp, plasma glucose levels (mean ± SD) were sequentially clamped 
at 5.0 ± 0.1 and 2.8 ± 0.1 mmol/L without differences between the groups (Fig. 2A). 
Insulin levels were also comparable during the clamps (data not shown).
Hypoglycemic symptom scores increased significantly in response to 
hypoglycemia in both healthy volunteers and in patients with NAH but not in 
patients with IAH (mean increase: 2.0 ± 0.9, 12.9 ± 3.9 and 17.4 ± 3.7 for patients 
with IAH, patients with NAH and healthy control subjects, respectively). 
Adrenaline responses to hypoglycemia were lower in patients than in healthy 
volunteers (P < 0.05), particularly in those with IAH, although the difference 
between the two patient groups was not statistically significant (P = 0.88) 
(Supplementary Table 1).
Baseline plasma lactate levels were similar across the three groups, but time 
courses during the clamp were different (Fig. 2B). During the hypoglycemic 
phase of the clamp, mean plasma lactate levels were significantly higher in 
healthy subjects than in subjects with diabetes (P < 0.01).
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Table 1: Subject characteristics 
T1DM IAH (n = 7) T1DM NAH (n = 7) Healthy subjects (n = 7)
Age, years 24.7±8.1 26.2±5.8 27.6±6.9
Sex, M/F 3/4 4/3 3/4
BMI, kg/m2 23.4±1.3 24.7±2.9 23.5±1.7
HbA1C, % (mmol/mol) 7.5±0.6 (58.7±6.3) 7.3±0.4 (56.6±3.8) -
Duration of diabetes, years 10.0 (2.5-17.5)  10.0 (6.0-14.0) -
Score on modified Cox questionnaire (range) 3.7±0.8 (3-5) 0.4±0.5 (0-1) -
Data are presented as n, mean ± SD, or median (interquartile range). F, female; M, male; T1DM, 
type 1 diabetes mellitus.
Figure 2: Time courses of plasma glucose (A) and plasma lactate (B). The dashed lines represent 
the beginning of the euglycemic phase, the end of the euglycemic phase, and the beginning 
of the hypoglycemic phase, respectively. Baseline values represent the sample obtained upon 
arrival at the research facility. Black triangles, patients with type 1 diabetes (T1DM) and IAH; 
black squares, patients with type 1 diabetes and NAH; open circles, healthy subjects.
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In one patient with NAH, the 1H-MR spectral quality was insufficient for analysis 
because of head movement during data acquisition. The J-edited difference 
spectra of all other subjects showed a clear lactate doublet at 1.3 ppm (Fig. 1B). 
The MR voxel contained 65.5 ± 2.9% white matter, 31.2 ± 2.8% gray matter and 3.2 
± 0.5% cerebral spinal fluid, with no differences between groups (data not shown). 
Brain lactate concentration dropped from 0.52 ± 0.02 to 0.41 ± 0.02 µmol/g 
wet weight (ww) in response to hypoglycemia in patients with IAH (P < 0.001), 
corresponding with a fall of ~ 20% (Fig. 3). In contrast, brain lactate concentrations 
remained stable during euglycemia and hypoglycemia in both healthy subjects 
(0.49 ± 0.02 versus 0.46 ± 0.01 µmol/g ww, P = 0.12) and patients with NAH 
(0.46 ± 0.03 versus 0.45 ± 0.03 µmol/g ww, P = 0.73). There were no differences 
between groups in absolute brain lactate concentrations during euglycemia (P = 
0.17) or during hypoglycemia (P = 0.36). 
1H-MR spectra without editing and a TE of 30 ms (Fig. 1C) revealed a significant 
drop in brain glutamate concentrations in response to hypoglycemia in healthy 
subjects (from 6.0 ± 0.3 to 5.7 ± 0.3 µmol/g ww P < 0.01) but not in patients with 
NAH (6.6 ± 0.3 vs. 6.4 ± 0.3 µmol/g ww, P = 0.13) or in patients with IAH (7.3 ± 
0.3 versus 7.1 ± 0.3 µmol/g ww, P = 0.11). There were no significant changes in 
response to hypoglycemia regarding other major brain metabolites.
Figure 3: Hypoglycemia-induced changes in brain lactate. Mean (with SEM) group differences 
(horizontal bars) as well as individual changes (black squares) between average euglycemic and 
hypoglycemic brain lactate concentrations (percent change from euglycemic value) are depicted. 
*P < 0.001 for euglycemia vs. hypoglycemia and †P < 0.05 vs. T1DM NAH and healthy subjects.
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Discussion
The major finding of this study is that brain lactate concentrations decrease by 
~20% in response to hypoglycemia in patients with type 1 diabetes and IAH but 
not in patients with type 1 diabetes and NAH or in healthy control subjects. This 
finding suggests that adaptations in cerebral lactate handling are involved in 
the etiology of IAH. 
A recent 1H-MRS study also reported decreased brain lactate concentrations in 
response to hypoglycemia, albeit this change was only significant in patients 
with diabetes and normal adrenaline responses to hypoglycemia (23). However, 
the MR methods in that study were focused on glutamate detection, and patients 
were stratified according to the observed adrenaline response to hypoglycemia 
rather than according to the awareness of hypoglycemic symptoms.
A change in brain lactate concentration reflects a change in the balance between 
uptake, export, production (through glycolysis), and oxidation of cerebral 
lactate (24). The hypoglycemia-induced reduction in brain lactate in patients 
with IAH most likely resulted from increased lactate oxidation as an adaptation 
to recurrent exposure to hypoglycemia to preserve brain metabolism when 
glucose supply is low. Our observation that plasma lactate levels fell in the IAH 
group argues against increased brain lactate export. Furthermore, it is unlikely 
that the lower brain lactate levels were the result of decreased cerebral lactate 
uptake, given that plasma lactate levels fell to a similar extent in both patient 
groups and that lactate transport capacity has been reported to be increased 
in patients with IAH (14). We cannot completely exclude that the fall in lactate 
reflected a decrease in glycolysis due to reduced neuronal activation (25). 
In a recent 13C-MRS study, De Feyter et al. (13) showed that the human brain 
oxidizes 13C-labeled lactate that was infused during hypoglycemia. Somewhat 
surprisingly, they found no differences in lactate oxidation between patients 
with diabetes and healthy control subjects, despite a higher calculated brain 
lactate concentration in the patients with diabetes, which seems at odds with 
our findings. However, inherit to their study design, infusion of 13C-lactate may 
have resulted in greater brain lactate availability. Therefore, the physiological 
context (blood lactate levels and its source, pH, etc.) may be different, which 
renders comparison with our data difficult.
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The strengths of our study include the ability to detect and quantify brain 
lactate concentrations in vivo in humans in a direct and optimized manner 
without the use of exogenous lactate and the three distinctly different groups 
of subjects, which enabled us to differentiate between the impact of diabetes 
and IAH. Although MR spectra were recorded continuously, 1H-MRS does not 
provide information about lactate fluxes or consumption, which is a limitation 
of our study. 
In conclusion, we found that brain lactate concentration dropped in response 
to acute hypoglycemia in patients with type 1 diabetes and IAH, but not in the 
other two groups. The fall in brain lactate is compatible with increased brain 
lactate oxidation during hypoglycemia in patients with IAH, and hence, the 
need for glucose by the brain and the consequent initiation of hypoglycemic 
symptoms are suppressed. Together our findings indicate that changes in brain 
lactate levels play an important role in the pathophysiology of IAH. 
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Supplementary Material
Supplementary Table 1. Counterregulatory hormone levels 
T1DM IAH T1DM NAH Healthy subjects
Euglycemia Hypoglycemia Euglycemia Hypoglycemia Euglycemia Hypoglycemia
Glucagon 
(pmol/L)
9.57 ± 2.61 22.71 ± 8.24† 11.29 ± 1.52 16.14 ± 1.82† 9.57 ± 1.45 58.43 ± 11.09*
Adrenaline 
(nmol/L)
0.30 ± 0.07 1.50 ± 0.25* 0.39 ± 0.05 2.18 ± 0.50* 0.22 ± 0.05 2.89 ± 0.52*
Noradrenaline 
(nmol/L)
1.29 ± 0.14 1.48 ± 0.18 1.01 ± 0.13 1.43 ± 0.14* 1.08 ± 0.11 1.60 ± 0.17*
Cortisol 
(µmol/L)
0.44 ± 0.10 0.62 ± 0.09* 0.54 ± 0.11 0.69 ± 0.12* 0.38 ± 0.06 0.64 ± 0.07*
hGH 
(mU/L)
3.80 ± 2.47 73.97 ± 11.62* 10.35 ± 6.01 55.97 ± 10.96* 2.64 ± 1.47 51.36 ± 4.86*
Data is presented as mean ± SEM. *P <0.05 for euglycemia versus hypoglycemia and †P <0.05 
versus healthy subjects
Plasma glucagon was measured by RIA, with a commercially available kit 
(Eurodiagnostica, Malmö, Sweden). Plasma growth hormone and cortisol were 
determined using a routine analysis method with an Electrochemiluminescent 
Immunoassay on a Modular Analytics E170 (Roche Diagnostics, GmbH, 
Manheim, Germany). Plasma adrenaline and noradrenaline were measured by 
HPLC combined with fluorometric detection (1). 
Reference
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Abstract 
Administration of lactate during hypoglycemia suppresses symptoms and 
counterregulatory responses, as seen in patients with type 1 diabetes and 
impaired awareness of hypoglycemia (IAH), presumably because lactate can 
substitute for glucose as a brain fuel. Here, we examined whether lactate 
administration, in a dose sufficient to impair awareness of hypoglycemia, 
affects brain lactate levels in patients with normal awareness of hypoglycemia 
(NAH). Patients with NAH (n = 6) underwent two euglycemic-hypoglycemic 
clamps (2.8 mmol/L), once with sodium lactate infusion (NAH w|lac) and once 
with saline infusion (NAH w|placebo). Results were compared to those obtained 
during lactate administration in patients with IAH (n = 7) (IAH w|lac). Brain 
lactate levels were determined continuously with J-difference editing 1H-MRS. 
During lactate infusion, symptom and adrenaline responses to hypoglycemia 
were considerably suppressed in NAH. Infusion of lactate increased brain lactate 
levels modestly, but comparably, in both groups (mean increase in NAH w|lac: 
0.12 ± 0.05 μmol/g and in IAH w|lac: 0.06 ± 0.04 μmol/g). The modest increase in 
brain lactate may suggest that the excess of lactate is immediately metabolized 
by the brain, which in turn may explain the suppressive effects of lactate on 
awareness of hypoglycemia observed in patients with NAH. 
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Introduction
Hypoglycemia is the most frequent side-effect of insulin therapy in patients 
with type 1 diabetes. When blood glucose levels drop, this normally initiates a 
hierarchically organized counterregulatory response, which includes release of 
counterregulatory hormones and the appearance of hypoglycemic symptoms. 
It has been demonstrated that the administration of lactate considerably 
diminishes symptomatic and hormonal responses to hypoglycemia and 
simultaneously mitigates cognitive dysfunction during hypoglycemia (1-3). 
These effects are suggested to be the result of lactate acting as an alternative 
fuel for the brain, when glucose supply is low (2). Clinically, the administration 
of lactate mimics the situation seen in patients with type 1 diabetes and 
impaired awareness of hypoglycemia (IAH). In IAH, the threshold for the onset 
of hypoglycemic symptoms and counterregulatory hormone responses is 
shifted to lower glucose values, which substantially increases the risk for severe 
hypoglycemia (4). 
Most studies that investigated the effects of lactate administration during 
hypoglycemia have focused on clinical effects (i.e., symptoms, hormonal 
responses and cognitive function), and did not examine physiological changes 
in the brain. Whether elevated plasma lactate levels lead to an accumulation 
of lactate in the brain is subject of debate. In a 13C-MR study, performed under 
euglycemic conditions in non-diabetic subjects, it was calculated that brain 
lactate levels and lactate oxidation increase almost linearly with the increase 
in plasma lactate levels (5). In contrast, other studies have reported direct 
oxidation of lactate after its transport across the blood-brain barrier, with 
limited accumulation in the brain (6; 7). Thus, lactate oxidation may even spare 
glucose as a cerebral fuel under euglycemic conditions (8). 
The only study that has investigated the effect of exogenous lactate on human 
brain lactate concentrations during hypoglycemia, calculated increased brain 
lactate concentrations without increased oxidation, in patients with type 1 
diabetes compared to healthy volunteers (9). Such elevated brain lactate levels 
are in line with studies that demonstrated an enhanced capacity to transport 
lactate into the brain in patients with diabetes and IAH (10; 11). The lack of 
a euglycemic control and a placebo arm (i.e. no lactate infusion) precluded 
conclusions about lactate accumulation during euglycemia versus hypoglycemia, 
or about the effect of lactate infusion on awareness of hypoglycemia. 
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In the current study, we aimed to show that infusion of lactate, in a dose 
sufficient to impair awareness of hypoglycemia in patients with type 1 diabetes 
and normal awareness of hypoglycemia (NAH), increases brain lactate levels. 
Secondly, we aimed to compare the effect of lactate administration on brain 
lactate levels during euglycemia and hypoglycemia between patients with NAH 
and those with IAH. 
Material and Methods
Participants
We enrolled seven patients with type 1 diabetes and NAH and seven patients 
with type 1 diabetes and IAH. The classification of awareness state was based on 
the Dutch modified version of the Cox questionnaire (12; 13). Patients with type 
1 diabetes were eligible if they were younger than 50 years, had an HbA1c below 
9.0% (75 mmol/mol) and were free from microvascular complications, except for 
background retinopathy. Exclusion criteria included contraindications to the MRI 
examination, a history of brain injury, epilepsy, liver or cardiovascular diseases, 
anxiety disorders, and the use of drugs other than insulin interfering with 
glucose metabolism. One participant with NAH moved too much during data 
acquisition, which hampered MR data quality and was consequently excluded 
from data analysis. The study was approved by and studied in accordance with 
the ethical standards of the institutional review board of the Radboud university 
medical center (Commissie Mensgebonden Onderzoek Arnhem-Nijmegen) 
and with the Helsinki declaration of 1975/1983. All participants gave written 
informed consent. 
Study protocol
Patients with NAH underwent two hyperinsulinemic euglycemic-hypoglycemic 
clamp studies, once with sodium lactate infusion (NAH w|lac) and once with 
saline infusion (NAH w|placebo), as described below. Experiments were carried 
out in a single-blind fashion (i.e. participants were blinded for the infusions) and 
in randomized order, scheduled at least two weeks apart. In female participants, 
both experiments were performed during equal phases of the menstrual cycle. 
Patients with IAH participated only in the sodium lactate infusion study arm 
(IAH w|lac). 
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Participants came to the research facility in the morning after an overnight fast, 
having abstained from smoking, alcohol and caffeine containing substances for 
24 hours prior to the experiment, and from strenuous exercise for at least two 
days before the experiment. In addition, participants were instructed to prevent 
hypoglycemia and to check their blood glucose levels regularly in the 24 hours 
before the experiment.
The brachial artery of the non-dominant arm was cannulated under local 
anesthesia (Xylocaine 2%) for frequent blood sampling. Blood was sampled 
every 5 min for the determination of plasma glucose and plasma lactate levels 
(Biosen C-line; EKF Diagnostics). An intravenous catheter was inserted in the 
antecubital vein of the contralateral arm for infusion of glucose 20% (Baxter 
B.V., Deerfield, IL), insulin (insulin aspart; Novo Nordisk, Bagsvaerd, Denmark) 
and sodium lactate (600 mmol/L; Spruyt Hillen, Ijsselstijn, The Netherlands and 
prepared by the Department of Pharmacy, Radboud university medical center, 
Nijmegen, The Netherlands) or normal saline (sodium chloride; 0.9%). 
After cannulations, a two-step hyperinsulinemic (60 mU/m2/min) euglycemic 
(5.0 mmol/L)-hypoglycemic (2.8 mmol/L) glucose clamp was initiated, and 
participants were placed in the MR scanner for baseline MR spectroscopy (MRS) 
data acquisition. At 15 min after the start of the euglycemic clamp, infusion of 
sodium lactate, or an equivalent volume of saline, was started while MRS data 
acquisition continued. We aimed for plasma lactate levels of approximately 
3.5 mmol/L and initially used a primed (50 µmol/kg/min for 15 min) continuous 
(30 µmol/kg/min) infusion of sodium lactate. Since achieved plasma lactate 
levels were slightly above target levels, the dose was lowered after the first two 
participants (both patients with NAH) to 40 µmol/kg/min for 15 min and 25 µmol/
kg/min for the remainder of the experiment. After ~25 min, blood glucose levels 
were allowed to drop to 2.8 mmol/L and were maintained at that level for 45 
min. Hypoglycemic symptoms were quantified with a validated questionnaire 
just prior to positioning the participant in the MR scanner and at the end of the 
stable hypoglycemic phase. Participants were asked to score from 0 to 6 (none to 
most severe) for each of 18 symptoms which included six autonomic symptoms, 
six neuroglycopenic symptoms, four general and two dummy symptoms. 
Additional blood samples were taken for determination of plasma insulin, pH, 
catecholamines, cortisol and growth hormone prior to the start of the sodium 
lactate or saline infusion (baseline), at the end of the euglycemic phase and at 
the end of the hypoglycemic phase. During hypoglycemia, counterregulatory 
hormone responses were determined at 15 min intervals (see Figure 1(a) for a 
90
Effect of lactate administration on brain lactate
schematic overview of the study protocol). After completing both experimental 
days, patients with NAH were asked on which day the hypoglycemic phase was 
most evident or felt more intense.
MRS protocol and data analysis
To measure brain lactate, we performed MR spectroscopy (MRS) on a 3T 
MR system (MAGNETOM Prisma, Siemens, Erlangen) using a body coil for 
excitation and a 12-channel receive-only head coil. A T1-weighted anatomical 
image (MPRAGE, echo time (TE) 2.4 ms, repetition time (TR) 1900 ms, and a 
field of view of 256x256 mm2) was acquired, and a 22.5 cm3 voxel for MRS data 
acquisition was placed in the periventricular and supraventricular region (Figure 
2(a)). Brain lactate levels were then determined continuously with an interleaved 
J-difference editing semi-LASER (14) spectroscopy sequence (TE 144 ms, TR 
3000 ms and 8 averages). J-difference editing was performed with frequency 
selective inversion MEGA pulses (15) (30 ms, 75 Hz bandwidth). Unsuppressed 
water spectra (TE 33 ms, TR 5000 ms and 8 averages) were acquired from the 
same voxel for signal quantification.
Additionally, at the end of euglycemia and at the end of hypoglycemia we 
acquired MR spectra without J-difference editing from the same voxel (sLASER, 
TE 33 ms, TR 3000 ms, 32 averages) to explore differences in other major brain 
metabolites.
The J-difference edited spectra were zerofilled from 1024 to 2048 data points 
and phase and frequency aligned (16). Motion-corrupted spectra, identified as 
a spectrum which deviated more than 2.6 standard deviations from the average 
spectrum of that participant (17), were discarded. Subsequently, spectra were 
subtracted pairwise. The difference spectra were averaged within participants 
across six different phases: baseline (i.e. before the start of lactate or placebo 
infusion), euglycemia, transition to hypoglycemia, and each 15 min block 
of hypoglycemia. From these final difference spectra, the cerebral lactate 
doublet at 1.3 ppm was quantified using the AMARES algorithm in jMRUI (18). 
Visual inspection of the difference spectra showed co-edited macromolecules 
at ~1.2 ppm, which were included in the fitting routine in AMARES to avoid 
overestimation of the lactate signal (19). The unsuppressed water signal 
was used as an internal standard for absolute quantification and we took the 
voxel composition and contribution of plasma lactate into account (20). We 
assumed a T2 of 240 ms for cerebral lactate (21), and a T2 of 80 ms and 110 ms 
for water in gray and white matter, respectively (22). The voxel composition 
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Figure 1: Study protocol, plasma glucose and plasma lactate levels. (a) Schematic overview of 
the study protocol. MRS measurements were performed continuously during euglycemia and 
hypoglycemia. Counterregulatory hormone responses (CH) and hypoglycemic symptoms (Symp) 
were determined at several time points during euglycemia and hypoglycemia, as indicated. (b) 
Time courses of plasma glucose and (c) plasma lactate levels. The dashed lines represent the start 
of the lactate or saline infusion (T = 0 min), the end of euglycemia, and the start of hypoglycemia. 
Open circles: patients with type 1 diabetes and NAH with saline infusion (NAH w|placebo); black 
circles: patients with type 1 diabetes and NAH with lactate infusion (NAH w|lac); black triangles: 
patients with type 1 diabetes and IAH with lactate infusion (IAH w|lac). 
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(i.e., percentages white matter, grey matter, and cerebrospinal fluid) was 
determined by segmenting the T1-weigthed anatomical images using SPM8 
(Wellcome Trust Centre for Neuroimaging, UCL, London, UK) and subsequently 
co-registering the segmented image with the MRS voxel location. As the voxel 
mainly contained white matter, we assumed a vessel volume of 2% (23; 24).
Figure 2: Example of difference spectra. (a) Typical location of the MRS voxel on a T1-weighted 
anatomical image. (b) Representative examples of difference spectra of one subject with NAH 
(NAH w|placebo and NAH w|lac) and one subject with IAH (IAH w|lac). The baseline difference 
spectra were recorded before the start of lactate or placebo infusion. Lac, lactate; MM, 
macromolecules.
Spectra acquired without J-difference editing were analyzed using the LCModel 
software (25). A basis set was created in Bruker TopSpin, and extended with 
a measured macromolecular baseline. Metabolites quantified with Cramér-
Rao lower bounds >50% were not included in the analysis (as recommended 
by the LCModel manual (26)). The unsuppressed water signal was used as a 
reference for absolute quantification of aspartate (Asp), total choline (tCho), 
total creatine (tCre), glutamate (Glu), glutamine (Gln), myo-inositol (mI), total 
N-acetylaspartate (tNAA), scyllo-inositol (scyllo) and taurine (Tau).
Analytical methods
Plasma insulin was determined by an in-house radioimmunoassay (RIA) (27). 
Plasma adrenaline and noradrenaline were analyzed by high-performance liquid 
chromatography combined with fluorometric detection (28). Plasma growth 
hormone and cortisol were determined using a routine analysis method with 
an Electrochemiluminescent immunoassay on a Modular Analytics E170 (Roche 
Baseline
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Transition to hypoglycemia
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Diagnostics GmbH, Mannheim, Germany). pH was measured by routine arterial 
blood gas analysis on the RapidPoint 500 (Siemens Nederland B.V., Den Haag, 
the Netherlands). 
Statistical analysis
Differences in means or medians within the NAH group (NAH w|lac vs. NAH 
w|placebo) and differences within groups between euglycemia and hypoglycemia 
were statistically tested with paired Student t tests or Wilcoxon signed rank 
tests when data were not normally distributed. Differences between NAH w|lac 
and IAH w|lac were compared with two-sided Student t tests or Mann-Whitney 
U tests, when appropriate. Serial data were compared between NAH w|lac 
and NAH w|placebo with a two-way repeated measures ANOVA. To analyze 
effects over time in patients with IAH, a one-way repeated measures ANOVA 
was performed. Since patients with IAH were only studied with lactate infusion, 
comparison to a placebo condition is not possible. Thus, to determine whether 
there was an effect of lactate infusion on brain lactate levels in patients with IAH, 
the area under the curve (AUC) of the baseline-corrected brain lactate levels 
was calculated by trapezoidal numerical integration, and a one-sample t test 
was performed. Differences in means at baseline across the three groups were 
analyzed by one-way ANOVA followed by pairwise Bonferroni post hoc tests. All 
data are expressed as mean ± SD unless otherwise indicated. Significance levels 
of Student t tests were not corrected for multiple testing. A P value < 0.05 was 
considered statistically significant. Statistical analyses were performed with 
IBM SPSS Statistics 20.
Results
Participants were well-matched for relevant clinical parameters, including 
age, duration of diabetes and glycemic control (Table 1). Upon arrival at the 
research facility, plasma glucose levels were slightly elevated with no significant 
differences between groups (9.4 ± 3.4, 7.4 ± 1.7 and 10.3 ± 4.9 mmol/L in NAH 
w|lac, NAH w|placebo and IAH w|lac, respectively). Stable euglycemia was 
achieved at a glucose level of 5.1 ± 0.2 mmol/L and stable hypoglycemia at 
2.8 ± 0.1 mmol/L, again with no differences between groups or intervention 
(Figure 1(b)). Plasma insulin levels during the clamp were similar for all groups 
and conditions (data not shown). Plasma lactate levels increased similarly in 
NAH w|lac and IAH w|lac by ~3.5-fold to 3.6 ± 0.5 mmol/L within ~15 min after 
starting the lactate infusion, and remained at that level for the remainder of 
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the experiment (Figure 1(c)). During the control experiment, i.e. when saline 
was infused, plasma lactate levels did not change significantly from baseline 
levels in NAH w|placebo (P = 0.58). Sodium lactate infusion caused the pH to 
increase in both groups to similar extent (from 7.41 ± 0.02 at baseline to 7.48 
± 0.01 at the end of hypoglycemia, P <0.001), whereas saline infusion did not 
affect the pH (7.40 ± 0.02 versus 7.42 ± 0.03). Glucose infusion rates (GIR) during 
hypoglycemia (Supplementary Figure 1) were not significantly different across 
groups and intervention (mean GIR: 3.1 ± 1.3, 2.7 ± 1.0 and 3.3 ± 1.3 mg/kg/min 
for NAH w|lac, NAH w|placebo, and IAH w|lac, respectively). 
Table 1: Participant characteristics
T1DM-NAH T1DM-IAH
Age (years) 28.0 ± 10.3 25.9 ± 6.0
Gender (M/F) 3/3 3/4
BMI (kg/m2) 24.0 ± 2.5 24.0 ± 2.1
Duration of T1DM (years) 11.6 ± 5.9 13.2 ± 5.8
HbA1c (mmol/mol [%])
54.7 ± 9.1 
[7.2 ± 0.8]
55.0 ± 5.0
[7.2 ± 0.5]
Self reported exercise (hours/week) 3.5 ± 0.9 2.9 ± 1.5 
Data are presented as number or means ± SD. M: male; F: female; BMI: body mass index; T1DM 
NAH: type 1 diabetes with normal awareness of hypoglycemia; T1DM IAH: type 1 diabetes with 
impaired awareness of hypoglycemia.
Table 2: Hypoglycemia-induced changes in symptom subscores (median [interquartile 
range])
T1DM-NAH T1DM-IAH
Placebo infusion Lactate infusion Lactate infusion
Autonomic 7.5 [2.5 ; 15.5] # 2.5 [-0.5 ; 4.5] 1 [-2 ; 3]
Neuroglycopenic 3.5 [0.75 ; 7] # 2 [-0.25 ; 3.5] 2 [-1 ; 2]
General 3.5 [3 ; 4.75]*,# 2 [0.75 ; 3.25] # 0 [-1 ; 1]
*P <0.05 vs. NAH w|lac, #P <0.05 vs euglycemia. T1DM NAH: type 1 diabetes with normal 
awareness of hypoglycemia; T1DM IAH: type 1 diabetes with impaired awareness of 
hypoglycemia. 
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Hypoglycemic symptoms and counterregulatory hormones
Lactate infusion clearly suppressed total symptom scores during hypoglycemia 
in patients with NAH, as compared to placebo (P = 0.03, Figure 3), and 
resembled symptom score of patients with IAH when lactate was infused 
(P = 0.18 between groups). Symptom subcategories are depicted in Table 2. Five 
out of six patients with NAH indicated that hypoglycemia was less severe on the 
day of the lactate infusion, one patient experienced no difference between both 
study days. In patients with IAH neither the total nor the subcategory symptom 
score changed significantly in response to hypoglycemia. Lactate infusion 
considerably suppressed the adrenaline response to hypoglycemia in patients 
with NAH as compared to placebo infusion (P < 0.01; Figure 4). Lactate infusion 
also suppressed cortisol and hGH responses to hypoglycemia in patients with 
NAH (both P <0.01), but did not significantly reduce noradrenaline responses 
(P = 0.18) (Supplementary Figure 2). 
Figure 3: Difference in symptom scores. Total symptoms scores in response to hypoglycemia 
in patients with type 1 diabetes and NAH with saline infusion (NAH w|placebo), patients with 
NAH with lactate infusion (NAH w|lac) and patients with IAH with lactate infusion (IAH w|lac). 
*P < 0.05, **P < 0.01.
Brain lactate
The tissue content of the MRS voxels was not different between groups and 
contained on average 64.1 ± 11.1% white matter, 32.8 ± 10.5% grey matter and 3.2 
± 1.6% cerebrospinal fluid. Baseline brain lactate levels (i.e., before the infusion 
of lactate or placebo) were similar across groups (0.58 ± 0.08, 0.64 ± 0.1 and 
IAH w|lacNAH w|lacNAH w|placebo
0
10
20
30
D
i
er
en
ce
 in
 s
ym
pt
om
 s
co
re
 (h
yp
og
ly
ce
m
ia
 - 
eu
gl
yc
em
ia
)
**
*
96
Effect of lactate administration on brain lactate
0.59 ± 0.05 µmol/g in NAH w|lac, NAH w|placebo, and IAH w|lac, respectively; 
P = 0.42). J-edited difference MR spectra, recorded during infusion of lactate, 
showed an increase of the lactate signal in the brain (Figure 2(b)). In patients 
with NAH, brain lactate levels were higher after infusion of lactate than after 
infusing saline (Figure 5(a); mean difference: 0.12 ± 0.05 µmol/g, equivalent to 
an increase of 20.7 ± 6.6%; P = 0.048). There was no significant interaction effect 
(time x infusion) or main effect of time. Although brain lactate levels in NAH 
w|lac tended to be elevated compared to placebo values at each time point, with 
post hoc analysis revealing that the difference in brain lactate levels reached 
significance during the final 30 min of the experiment.
Figure 4: Adrenaline responses. Adrenaline levels were determined at baseline (Bsln; i.e. 
before the infusion of lactate or saline), during euglycemia (Eu) and at 15-min intervals during 
hypoglycemia. Open circles: patients with type 1 diabetes and NAH with saline infusion (NAH 
w|placebo); black circles: patients with type 1 diabetes and NAH with lactate infusion (NAH 
w|lac); black triangles: patients with type 1 diabetes and IAH with lactate infusion (IAH w|lac).
In patients with IAH, lactate infusion resulted in an increase in brain lactate 
levels compared to baseline values (Figure 5(b); mean increase: 0.06 ± 0.04 
µmol/g, equivalent to an increase of 10.2 ± 4.2%; AUC of baseline-corrected 
brain lactate levels: 4.4 ± 4.3 µmol·min/g; P = 0.03). In these patients, brain 
lactate levels showed a trend towards an increase at each time point compared 
to baseline values, but the trend was stronger at the beginning of lactate 
infusion and disappeared at the end of hypoglycemia. When comparing brain 
lactate time curves with lactate infusion between patients with IAH and NAH, 
the increase in brain lactate levels in IAH w|lac seemed less pronounced 
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compared to NAH w|lac, but this difference was not statistically significant 
(P = 0.36). Brain lactate levels did not change in patients with NAH in response to 
hypoglycemia when saline was infused. Notably, there was no correlation, 
whatsoever, between brain lactate levels and plasma lactate levels (R2=0.01, 
P = 0.27).
Figure 5: Brain lactate levels. Mean (± SEM) baseline corrected and percentage change in 
cerebral lactate levels in (a) patients with type 1 diabetes and NAH (NAH w|placebo and NAH 
w|lac) and (b) patients with type 1 diabetes and IAH (IAH w|lac). The dashed line represent the 
start of hypoglycemia. P values indicate significance of time-series analysis.
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Other brain metabolites
Brain glutamate levels decreased in response to hypoglycemia in patients with 
NAH, both during lactate infusion (from 7.5 ± 0.7 to 7.1 ± 1.0 µmol/g, P = 0.03) and 
while infusing placebo (from 7.6 ± 0.6 to 7.0 ± 0.8 µmol/g, P = 0.01). In contrast, 
hypoglycemia did not change brain glutamate levels in patients with IAH (8.0 ± 
0.7 versus 7.8 ± 0.9 µmol/g, P = 0.59). Additionally, we found an increase in myo-
inositol in IAH w|lac and a slight decrease in myo-inositol in NAH w|lac. None of 
the other major brain metabolites (Asp, tCho, tCre, Gln, tNAA, scyollo and Tau) 
was significantly altered by the hypoglycemic condition in any of the groups 
(Supplementary Figure 3). 
Discussion
The results of the present study confirm that lactate infusion considerably 
suppresses counterregulatory hormone responses to and symptomatic 
awareness of hypoglycemia in patients with NAH. While lactate infusion did 
increase brain lactate content, the increase was modest and not clearly different 
between patients with NAH and IAH. The lack of pronounced brain lactate 
accumulation suggests that the excess of lactate is immediately oxidized by 
the brain which may explain the suppressive effects of lactate on awareness of 
hypoglycemia in patients with NAH. 
Our results are in line with those of several other studies reporting that elevated 
plasma lactate levels result in an increase in cerebral lactate transport and oxidation, 
preventing substantial accumulation of brain lactate upon infusion (6-8). However, 
an earlier study reported fivefold higher brain lactate concentrations in the brain 
of patients with type 1 diabetes who were exposed to frequent hypoglycemia, 
as compared to healthy controls, when 13C-labelled lactate was administered 
during hypoglycemia (9). Another 13C study that used a similar methodology in 
healthy volunteers, found a linear correlation between plasma and brain lactate 
concentrations during euglycemia (5). According to these calculations, brain 
lactate levels should have been as high as ~2 µmol/g rather than ~0.7 µmol/g with 
the plasma lactate levels of 3.5 mmol/L that we achieved. It should be noted that 
13C-MRS calculates brain lactate levels indirectly. These calculations require a 
number of critical assumptions, which may have resulted in an overestimation of 
brain lactate levels. Here we used 1H-MRS to measure the signal intensity of brain 
lactate, which is directly proportional to the tissue concentration of lactate, thus 
providing a direct measurement of brain lactate levels. 
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Lactate is taken up by the brain through proton-linked facilitated diffusion by 
monocarboxylate transporters (MCTs), and its uptake is driven by a concentration 
gradient from blood to brain and further enhanced by neuronal activation (29; 
30). Therefore, it is likely that elevated plasma lactate levels result in an increased 
uptake of lactate by the brain. Furthermore, it has repeatedly been shown that 
lactate can serve as a metabolic substrate for the brain (5; 7-9; 31), especially 
when plasma lactate levels are elevated (7; 32; 33). Lactate taken up by the brain 
needs to be converted to pyruvate before it enters the citric acid cycle, a process 
catalyzed by lactate dehydrogenase (LDH). Even relatively small increases in 
local brain lactate concentration can drive lactate utilization by shifting the LDH 
reaction to pyruvate formation and to subsequent oxidation (34). As we found 
only a small increase in brain lactate levels, we posit that lactate taken up by the 
brain is largely oxidized, both during euglycemia and hypoglycemia. Increased 
brain lactate concentrations during hypoglycemia are likely responsible for 
the suppressive effects on counterregulatory responses in patients with NAH, 
presumably because of increased brain lactate oxidation. Alternatively, lactate 
may exert its suppressive effects via alterations in cerebral blood flow, redox 
signaling or neuronal activity (35; 36). 
Since brain lactate transport capacity is reported to be upregulated in patients 
with IAH (10; 11), one can expect higher brain lactate levels in patients with 
IAH than in patients with NAH. Brain lactate concentrations are the result of a 
balance between its uptake, production, oxidation and export. The absence of a 
difference in brain lactate concentrations between NAH w|lac and IAH w|lac at 
the currently elevated plasma lactate levels either indicates comparable brain 
lactate uptake in both groups, or upregulation of both lactate uptake and lactate 
oxidation in patients with IAH. Without the use of exogenous lactate infusion, 
we previously showed that brain lactate levels fall in response to hypoglycemia 
in patients with IAH, but not in those with NAH (37). This may indeed indicate 
upregulated capacity to oxidize lactate in patients with IAH. Analogously, the 
trend towards increased brain lactate levels in the current study disappeared 
at the end of hypoglycemia in patients with IAH, again hinting at upregulated 
capacity to oxidize lactate. When we used intense exercise to raise endogenous 
plasma lactate to much higher levels, we observed higher brain lactate levels 
in patients with IAH than in those with NAH (38). Cerebral lactate uptake is 
not only dependent on plasma lactate concentrations but also on pH levels in 
plasma and in brain (30). The lactate-induced increase in plasma pH value (i.e., 
a decrease in H+ concentration) observed in the current study may have limited 
brain lactate uptake in comparison to an exercise-induced decrease in plasma 
100
Effect of lactate administration on brain lactate
pH. However, these effects are generally small when pH values remain within 
the physiological range. 
We found brain glutamate levels to fall in response to hypoglycemia in patients 
with NAH, which is in line with previous observations (39) and has been attributed 
to glutamate oxidation (39-41). This decrease in brain glutamate was also present 
in patients with NAH when lactate was infused, which suppressed adrenaline 
responses to hypoglycemia. This is in line with the absence of a relation between 
the hypoglycemia-induced decrease in glutamate and the adrenaline response 
to hypoglycemia, as reported by Terpstra et al. (39), and may indicate that even 
though lactate is abundantly available, it is not sufficient to compensate for the 
decrease in glucose supply to the brain in patients with NAH, or alternatively, 
that lactate oxidation is already saturated in these patients. In contrast, but 
again in line with previous data without lactate infusion (39), brain glutamate 
did not decrease in patients with IAH, possibly because of their greater capacity 
to use (the excess of) lactate, thus eliminating the need to oxidize glutamate. 
Our study has a small sample size, though based on power calculations. 
However, the study population was homogenous in terms of age, HbA1c and 
diabetes duration, and plasma glucose and lactate levels during the clamps 
were stable and almost identical in all groups. The homogeneity of the study 
population enables efficient comparison, but on the other hand, may limit the 
generalisability of the results. Importantly, to quantify the cerebral lactate 
content, we took the contribution of plasma lactate (ranging from ~0.8 mmol/L 
to ~3.5 mmol/L) to the MR signal of brain lactate into account. Since the voxel 
consisted of mainly white matter we estimated a 2% vessel volume, based on 
literature (23; 24). Deviations from this estimation (within the physiological 
range) may affect the magnitude of the outcome, but will not affect the main 
conclusion of the study. 
In conclusion, we show that intravenous lactate administration reduces 
awareness of hypoglycemia and translates into a small increase in brain lactate 
levels, with no differences between patients with NAH and IAH. The rather limited 
increase in brain lactate suggests that the excess of lactate is immediately used 
by the brain both under euglycemic and hypoglycemic conditions. An increase 
in brain lactate oxidation during hypoglycemia may explain the suppressive 
effects of lactate on awareness of hypoglycemia observed in patients with NAH.
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Fig S1: Glucose infusion rates during hypoglycemia (GIR). Black triangles: patients with type 
1 diabetes and IAH with lactate infusion (IAH w|lac); black circles: T1DM NAH with lactate 
infusion (NAH w|lac); Open circles: T1DM NAH with saline infusion (NAH w|placebo)
Fig S2: Counterregulatory hormone 
responses to hypoglycemia. (A) 
Noradrenaline, (B) cortisol, and (C) 
growth hormone (hGH) responses 
to hypoglycemia. Black triangles: 
patients with type 1 diabetes and 
IAH with lactate infusion (IAH w|lac); 
black circles: T1DM NAH with lactate 
infusion (NAH w|lac); Open circles: 
T1DM NAH with saline infusion (NAH 
w|placebo). 
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Fig S3: Concentrations of major brain metabolites quantified during euglycemia (white bars) 
and hypoglycemia (black bars). P values indicate significant differences for euglycemia vs. 
hypoglycemia within a group. Asp, aspartate; tCho, total choline; tCre, total creatine; Glu, 
glutamate; Gln, glutamine; mI, myo-inositol; tNAA, total N-acetylaspartate; scyllo, scyllo-
inositol; Tau, taurine
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Effect of HIIT on brain lactate during hypoglycemia
Abstract 
Since altered brain lactate handling has been implicated in the development 
of impaired awareness of hypoglycemia (IAH) in type 1 diabetes, the capacity 
to transport lactate into the brain during hypoglycemia may be relevant in its 
pathogenesis. High-intensity interval training (HIIT) increases plasma lactate 
levels. We compared the effect of HIIT-induced hyperlacticacidemia on brain 
lactate during hypoglycemia between 1) patients with type 1 diabetes and IAH, 
2) patients with type 1 diabetes and normal awareness of hypoglycemia (NAH), 
and 3) healthy participants without diabetes (n = 6 per group). All participants 
underwent a hypoglycemic (2.8 mmol/L) clamp after performing a bout of HIIT 
on a cycle ergometer. Before HIIT (baseline) and during hypoglycemia, brain 
lactate levels were determined continuously with J-difference-editing 1H-MRS, 
and time curves were analyzed using nonlinear mixed effects modeling. At the 
beginning of hypoglycemia (after HIIT), brain lactate levels were elevated in all 
groups, but most pronounced in patients with IAH. During hypoglycemia, brain 
lactate decreased ~30% below baseline in patients with IAH but returned to 
baseline levels and remained there in the other two groups. Our results support 
the concept of enhanced lactate transport as well as increased lactate oxidation 
in patients with type 1 diabetes and IAH. 
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Introduction
Impaired awareness of hypoglycemia (IAH) affects 25-30% of patients with type 1 
diabetes, is characterized by the suppression of symptoms during hypoglycemia 
(1; 2), and considerably increases the risk for severe hypoglycemia (1). IAH results 
from habituation to prior hypoglycemia (3), but the underlying mediators have 
yet to be fully revealed. 
One likely mediator is brain lactate (4-6). We have previously shown that brain 
lactate levels fall in response to hypoglycemia in patients with type 1 diabetes 
and IAH, whereas lactate levels remain unaltered in patients with normal 
awareness of hypoglycemia (NAH) and in healthy participants (6). This fall in 
brain lactate likely reflects increased cerebral lactate oxidation, which may 
preserve brain metabolism and interferes with the brain’s capacity to detect 
hypoglycemia. 
This concept is supported by the finding that intravenous administration 
of lactate has brain glucose-sparing effects under euglycemic conditions 
(7), suppresses counterregulatory hormone and symptom responses to 
hypoglycemia, and preserves cognitive function (8; 9). We observed similar, 
albeit less pronounced, effects when plasma lactate levels were endogenously 
raised during hypoglycemia after a bout of high-intensity interval training (HIIT) 
in patients with type 1 diabetes and NAH (10).
Using isotopically enriched lactate infusions, de Feyter et al. (5) observed 
increased brain lactate concentrations during hypoglycemia in patients with 
IAH compared with volunteers without diabetes but no increase in cerebral 
lactate oxidation. This finding contrasts with observations that endogenous 
hyperlacticacidemia after exercise enhances both brain lactate uptake (7; 11; 
12) and oxidation (7; 13; 14), at least under euglycemic conditions. The effect 
of endogenously elevated plasma lactate levels on brain lactate concentrations 
during hypoglycemia is currently not known. Therefore, we used a single bout 
of HIIT to raise endogenous plasma lactate levels, and used 1H-MRS to assess 
cerebral lactate levels during subsequent hypoglycemia in patients with type 1 
diabetes with and without IAH and healthy participants.
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Research Design and Methods
Participants
We enrolled six patients with type 1 diabetes and IAH, six patients with type 1 
diabetes and NAH, and six healthy participants. Patient assignment was initially 
based on the Dutch modified version of the Cox questionnaire (15), but one patient 
initially classified as having IAH switched groups because of intact hormonal and 
symptomatic responses to hypoglycemia. Patients with type 1 diabetes were 
excluded from participation if their HbA1c levels exceeded 75 mmol/mol (9.0%) or if 
they had microvascular complications, except for background retinopathy. Other 
exclusion criteria were as follows: age >40 years, BMI >30 kg/m2, cardiopulmonary 
disease, contraindications for MRI examination, and a history of brain injury. The 
study was approved by the institutional review board of the Radboud university 
medical center, and all participants gave written informed consent. 
Study protocol
All participants presented in the morning (8:00 A.M.) after an overnight fast, 
having abstained from caffeine, alcohol and smoking for 24 h and from strenuous 
exercise for 2 days. Patients with type 1 diabetes were instructed to check their 
plasma glucose levels regularly in the 24 h before the experimental day to prevent 
hypoglycemia and to omit their morning prandial insulin dose. An intravenous 
catheter was inserted in the antecubital vein to administer insulin (insulin aspart; 
Novo Nordisk, Bagsvaerd, Denmark) and glucose 20% (Baxter, Deerfield, IL). The 
brachial artery of the contralateral arm was cannulated under local anesthesia for 
frequent blood sampling to determine plasma glucose and plasma lactate levels 
every 5 minutes (Biosen C-line; EKF Diagnostics).
After cannulations, a hyperinsulinemic (60 mU/m2/min)-euglycemic (5.0 mmol/L) 
glucose clamp was initiated, and baseline magnetic resonance (MR) measurements 
were acquired. Participants were subsequently taken out of the scanner and 
performed a HIIT session on a cycle ergometer, consisting of three 30-s all-out 
sprints interspersed with 4 min of active recovery, as described previously (10). 
After the HIIT session, participants were placed in the MR scanner at the earliest 
opportunity, and meanwhile plasma glucose levels were gradually decreased to 2.8 
mmol/L and maintained there for 50-60 min.
Before the HIIT session and at the end of hypoglycemia, participants completed an 
18-item questionnaire in which hypoglycemic symptoms were scored from 0 (none) 
to 6 (most severe), and blood samples were drawn to determine counterregulatory 
hormone responses and insulin levels (see Fig. 1A for a schematic overview of the 
study protocol).
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MRS protocol and data analysis
MR data were acquired using a 3T MR system (TIM Magnetom Trio; Siemens, 
Erlangen, Germany). Each MR session, i.e., at baseline and postexercise, started 
with the acquisition of an anatomical image (T1-weighted MPRAGE, 256 x 256 
mm² field of view, 256 slices) for voxel localization and for later voxel content 
determination. The 20 x 45 x 25 mm voxel was placed in the periventricular 
region of the brain (Fig. 2A). During both MR sessions, brain lactate levels were 
determined continuously with a time resolution of ~4 min, using a J-difference-
editing MEGA-semi-LASER sequence (TE 144 ms, TR 3,000 ms, and 32 averages), 
as described previously (6). 
The J-difference-edited spectra were zero-filled from 1,024 to 2,048 points and 
Fourier transformed. Thereafter, spectra were phase and frequency aligned (16), 
subtracted pairwise, and apodized in the time-domain with a 5-Hz Lorentzian. A 
three-point moving average filter over time was applied. The lactate doublets at 
1.3 ppm in the final difference spectra were fitted with the AMARES algorithm in 
jMRUI (17). Cerebral lactate was quantified using the unsuppressed water signal 
as a reference, taking voxel composition, differences in T2 relaxation, and the 
contribution of plasma lactate into account, assuming a vessel volume in the 
(mainly white matter voxel) of 2% (18). Baseline cerebral lactate levels (before 
HIIT) were averaged; cerebral lactate levels acquired after HIIT were analyzed 
over time.
Analytical methods
Plasma insulin was determined by an in-house radioimmunoassay (RIA) 
(19) and plasma glucagon by a commercially available RIA (Eurdiagnostica, 
Malmö, Sweden). Plasma adrenaline and noradrenaline were analyzed by high-
performance liquid chromatography combined with fluorometric detection (20). 
Statistical analysis
Within-group differences were compared with two-sided Student t tests 
or Wilcoxon signed rank test for nonparametric data, and between-group 
differences with ANOVA followed by Bonferroni post hoc tests or with the 
Kruskal-Wallis test and post hoc Mann-Whitney U tests. The change in brain 
lactate from baseline to the start of hypoglycemia (ΔLacstartHypo, the difference 
in steady state lactate levels between hypoglycemia and baseline (ΔLacPlateau), 
and the decay rate (k) were estimated per group using a nonlinear mixed effects 
(NLME) model. The following exponential decay function was fitted to the data:
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Lac(t) = (ΔLacstartHypo − ΔLacPlateau)e
−kt + ΔLacPlateau eq.1
Differences in model-parameters (i.e., ΔLacstartHypo, ΔLacPlateau and (k) were 
compared between groups and within groups. All data are expressed as mean 
± SD, unless otherwise stated. P < 0.05 was considered statistically significant. 
Statistical analyses were performed in SAS 9.2 (NLMIXED procedure) or with 
IBM SPSS Statistics 20. 
Results
The study participants were well matched for relevant parameters (Table 1). 
Upon arrival, plasma glucose levels were elevated to a similar extent in both 
patient groups (7.9 ± 3.1 and 9.5 ± 2.2 mmol/L for type 1 diabetes and IAH and 
type 1 diabetes and NAH, respectively). Insulin levels at baseline and during 
hypoglycemia did not differ between groups (data not shown). During the 
clamp, plasma glucose levels were maintained at 5.1 ± 0.1 mmol/L and 2.8 ± 
0.1 mmol/L, without differences between study groups (Fig. 1B). Plasma lactate 
levels for the three groups were comparable at baseline and increased markedly 
and to a similar extent in response to HIIT. During hypoglycemia, plasma lactate 
fell gradually but remained above baseline levels (Fig. 1C).
115
5
Figure 1: Study protocol and plasma glucose and plasma lactate levels. A: Schematic overview 
of the study protocol. MRS measurements were performed prior to HIIT (baseline) and during 
hypoglycemia. Counterregulatory hormone responses and hypoglycemic symptom score were 
assessed prior to the HIIT session and at the end of hypoglycemia. Time courses of plasma 
glucose (B) and plasma lactate (C) levels. The HIIT session is indicated by the gray area. The 
dashed lines represent the beginning and the end of the hypoglycemic phase. Open circles, 
patients with type 1 diabetes (T1DM) and IAH; open triangles, patients with T1DM and NAH; 
open squares, healthy participants.
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Figure 2: Example of difference spectra. A: Typical location of the MRS voxel, indicated by the 
white rectangles, (20 x 45 x 25 mm) on a T1-weighted anatomical image of one subject with 
type 1 diabetes and IAH. B: Representative difference spectra (i.e., MEGA on – MEGA off) of one 
subject with type 1 diabetes and IAH, depicting the lactate doublet at 1.3 ppm over time. The 
baseline difference spectra was recorded before HIIT. After HIIT, hypoglycemia was induced 
and brain lactate concentrations were measured continuously.
Table 1: Participant characteristics
T1DM IAH T1DM NAH Healthy participants
Age (years) 23.5 ± 6.1 21.5 ± 2.5 23.8 ± 3.0
Sex (male/female) 3/3 3/3 3/3
BMI (kg/m2) 22.8 ± 1.2 22.7 ± 2.4 23.5 ± 1.6
Duration of T1DM (years) 12.0 ± 8.8 10.2 ± 4.8 -
HbA1c (mmol/mol [%]) 51.7 ± 10.0 [6.9 ± 0.91] 60.7 ± 8.1 [7.7 ± 0.74] -
Self reported exercise (h/week) 4.9 ± 3.0 4.8 ± 3.1 3.3 ± 2.0
Data are presented as number or mean ±  SD. T1DM, type 1 diabetes.  
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Figure 3: Brain lactate levels. Mean cerebral lactate levels before (baseline) and after HIIT 
during hypoglycemia. For illustration purpose only, mean (± SEM) brain lactate levels after the 
HIIT training were calculated on a 4 minute time-interval grid (±SD). Dashed lines represent the 
NLME model fit. Open circles, patients with type 1 diabetes (T1DM) and IAH; open triangles, 
patients with T1DM and NAH; open squares, healthy participants.
As expected, total symptom scores did not change in response to hypoglycemia 
in patients with IAH (mean increase: 0.67 ± 1.26) but increased considerably in 
patients with NAH and in healthy participants (14.83 ± 3.61 and 10.83 ± 2.06, 
respectively). The plasma adrenaline response to hypoglycemia was reduced in 
patients with IAH compared with patients with NAH and healthy participants 
(Supplementary Table 1). 
Baseline brain lactate levels were similar across the three groups (Fig. 3). The first 
MR spectra were acquired on average 38.5 ± 5.5 min after the HIIT session, when 
plasma glucose levels were <3.6 mmol/L. Figure 2B shows a typical example of 
difference spectra with the evolution of the lactate doublet over time. According 
to the NLME model, brain lactate levels at the beginning of hypoglycemia were 
elevated compared to baseline levels (ΔLacstartHypo in Eq. 1) by 0.20 ± 0.05 µmol/g (P 
= 0.01) in patients with IAH, by 0.11 ± 0.05 µmol/g (P = 0.03) in patients with NAH, 
and by 0.06 ± 0.02 (P = 0.01) in healthy participants. The increase in brain lactate 
after HIIT was higher in patients with IAH compared with healthy participants 
(P = 0.04). During hypoglycemia, brain lactate levels returned to and remained 
at baseline levels in patients with NAH and healthy participants (0.00 ± 0.04 
and -0.07 ± 0.04 µmol/g), whereas a further -0.20 ± 0.06 µmol/g decrease below 
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baseline (P = 0.02) (Fig. 3) was observed in patients with type 1 diabetes and IAH 
during hypoglycemia ( ΔLacPlateau  in Eq. 1). There was no difference in the estimated 
exponential decay rate of brain lactate between groups (P = 0.52). 
Discussion
The current study shows that endogenously raised plasma lactate levels by a 
single bout of HIIT result in increased brain lactate concentrations at the start of 
hypoglycemia. This increase is most pronounced in patients with IAH, and this 
was the only group where brain lactate levels decreased below baseline values at 
the end of the hypoglycemic episode. These findings support altered brain lactate 
handling in IAH. 
The HIIT-induced increase in brain lactate content is in line with previous studies 
using 1H-MRS in healthy participants in response to endogenously raised plasma 
lactate levels by vigorous exercise, albeit under euglycemic conditions (11; 12). 
Cerebral lactate uptake is driven by a concentration gradient from blood to 
brain. Interestingly, although plasma lactate levels were similar between groups, 
we found that the increase in brain lactate concentrations after HIIT was most 
pronounced in patients with type 1 diabetes and IAH, which supports enhanced 
brain lactate transport capacity in patients with IAH (21; 22). This difference is most 
visible at the beginning of hypoglycemia, when plasma lactate levels are highest. 
During hypoglycemia, we showed that brain lactate levels returned to baseline 
values in healthy volunteers and patients with NAH but dropped to levels below 
baseline in patients with IAH, which could not be explained by differences in 
plasma lactate levels between the study groups. This decrease matches the 
hypoglycemia-induced fall in brain lactate in patients with IAH that we observed 
in a previous study, in which plasma lactate levels were not elevated (6), and may 
reflect enhanced brain lactate oxidation. Previous studies have found that lactate 
contributes substantially to cerebral energy metabolism, when its availability is 
high (7; 23-25). Increased lactate oxidation may protect the brain by maintaining 
metabolism when glucose supply is low, while at the same time it could impede the 
brain’s capacity for hypoglycemia sensing. This is in line with the observation that 
a prior bout of HIIT attenuated awareness of and cognitive deterioration during 
subsequent hypoglycemia, particularly in patients with NAH (10), which may have 
been mediated by brain lactate.
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HIIT not only increases plasma lactate levels but also has an impact on (stress) 
hormones, brain activation, and physical parameters, which may have influenced 
our results. Because the HIIT session was performed outside the MR system, we 
were unable to capture early changes in brain lactate after exercise. Brain lactate 
levels may have been higher in the time gap between HIIT and the post-HIIT scans. 
All participants were young, healthy, and fit, which should be kept in mind when 
interpreting the results. A strength of our study is the inclusion of three clinically 
distinct, but well-matched, groups of participants, allowing the differentiation 
between the effect of type 1 diabetes and the effect of IAH. Furthermore, plasma 
glucose and lactate levels were almost identical among the groups.
In conclusion, we found that brain lactate concentrations increase after a 
bout of HIIT, particularly in patients with diabetes and IAH. In addition, brain 
lactate levels fall below baseline during the subsequent hypoglycemic period 
in patients with IAH but not in those with NAH or in healthy participants. 
These results support upregulation of lactate transport capacity and increased 
cerebral lactate oxidation during hypoglycemia in patients with IAH. Both 
adaptations in cerebral lactate handling may contribute to IAH by lactate 
serving as an alternative nonglucose fuel for the brain during hypoglycemia.
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Supplementary material
Table S1: Hypoglycemia-induced changes in symptom scores and counterregulatory 
hormones
T1DM IAH T1DM NAH Healthy participants
Total symptom scores 0.67 ± 1.26 14.83 ± 3.61*# 10.83 ± 2.06*#
Adrenaline (nmol/L) 0.60 ± 0.11* 2.81 ± 1.22*# 2.47 ± 0.33*#
Noradrenaline (nmol/L) 0.41 ± 0.17 0.71 ± 0.34 0.26 ± 0.08
Glucagon (pmol/L) -1.70 ± 1.00 2.68 ± 1.43 29.02 ± 7.28*# +
Data are presented as mean (± SEM). * P < 0.05 for euglycemia vs. hypoglycemia; # P < 0.05 vs. 
T1DM IAH; + P < 0.05 vs. T1DM NAH.
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Abstract
High-intensity interval training (HIIT) has gained increasing popularity in 
patients with diabetes. HIIT acutely increases plasma lactate levels. This may 
be important, since administration of lactate during hypoglycemia suppresses 
symptoms and counterregulation while preserving cognitive function. We tested 
the hypothesis that, in the short term, HIIT reduces awareness of hypoglycemia 
and attenuates hypoglycemia-induced cognitive dysfunction. In a randomized 
crossover trial, patients with type 1 diabetes and normal awareness of 
hypoglycemia (NAH), patients with impaired awareness of hypoglycemia (IAH), 
and healthy participants (n = 10 per group) underwent a hyperinsulinemic-
hypoglycemic (2.6 mmol/L) clamp, either after a HIIT session or after seated 
rest. Compared with rest, HIIT reduced symptoms of hypoglycemia in patients 
with NAH but not in healthy participants or patients with IAH. HIIT attenuated 
hypoglycemia-induced cognitive dysfunction, which was mainly driven by 
changes in the NAH subgroup. HIIT suppressed cortisol and growth hormone 
responses, but not catecholamine responses to hypoglycemia. The present 
findings demonstrate that a single HIIT session rapidly reduces awareness of 
subsequent hypoglycemia in patients with type 1 diabetes and NAH, but does 
not in patients with IAH, and attenuates hypoglycemia-induced cognitive 
dysfunction. The role of exercise-induced lactate in mediating these effects, 
potentially serving as an alternative fuel for the brain, should be further explored.
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Introduction
Regular exercise is recommended for patients with type 1 diabetes, as it 
improves physical fitness, insulin sensitivity, and general well-being, while 
reducing cardiovascular risk factors (1; 2). High-intensity interval training (HIIT) 
is a relatively new training modality that consists of repeated, brief bouts of 
exercise at high-intensity (i.e. ≥85% peak oxygen uptake), interspersed by 
periods of rest or low-intensity exercise (3; 4). HIIT is becoming increasingly 
popular because it has similar or superior training effects compared with 
endurance training, despite having a lower time commitment (3). In patients 
with type 1 diabetes, high-intensity (interval) training has been reported to 
exert a short-term glucose-stabilizing effect when compared with endurance 
exercise (5-7). Notwithstanding this short-term effect, the risk of late nocturnal 
hypoglycemia after HIIT may be increased (8). It is currently unknown whether 
HIIT affects awareness of subsequent hypoglycemic episodes. 
Performance of HIIT markedly increases plasma lactate levels (9). This is highly 
relevant since previous studies have demonstrated that the administration 
of lactate during hypoglycemia suppresses counterregulatory hormone 
responses and hypoglycemic symptoms (10-13). In addition, the infusion of 
lactate attenuates the decline in cognitive function that normally occurs during 
hypoglycemia (10-13). These effects are presumed to result from increased 
use of lactate by the brain (12; 13), which can substitute for glucose and act as 
an alternative energy source under hypoglycemic conditions. Elevated levels 
of endogenous lactate induced by HIIT may thus be expected to have similar 
effects as exogenous lactate and to suppress normal physiological responses to 
subsequent hypoglycemia (i.e., reduced counterregulatory hormones, reduced 
hypoglycemic symptoms and attenuated cognitive dysfunction).
Such a suppressive effect would be particularly worrisome for the ~25% of 
patients with type 1 diabetes and impaired awareness of hypoglycemia (IAH) 
who already have compromised symptomatic and hormonal responses to 
hypoglycemia (14) and are at high risk of severe hypoglycemia (15). In these 
patients, high levels of endogenous lactate after HIIT might even further impair 
counterregulation. Therefore, the aim of the present study was to investigate 
the effect of HIIT on hypoglycemic symptoms, counterregulatory hormone 
responses, and cognitive function during subsequent hypoglycemia in patients 
with type 1 diabetes and normal awareness of hypoglycemia (NAH) and IAH but 
also in healthy participants. 
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Research design and methods
Participants
We recruited 10 patients without diabetes, 10 patients with type 1 diabetes and 
NAH, and 10 patients with type 1 diabetes and IAH. Patients with type 1 diabetes 
were eligible if they had an HbA1c level <9.0% (75 mmol/mol) and were free 
from macrovascular and microvascular  complications, except for background 
retinopathy. Exclusion criteria included a history of cardiopulmonary disease, 
anxiety disorders, brain injury, age > 40 years, and the use of drugs other than 
insulin interfering with glucose metabolism. Awareness state was first assessed 
by a Dutch version of the Clarke questionnaire (16; 17), but final stratification 
was based on adrenaline and symptomatic responses to the hypoglycemic 
clamps. Eighteen out of 20 patients were rightly characterized as having IAH 
or NAH by the Clarke questionnaire. One patient initially classified as having 
intact awareness (i.e., NAH) had very low adrenaline and symptom responses to 
the hypoglycemic clamp, whereas another patient, presumably with impaired 
awareness, displayed normal responses to the clamp. The latter two patients 
switched groups. All participants were recreationally active. The institutional 
review board of the Radboud university medical center approved the study, and 
all study participants gave written informed consent before participation.
Experimental design
In a random order, all enrolled participants underwent two hyperinsulinemic-
hypoglycemic glucose clamp (nadir, 2.6 mmol/L) experiments, one that was 
preceded by a HIIT session and one that was preceded by seated rest (duration 
equivalent of HIIT session). The two experiments were scheduled at least two 
weeks apart, except in the women participating, in whom experiments were 
conducted during similar phases of the menstrual cycle. 
Participants presented between 8.00 and 8.30 A.M. at the clinical research 
facility after an overnight fast, having abstained from caffeine, alcohol and 
smoking for 24h and from strenuous exercise for two days. Participants with 
diabetes received specific instructions to avoid (nocturnal) hypoglycemia the 
day before the clamp. Experiments were rescheduled in cases of hypoglycemia 
in the 24 h before the clamp. Upon arrival, intravenous cannulae were inserted 
into the antecubital veins of both forearms. One forearm was placed in a heated 
box (55°C), so that arterialized venous blood could be obtained for frequent 
blood sampling. The cannula in the contralateral arm was used for infusion 
of glucose 20% (Baxter B.V., Deerfield, IL) and insulin (insulin aspart; Novo 
Nordisk, Bagsvaerd, Denmark). Baseline plasma glucose and lactate levels were 
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determined (Biosen C-Line, EKF Diagnostics, Cardiff, U.K.), and hyperglycemia 
in patients with diabetes was corrected as needed with a small bolus of insulin. 
Subsequently, a two-step hyperinsulinemic (60 mU/m2/min) euglycemic (5.0 
mmol/L)-hypoglycemic (2.6mmol/L) glucose clamp was initiated. Plasma 
glucose and lactate values were determined every five minutes. Blood samples 
for measurement of catecholamines and cortisol were taken at euglycemia, 5 min 
after exercise, and at 20-min intervals during hypoglycemia. Insulin, glucagon, 
growth hormone (GH) and pH were measured at euglycemia, after exercise 
(only GH and pH) and at the end of hypoglycemia. Under clamped, euglycemic 
conditions, participants performed HIIT or rested for the same period of time. 
Subsequently, plasma glucose levels were allowed to fall to 2.6 mmol/L over ~35 
min and were maintained there for another 60 min. 
Exercise protocol
The HIIT session was performed on a cycle ergometer (Lode Corival; Procare, 
Groningen, The Netherlands) and had a total duration of ~15 min. Prior to the 
start, a short 10-s test sprint was performed to determine optimal resistance of 
the ergometer (equaling ~0.1 kg/kg body mass, depending on the participant’s 
physical activity level and cycling experience). The exercise protocol consisted 
of a 4-min warm-up at 50 W, followed by three 30-s all-out sprints during which 
participants had to cycle as fast as possible, interspersed with 4 min active 
recovery (at 50W). The resistance applied during the all-out sprints was adjusted 
depending on the perceived intensity of the previous sprint, measured with the 
Borg scale (18), aiming at a Borg score of >15 (running from 6, indicating no 
exertion, to 20, indicating maximal exertion). The scale was displayed in front 
of the participants while exercising, and after each all-out sprint participants 
selected the number that best described their perceived level of exertion. 
Symptom scores
Participants were asked to complete a semiquantitative symptom questionnaire 
at euglycemia, and at 20, 40 and 60 min of hypoglycemia. Symptoms were scored 
from 0 (none) to 6 (severe) and included six autonomic symptoms (trembling, 
palpitations, anxiety, sweating, hunger, and tingling), six neuroglycopenic 
symptoms (blurred vision, difficulty speaking, feeling faint, difficulty thinking, 
fatigue, and confusion), four general symptoms (dry mouth, weakness, nausea, 
and headache) and two dummy symptoms (yellow vision and pain in the legs). 
Total symptom scores (i.e., scores including all symptom subcategories) and 
subscores were averaged over the three time points (after 20, 40 and 60 min 
of hypoglycemia). Peak symptom scores were defined as the highest total 
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symptom score during hypoglycemia, irrespective of the time point.
Cognitive function tests
The following cognitive function tests were applied during the screening visit 
and during hypoglycemia, starting 15 min after hypoglycemia was reached. In 
cases of hypoglycemia (n=2) or hyperglycemia (n=1) during the screening visit, 
the first battery of cognitive function tests was applied during the euglycemic 
phase of the first test day. Non-specific practice effects were controlled for by 
counterbalancing the order of the rest and HIIT intervention, and parallel forms 
were used to avoid material-specific practice effects if applicable.
Digit span forward and backward. A subtest of the Dutch version of the Wechsler 
Adult Intelligence Scale-III that measures attention and working memory was 
conducted (19). Sequences of digits of increasing lengths were presented 
verbally, and participants were asked to recall the digits in the presented order 
and in the reverse order.
Verbal fluency test. A Dutch version of the Controlled Oral Word Association 
Test (COWAT) that serves as an index of executive function was conducted (20). 
Participants were given 1 min to name as many words as possible starting with 
a given letter. Parallel sets of letter triads (D-A-T, K-O-M, and P-G-R) were used 
for baseline, HIIT and rest measurements.
Paced Auditory Serial Addition Test (PASAT). The Paced Auditory Serial 
Addition Test evaluates the speed of information processing and divided and 
sustained attention (21). Continuous sequences of 61 digits are auditorily 
presented, and participants are asked to add each new digit to the one 
immediately prior to it and say the answer out loud. Sequences were presented 
at three rates of presentation (i.e., every 2.4, 2.0 or 1.6 s).
In order to provide a composite score of cognitive function, raw scores of each 
test were transformed into z scores, based on the distribution of test scores at 
baseline (including all three study groups), and were averaged (22).
Analytical methods
Plasma insulin was assessed by an in-house radioimmunoassay (23). After 
extraction (24), plasma glucagon was measured by radioimmunoassay with 
a commercially available kit (Eurodiagnostica, Malmö, Sweden). Plasma 
GH and cortisol were determined using a routine analysis method with an 
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Electrochemiluminescent Immunoassay on a Modular Analytics E170 (Roche 
Diagnostics, GmbH, Manheim, Germany). Plasma adrenaline and noradrenaline 
were analyzed by high-performance liquid chromatography combined with 
fluorometric detection (25). pH was measured by routine venous blood gas 
analysis in lithium heparin-anticoagulated blood immediately after withdrawal, 
on the RapidPoint 500 (Siemens Nederland B.V., Den Haag, the Netherlands). 
Statistical analysis
Data were tested for normality using the Shapiro-Wilk test and QQ-plots. 
Differences in means within groups were analyzed with paired Student t tests or 
Wilcoxon signed rank test when data were not normally distributed. Differences 
in means between groups were analyzed by ANOVA followed by Bonferroni post 
hoc tests to delineate statistical significance, and for non-parametric data with 
the Kruskal-Wallis test and post hoc Mann-Whitney U tests. Serial data (hormone 
responses and glucose infusion rates) were analyzed by two-way repeated 
measures ANOVA, in which missing data were replaced with the last observed 
value. The cognitive tests were analyzed with a repeated-measures general linear 
model ANOVA with study group (healthy control subjects, patients with NAH, or 
patients with IAH) as a between-subject factor and intervention (HIIT or rest) as 
a within-subject factor, followed by post hoc paired Student t tests. All data are 
expressed as the mean ± SEM, unless otherwise specified. Alpha was set at 0.05 
throughout. Statistical analyses were performed with IBM SPSS Statistics 20.
Results
The three groups of participants were well matched for age, sex and BMI 
(Table 1). Diabetes duration did not differ significantly between the two 
diabetes groups, and the HbA1c level was borderline significantly lower in 
patients with IAH compared with those with NAH (P = 0.05). Glucose levels 
during the clamps are shown in Fig. 1A and B. 
Physiological effects of exercise
Average workload during all-out sprints for the whole study population was 
437 ± 17 W and mean perceived exertion was 16 ± 0.4 on the Borg scale, with 
no difference between groups. HIIT markedly increased plasma lactate levels 
from 1.2 ± 0.1 to 13.1 ± 0.5 mmol/L (Fig. 1D) and decreased pH from 7.36 ± 
0.00 to 7.19 ± 0.01 to a similar extent in all groups. After reaching peak levels, 
plasma lactate levels fell gradually but remained well above baseline levels 
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during the subsequent hypoglycemic clamp in both patient groups and for 
40 minutes of hypoglycemia in healthy participants. Immediately after HIIT, 
plasma glucose levels increased slightly in all three groups, but remained 
within the normoglycemic range (Fig. 1B). HIIT increased plasma levels of 
adrenaline by 0.11 ± 0.04 nmol/L, noradrenaline by 4.1 ± 0.4 nmol/L, and GH 
by 14 ± 4.7 mU/L (all P values <0.05), whereas plasma cortisol levels tended to 
increase (mean increase 0.04 ± 0.02 µmol/L; P = 0.06). Hormonal responses to 
exercise were similar between all groups. All hormone levels returned to levels 
indistinguishable from those at rest days prior to the beginning of hypoglycemia 
(~ 40 min after exercise) with the exception of plasma cortisol, which remained 
slightly elevated in patients with diabetes and IAH. 
Table 1: Participant characteristics 
Healthy controls Patients with T1DM-NAH Patients with T1DM-IAH
Age, years 25.2±5.5 (19-37) 23.9±4.4 (19-34) 25.7±5.8 (19-35) 
Sex, M:F 5:5 4:6 5:5 
BMI, kg/m2 22.5±1.8 23.0±2.3 23.4±1 .4 
Exercise, h/week 3.7±2.2 4.3±2.9 4.9±3.7 
Score on modified Cox 
questionnaire
- 0.8±1.3 (0-4) 3.7±1.3 (1-5)
HbA1C, % (mmol/mol) - 7.5±0.6 (59.0±6.9) 6.9±0.7 (52.1±7.7) 
Duration of diabetes, years - 10.7±4.5 13.9±8.1 
Insulin dose, units/kg/day - 0.7±0.4 (0.4-0.9) 0.6±0.4 (0.4-0.8)
Insulin regimen, n
Multi-injection therapy
Pump therapy
-
5
5
2
8
Data are presented as number or means ± SD (range). F, female; M, male;  T1DM, type 1 
diabetes mellitus.
Responses to hypoglycemia after HIIT or rest
Hypoglycemic symptoms. Compared with seated rest, HIIT reduced the mean 
total hypoglycemic symptom scores (P = 0.01) (Fig. 2) and peak symptom scores 
in patients with type 1 diabetes and NAH (P = 0.04) (Table 2). These decreases 
were mainly due to reduced neurogenic and general symptom responses (P = 
0.008 and P = 0.04) (Table 2). In healthy participants, HIIT numerically decreased 
all symptom categories, but this failed to reach statistical significance (P = 0.19) 
(Fig. 2, Table 2). On both test days, patients with diabetes and IAH had the 
lowest hypoglycemic symptom scores compared with the other two groups; 
their scores were not affected by prior HIIT (P = 0.80) (Fig.2, Table 2). 
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6Figure 1: Time courses of plasma glucose (A and B) and plasma lactate (C and D) during the rest 
day (left panels) or HIIT day (right panels). Dashed lines represent the beginning and end of 
the euglycemic phase and the beginning of the hypoglycemic phase, respectively. During the 
euglycemic phase, participants performed HIIT or rested. Baseline values represent the first 
sample obtained upon arrival. Open circles, healthy controls; black squares, patients with type 
1 diabetes (T1DM) and NAH (T1DM-NAH); black triangles, patients with IAH (T1DM-IAH).
Counterregulatory hormones and glucose infusion rate. HIIT did not affect 
plasma adrenaline or noradrenaline responses to hypoglycemia in either 
subgroup (Fig. 3A-F). Plasma levels of glucagon increased to a similar extent 
in response to hypoglycemia on both test days in healthy participants, but, 
as expected, did not change on either day in the two patient groups (data not 
shown). HIIT suppressed the plasma cortisol response to hypoglycemia in healthy 
participants and patients with NAH (Fig. 3G-I) and suppressed the plasma GH 
responses in all groups (Fig. 4A-C). Glucose infusion rates during hypoglycemia 
were not different between HIIT and rest days in any group (5.6 ± 0.5 versus 4.8 ± 
1.0 mg · kg-1 · min-1, 4.4 ± 0.6 versus 3.7 ± 0.7 mg · kg-1 · min-1, and 4.4 ± 0.4 versus 
4.6 ± 0.4 mg · kg-1 · min-1, respectively, for healthy participants, patients with 
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NAH, and patients with IAH). The plasma adrenaline response to hypoglycemia 
was significantly lower in patients with IAH compared with patients with NAH 
and healthy participants, on both study days (P < 0.005) (Fig. 3A-C).
Figure 2: Average total hypoglycemic symptom scores. Average individual (individual dots) 
and average group total symptom scores (gray bars) during hypoglycemia after prior HIIT or 
seated rest in healthy controls (A), type 1 diabetes mellitus (T1DM)-NAH (B) and T1DM-IAH (C). 
Symptom scores after 20, 40 and 60 minutes of hypoglycemia were averaged to provide one 
composite score. 
Table 2. Symptom scores during hypoglycemia
Healthy controls T1DM-NAH T1DM-IAH
Rest HIIT Rest HIIT Rest HIIT
Peak 20.3 ± 3.5† 17.8 ± 2.7 31.1 ± 5.6† 21.9 ± 3.9*† 10.5 ± 1.6 10.9 ± 2.0
Neurogenic 7.7 ± 1.4† 6.6 ± 0.9† 10.9 ± 2.0† 7.0 ± 1.6* 3.3 ± 0.5 3.3 ± 0.6
Neuroglycopenic 5.6 ± 1.4† 4.3 ± 1.1 9.2 ± 1.8† 6.7 ± 1.3† 2.9 ± 0.5 3.0 ± 0.6
General 3.5 ± 0.9† 3.3 ± 0.7 5.2 ± 0.9† 3.8 ± 0.7*† 1.1 ± 0.3 1.6 ± 0.5
The peak scores (±SEM) represent the highest total symptom score during hypoglycemia, 
irrespective of the time point. All other symptom scores were averaged over the three time 
points (after 20, 40 and 60 minutes of hypoglycemia, mean ± SEM). T1DM, type 1 diabetes 
mellitus. *P  < 0.05 for HIIT vs. Rest, † P  < 0.05 versus T1DM-IAH.
Cognitive function. All three subgroups performed worse on cognitive tests 
during hypoglycemia compared with the screening visit, with mean decreases 
in z scores of 0.6 ± 0.1 and 0.9 ± 0.1 on the HIIT and rest day (all P < 0.05) 
(Fig. 5). Hypoglycemia-induced cognitive dysfunction was less pronounced after 
prior HIIT than after prior rest (main effect of intervention, P = 0.01). There was 
no significant interaction effect (timepoint x study group, P = 0.27). Post hoc 
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analysis revealed that the attenuating effect of HIIT on hypoglycemia-induced 
cognitive deterioration was significant only in patients with diabetes and NAH 
(P < 0.05), but did not reach significance in the other two subgroups (P = 0.11 for 
healthy participants and P = 0.46 for patients with IAH). 
Figure 3: Adrenaline, noradrenaline, and cortisol responses to hypoglycemia after prior rest 
(open circles) or prior HIIT (black squares) in healthy controls (left) and patients with type 
1 diabetes mellitus (T1DM)-NAH (middle) and T1DM-IAH (right). Eu, euglycemia; Hypo, 
hypoglycemia. 
136
Effects of HIIT on awareness of hypoglycemia
Figure 4: GH responses to hypoglycemia after prior rest (open bars) or prior HIIT (black bars) in 
healthy control subjects (left) and patients with type 1 diabetes mellitus (T1DM)-NAH (middle) 
and T1DM-IAH (right). Eu, euglycemia; hGH, human GH; Hypo, hypoglycemia, * P < 0.05.
Figure 5: Hypoglycemia-induced change in cognitive function after seated rest (open bars) or 
HIIT (closed bars). Mean (with SEM) differences in z scores between the screening visit and 
hypoglycemia are depicted. * P < 0.05. 
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Discussion 
The main finding of the current study is that a bout of HIIT suppresses symptoms 
of subsequent hypoglycemia in patients with type 1 diabetes and NAH. HIIT also 
causes less hypoglycemia-induced cognitive deterioration, an effect that was 
mainly driven by the NAH patient subgroup. HIIT did not affect hypoglycemic 
awareness in patients with IAH, likely because of a ‘floor’ effect in that symptom 
reponses could not be further suppressed than they already were. In healthy 
participants, HIIT numerically decreased symptoms of hypoglycemia, but this 
failed to reach statistical significance. These data demonstrate that one short 
HIIT session is able to rapidly blunt hormonal and symptomatic defenses against 
hypoglycemia in patients with NAH, which may increase the risk of post-exercise 
hypoglycemia. 
Our findings of the suppressive effect of antecedent HIIT on defenses against 
hypoglycemia extend those of other exercise studies (26-29). However, there 
is substantial variation in the specific counterregulatory responses that are 
affected by antecedent exercise. Antecendent low- to moderate-intensity 
exercise (at 30% and 50% peak oxygen uptake) has been shown to cause a 
universal suppression of hormonal and symptomatic responses to next-day 
hypoglycemia (28). Remarkably, two bouts of more vigorous exercise (~70% 
peak oxygen uptake) had limited effects, in that only adrenaline responses to 
subsequent hypoglycemia were attenuated (27). We now demonstrate that 
an even more intensive exercise test causes blunting of symptomatic, cortisol 
and GH responses to subsequent hypoglycemia but not of catecholamine 
responses. Similar defects in counterregulatory hormones were observed in 
antecedent hypoglycemia studies in which the interval between the stimulus 
and subsequent hypoglycemia was relatively short (30; 31). Taken together, it 
appears that antecedent exercise, similar to antecedent hypoglycemia, is able 
to induce a range of counterregulatory defects, the magnitude and components 
of which seem to depend on the particular exercise protocol used (e.g., exercise 
intensity and duration) and the time frame between exercise and subsequent 
hypoglycemia.   
The mechanisms underlying exercise-induced attenuation of counterregulatory 
hormone and symptom responses are currently not known. We hypothesize 
that elevated lactate levels in response to HIIT mediate a suppressive effect. 
High plasma lactate levels lead to an increase in brain lactate use, both after 
intravenous administration (32) and after vigorous exercise (33; 34). An increase 
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in brain lactate oxidation during hypoglycemia has been suggested to preserve 
brain metabolism (10; 12). This may prevent hypoglycemia-induced cognitive 
dysfunction since the brain is no longer deprived of fuel. Maintenance of brain 
metabolism may simultaneously impede hypoglycemia sensing by the brain 
and thus suppress the consequent initiation of protective counterregulatory 
and symptom responses (35). Previous work found that administration of 
exogenous lactate during hypoglycemia suppresses symptoms and hormone 
responses, while preserving cognitive function, thus mimicking the situation 
seen in patients with IAH (10-13). In these patients, several cerebral adaptations 
have been observed during hypoglycemia, including increased capacity to use 
lactate (35-38). Alternatively, lactate may act as a metabolic regulator in the 
brain rather than as a fuel per se (39; 40). 
Several arguments support a role for elevated lactate levels in the suppression 
of physiological responses to hypoglycemia after HIIT. First, we showed that the 
deterioration of cognitive function during hypoglycemia was less after HIIT than 
rest, which is in accordance with previous studies that infused lactate during 
hypoglycemia (10; 12). In addition, a recent exercise study found that higher 
lactate levels after HIIT were associated with better executive function during 
post-exercise recovery under euglycemic conditions (41). We also observed fast 
suppression of hypoglycemic symptoms and cortisol and GH responses after HIIT 
(i.e., < 1 h after the initial stimulus). Whereas central nervous system adaptations 
to hypoglycemia are thought to take hours to days to become manifest (42), the 
suppressive effects of lactate are known to occur rapidly and probably do not 
involve an adaptation process (13). Interestingly, the blunting of symptoms was 
most pronounced in participants with the highest symptom scores. Changes in 
symptoms were not correlated to changes in adrenaline responses. Increased 
capacity to transport lactate over the blood-brain barrier in patients with type 
1 diabetes (as a result of prior exposure to hypoglycemia) may in part explain 
differential effects of HIIT in patients with NAH and healthy control subjects 
(43). However, quantitative comparisons with studies using exogenous lactate 
during hypoglycemia need to acknowledge the influence of exercise itself, pH 
differences, and the duration and stability of elevations in plasma lactate levels.
The habituation of the brain in response to recurrent hypoglycemia is thought 
to underlie the development of IAH (44), and restoration of IAH can be 
achieved by scrupulous avoidance of hypoglycemia (45; 46). It has recently 
been speculated that ‘resensitizing’ the brain to hypoglycemia might also be 
achieved by exposure to high-intensity exercise as a novel stimulus in an animal 
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model of IAH (47). In this model, antecedent hypoglycemia-induced defects in 
glucose counterregulation were restored 24 hours after a bout of high-intensity 
exercise. This differs from our findings, in that we observed no improvements in 
counterregulatory responses to hypoglycemia after HIIT in patients with type 1 
diabetes and IAH. However, differences in species and study design, particularly 
the timeframe between exercise and hypoglycemia, should be acknowledged 
when explaining these seemingly contradictory results. 
Our study design differed from most studies that addressed the impact of 
antecedent exercise on defenses against hypoglycemia since the timeframe 
between exercise and hypoglycemia was short. This approach was chosen 
because we wanted to assess the effect of high endogenous plasma lactate 
levels during hypoglycemia, in view of the known effects of exogenous lactate 
during hypoglycemia. Although we provide arguments for increased lactate 
levels as an explanation for the suppression of awareness of hypoglycemia and 
attenuation of cognitive dysfunction, our studies cannot prove a cause-and-
effect relationship. Although less likely, mechanisms other than lactate may 
explain the acute beneficial effects of HIIT on cognition, including increased 
arousal (48; 49). Participants could not be blinded for the intervention (HIIT 
vs. rest): although unlikely, some influence of participant expectations on the 
results cannot be excluded. The strengths of our study include the randomized 
crossover design that allowed us to compare responses to HIIT and rest in the 
same participants under similar conditions. 
In conclusion, a short bout of high-intensity interval exercise suppresses 
symptoms of subsequent hypoglycemia in patients with type 1 diabetes but 
does not affect awareness in patients with IAH. The role of exercise-induced 
lactate in mediating the suppressive effects of HIIT on hypoglycemic awareness 
should be further explored. Reduced symptomatic responses may increase the 
risk of hypoglycemia after intensive exercise. 
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Abstract 
Severe hypoglycemic events have been associated with increased cardiovascular 
mortality in patients with diabetes, which may be explained by hypoglycemia-
induced inflammation. We used ex vivo stimulations of peripheral blood 
mononuclear cells (PBMCs) and monocytes obtained during hyperinsulinemic-
euglycemic (5.0 mmol/L)-hypoglycemic (2.6 mmol/L) clamps in 11 healthy 
participants, 10 patients with type 1 diabetes and normal awareness of 
hypoglycemia (NAH), and 10 patients with type 1 diabetes and impaired 
awareness (IAH) to test whether the composition and inflammatory function 
of immune cells adapt to a more proinflammatory state after hypoglycemia. 
Hypoglycemia increased leukocyte numbers in healthy control participants 
and patients with NAH but not in patients with IAH. Leukocytosis strongly 
correlated with the adrenaline response to hypoglycemia. Ex vivo, PBMCs and 
monocytes displayed a more robust cytokine response to microbial stimulation 
after hypoglycemia compared with euglycemia, although it was less pronounced 
in patients with IAH. Of note, hypoglycemia increased the expression of 
markers of demargination and inflammation in PBMCs. We conclude that 
hypoglycemia promotes mobilization of specific leukocyte subsets from the 
marginal pool and induces proinflammatory functional changes in immune 
cells. Inflammatory responses were less pronounced in IAH, indicating that 
counterregulatory hormone responses are key modulators of hypoglycemia-
induced proinflammatory effects. Hypoglycemia-induced proinflammatory 
changes may promote a sustained inflammatory state.
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Introduction
Hypoglycemia is the most common complication of insulin therapy in people 
with type 1 diabetes (1). Patients with type 1 diabetes experience, on average, 
two hypoglycemic events per week and one severe event per year (2). The extent 
to which hypoglycemia contributes to cardiovascular disease risks in diabetes is 
debated: an association between severe hypoglycemia and increased mortality 
from cardiovascular events has been established in patients with type 2 diabetes 
(3-6) but is less consistent in type 1 diabetes (6-10), even though hypoglycemia 
occurs much more frequently in patients with type 1 than in those with type 2 
diabetes (11). 
An increase in circulating proatherothrombotic factors in response to acute 
insulin-induced hypoglycemia can link hypoglycemia to cardiovascular 
complications (12-14). In addition, hypoglycemia has been reported to increase 
leukocyte counts and circulating proinflammatory cytokines in both healthy 
individuals (15-18) and patients with type 1 diabetes (14; 19), supporting the 
concept that hypoglycemia-induced systemic inflammation contributes to 
cardiovascular complications (12; 13; 15). 
Adrenaline, the main counterregulatory hormone response to hypoglycemia 
in patients with type 1 diabetes, may play a role in the hypoglycemia-induced 
proinflammatory response. When adrenaline is administered to healthy 
individuals (normoglycemic conditions), it specifically mobilizes leukocytes 
equipped with cytotoxic effector potential from the marginal pool (vascular 
epithelium) (20). However, knowledge about the role of adrenaline in 
hypoglycemia-induced changes related to inflammation is lacking.
Patients with impaired awareness of hypoglycemia (IAH) are at particularly high 
risk of hypoglycemia (21) because they lack hypoglycemia warning symptoms 
and have attenuated adrenaline responses (1; 22). If adrenaline contributes 
to hypoglycemia-induced proinflammatory responses, such effects may be 
altered in patients with type 1 diabetes and IAH. Under euglycemic conditions, 
patients with IAH were found to have higher leukocyte counts and a higher rate 
of endothelial dysfunction and preclinical atherosclerosis than sex- and age-
matched patients without IAH (23). In accordance, Joy et al. (16) reported that 
antecedent hypoglycemia, which underlies the emergence of IAH, results in 
greater endothelial dysfunction, but inflammatory responses to hypoglycemia 
are not enhanced after prior hypoglycemia. 
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Thus, hypoglycemia has been shown to increase circulating proinflammatory 
cytokines, but the underlying mechanisms, the role of repeated hypoglycemia, 
and the relationship with counterregulatory hormone responses, 
particularly adrenaline, are incompletely understood. Because an enhanced 
proinflammatory state is not exclusively reflected in the levels of circulating 
cytokines, we studied the effects of acute hypoglycemia on the composition 
and inflammatory output of immune cells. We investigated these aspects using 
ex vivo stimulation of peripheral blood mononuclear cells (PBMCs) obtained 
at various time points during hyperinsulinemic-euglycemic-hypoglycemic 
clamps in healthy participants and patients with type 1 diabetes. To assess 
the role of sympathoadrenal responses to hypoglycemia in inducing potential 
proinflammatory effects, we also included patients with type 1 diabetes and 
IAH characterized by impaired counterregulatory hormone responses to 
hypoglycemia. 
Research Design and Methods
Participants
We recruited 11 participants without diabetes, 10 patients with type 1 diabetes 
and normal awareness of hypoglycemia (NAH), and 10 patients type 1 diabetes 
and IAH. Patients were otherwise healthy and did not use drugs that interfered 
with glucose metabolism other than insulin. Hypoglycemia awareness state, 
initially assessed by a Dutch version of the Cox questionnaire in which a score of 
0-1 of 5 indicates normal awareness and a score ≥ 3 indicates impaired awareness 
(24; 25), was determined on the basis of adrenaline and symptomatic responses 
to the hypoglycemic clamp. Eighteen out of the 20 patients were correctly 
characterized as having IAH or NAH through the Cox questionnaire. The 
institutional review board of the Radboud university medical center (Nijmegen, 
the Netherlands) approved the study, and all participants gave written informed 
consent before participation. 
Experimental design
All participants presented between 8.00 and 8.30 A.M. at the clinical research 
facility after an overnight fast and having abstained from caffeine, alcohol, 
and smoking for 24h. Patients with diabetes received specific instructions to 
avoid (nocturnal) hypoglycemia the day before the clamp. Experiments were 
rescheduled in cases of hypoglycemia in the 24 h before the clamp. Upon arrival, 
two intravenous cannulae were inserted, one into the antecubital vein of each 
forearm. One forearm was placed in a heated box (55°C) so that arterialized 
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venous blood could be obtained for frequent blood sampling. The cannula in the 
contralateral arm was used for infusion of glucose 20% (Baxter B.V., Deerfield, IL) 
and insulin (insulin aspart; Novo Nordisk, Bagsvaerd, Denmark). Baseline plasma 
glucose levels were determined (Biosen C-Line; EKF Diagnostics, Cardiff, U.K.) 
and a two-step hyperinsulinemic (60 mU/m2/min)- euglycemic (5.0 ± 0.2 mmol/
L)-hypoglycemic (2.6 ± 0.1 mmol/L) glucose clamp was initiated. Plasma glucose 
levels were determined every five min, and after a short euglycemic phase (~20 
min), plasma glucose levels were gradually decreased to 2.6 mmol/l and were 
maintained there for 60 min. Blood samples for measurement of adrenaline 
were taken at euglycemia and every 20 min during hypoglycemia. Insulin and 
glucagon were determined at euglycemia and at 60 min of hypoglycemia.
Analytical methods
Plasma insulin was assessed by an in-house radioimmunoassay (RIA) (26). 
After extraction (27), plasma glucagon was measured with a commercially 
available radioimmunoassay kit (Eurodiagnostica, Malmö, Sweden). Plasma 
growth hormone and cortisol were determined by routine analysis with an 
electrochemiluminescent immunoassay on a Modular Analytics E170 (Roche 
Diagnostics, GmbH, Manheim, Germany). Plasma adrenaline and noradrenaline 
were analyzed by high-performance liquid chromatography combined with 
fluorometric detection (28). Peripheral total and differential white blood cell 
counts were determined by routine patient sample analysisd (flow cytometric 
analysis on a Sysmex XE-5000). 
Isolation of PBMCs and CD14+ monocytes 
Blood samples were processed for isolation of cells immediately after being 
drawn to ensure equal quality of the samples because previous experiments 
showed that cytokine responses are altered when blood samples are processed 
for isolation at different time points after being drawn (data not shown). Isolation 
of PBMCs was performed by differential centrifugation over Ficoll-Paque PLUS 
(GE Healthcare). PBMCs were washed three times with PBS and counted with 
a Coulter counter (Coulter Electronics).  CD14+ monocytes were purified from 
freshly isolated PBMCs by using MACS MicroBeads (Miltenyi Biotec, Germany) 
for positive selection according to the manufacturer’s instructions. 
Stimulation experiments
For analysis of cytokine release, glucose consumption and lactate production, 
5 x 105 PBMCs or 1 x 105 monocytes were used per well in a 96-well plate. Cells 
were cultured in RPMI medium (no glucose, Gibco) supplemented with 10 μg/mL 
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gentamicin (Gibco), 10 mM pyruvate (Gibco), 10 mmol/L HEPES (Sigma-Aldrich), 
5.5 mmol/L glucose (Sigma-Aldrich) and stimulated with either RPMI medium, 
10 ng/mL of the TLR4 agonist lipopolysaccharide (LPS) from Escherichia coli 
(Sigma-Aldrich), 10 μg/mL of the TLR2 agonist Pam3CysSK4 (Pam3Cys) (EMC 
Microcollections, Tübingen, Germany), 1 μg/mL Mycobacterium tuberculosis 
(H37Rv) lysate, or 1 x 106 heat-killed organisms/mL Candida albicans conidia for 
24 h. Cell culture supernatants were collected and stored at −20°C. 
Cytokine measurements
The production of interleukin-1β (IL-1 β), tumor necrosis factor-α (TNF- α ) 
(R&D Systems), IL-10, IL-6 (Sanquin) and MCP-1 (eBioscience) was measured by 
ELISA. In the analysis of cytokine production by CD14+ monocytes, participants 
were excluded from analysis when cytokine production upon stimulation of 
cells after both euglycemia and hypoglycemia was below detection limits. The 
number of ‘non-responders’ was comparable between groups. 
Glucose consumption and lactate measurements
Glucose and lactate concentrations were measured in cell culture supernatants. 
Measurements were based on an enzymatic reaction in which glucose or lactate 
is oxidized and the resulting H2O2 is coupled to the conversion of Amplex Red 
reagent to fluorescent resorufin by horseradish peroxidise. The fluorescence of 
resorufin (excitation/emission maxima 570/585 nm) was measured on a 96-well 
plate reader (BioTek). Glucose consumption was calculated by subtracting the 
glucose concentration measured in cell culture supernatants from that in culture 
medium incubated for 24 h without cells.  
RNA isolation and qRT-PCRs
For mRNA expression analyses, PBMCs (1,5 x 106 PBMCs/condition) were lysed in 
TRIzol reagent (Invitrogen) directly after isolation and stored at −80°C until RNA 
isolation was performed according to the manufacturer’s instructions. RNA was 
transcribed into cDNA by reverse transcription using the iScript cDNA synthesis 
kit (Bio-Rad). Primer sequences used for quantitative real-time PCR (qRT-PCR) 
are listed in Supplementary Table 2. Power SYBR Green PCR Master Mix (Applied 
Biosystems) was used for qRT-PCR in the CFX384 Real-Time PCR Detection 
System (Bio-Rad). Expression data were normalized to the housekeeping gene 
human β2M. 
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Statistical analysis
Data were tested for normality using the Shapiro-Wilk test and Q-Q plots. 
Within-group differences were compared with paired Student t or Wilcoxon 
signed rank tests when data were not normally distributed. Between-group 
differences were analyzed by ANOVA followed by pair wise Bonferroni post hoc 
tests to delineate statistical significance and for nonparametric data with the 
Kruskal-Wallis test and post hoc Mann-Whitney U tests. For correlation analysis 
Pearson correlation coefficient was used for normally distributed variables and 
Spearman rank sum test for nonnormally distributed data. All data are expressed 
as mean ± SEM unless otherwise specified.  P < 0.05 was considered statistically 
significant. Statistical analyses were performed with SPSS version 20 software 
(IBM Corporation).
Results
Study participants were well matched for age, sex, and BMI (Table 1). Duration of 
diabetes and HbA1C did not differ significantly between patient groups. Plasma 
glucose levels (Fig. 1A) and plasma insulin levels (data not shown) were similar 
in all groups during both the euglycemic and the hypoglycemic phase, whereas 
glucagon levels increased in response to hypoglycemia in healthy control 
participants but did not change in either patient group (Supplemantary Table 1). 
Adrenaline levels during hypoglycemia were significantly lower in patients with 
IAH than in healthy control participants and patients with NAH (0.39 ± 0.07, 1.94 
± 0.29, and 1.90 ± 0.46 nmol/L, respectively).
Table 1. Participant characteristics
Healthy control 
participants (n = 11)
Patients with type 1 
diabetes and NAH (n = 10)
Patients with type 1 
diabetes and IAH (n = 10)
Age (years) 24.5 ± 5.3 24.2 ± 5.1 25.3 ± 6.0
Sex, M/F 6:5 4:6 5:5
BMI, kg/m2 22.9 ± 1.8 22.7 ± 2.2 23.4 ± 1.4
HbA1C, % (mmol/mol) - 7.5 ± 0.6 (58.5 ± 6.9) 6.9 ± 0.7 (52.1 ± 7.8)
Duration of diabetes (years) - 10.9 ± 4.7 13.9 ± 8.1
Total daily insulin dose (IU) - 48.2 ± 12.6 48.2 ± 13.2
Data are mean ± SD or n.
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Figure 1: Hypoglycemia induces leukocytosis in healthy control participants (HC) and patients 
with type 1 diabetes (T1DM) and NAH but not in T1DM and IAH who have attenuated adrenaline 
responses to hypoglycemia. A: Time courses of plasma glucose levels during the clamp. Dashed 
lines represent the end of the euglycemic phase and the beginning and end of the hypoglycemic 
phase. B-E and G:Number of circulating leukocytes (B), neutrophils (C), lymphocytes (D) and 
monocytes (E) and composition of leukocytes (G) measured with a routine patient sample 
analysis at euglycemia and after 1 h of hypoglycemia. F: Correlation between the difference in 
leukocyte numbers during hypoglycemia vs. euglycemia and the difference in adrenaline levels 
between hypoglycemia and euglycemia. *P < 0.05, ** P < 0.01. 
A B
C D
E F
G
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Hypoglycemia increases total leukocyte count
The total leukocyte count increased in response to hypoglycemia in healthy 
control participants and patients with NAH but not in patients with IAH 
(Fig. 1B). This increase was mainly due to an increase in the number of 
lymphocytes and, to a lesser extent, an increase in the number of monocytes 
(Fig. 1C-E). Consequently, neutrophil-to-lymphocyte ratios decreased in 
response to hypoglycemia (Fig. 1G). The change in total leukocyte count 
correlated positively with the adrenaline response to hypoglycemia (R2 = 0.70, 
P < 0.001) (Fig. 1F). The positive correlation was strongest in lymphocytes 
(R2 = 0.75, P < 0.001 ), but was also seen in monocytes (R2 = 0.33, P = 0.003) 
and neutrophils (R2 = 0.29, P = 0.007) (Supplementary Fig. 1). By looking at the 
separate groups, the positive correlation between the change in total leukocyte 
count and adrenaline response was significant in healthy control participants 
and patients with NAH, but not in patients with IAH.
Hypoglycemia increases ex vivo proinflammatory cytokine production 
PBMCs from healthy control participants and patients with NAH isolated after 
1 h of hypoglycemia and stimulated with the TLR4 agonist LPS produced more 
proinflammatory cytokines (IL-6, IL1β, and TNFα) than PBMCs isolated after 
euglycemia. Hypoglycemia had no effect on LPS-stimulated cytokine production 
of PBMCs isolated from patients with IAH (Fig. 2A-C). Hypoglycemia increased 
the production of the chemokine MCP-1 in healthy control participants (Fig. 2D) 
but did not affect levels of the anti-inflammatory cytokine IL-10 in any group 
(Fig. 2E). 
Hypoglycemia enhanced the TNF-α response of PBMCs stimulated with 
Pam3Cys, M. Tuberculosis, and C. albicans in all three groups. Hypoglycemia also 
increased the IL-6 response to M. tuberculosis in healthy control participants and 
patients with NAH but had virtually no effect on the IL-6 and IL-1β responses 
to Pam3Cys or C. albicans in any of the three groups (Supplementary Fig. 2). 
Altogether, hypoglycemia enhanced cytokine responses of PBMCs, with the 
most prominent increase in TNF-α responses (Fig. 2F).
Of note, cytokine release of stimulated PBMCs from patients with IAH 
isolated during euglycemia tended to be higher than cells from healthy 
control participants and patients with NAH, although the differences were not 
statistically significant. 
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Figure 2: PBMCs isolated after hypoglycemia produce more proinflammatory cytokines than 
PBMCs isolated after euglycemia. A-E: IL-6 (A), IL-1β (B), TNF-α (C), MCP-1 (D), and IL-10 (E) 
production of PBMCs isolated from euglycemic or hypoglycemic conditions and stimulated 
for 24 h with LPS. F: Fold change in cytokine production (IL-6, IL-1β, TNF-α) by PBMCs upon 
hypoglycemia vs. euglycemia. The gray dashed line represents euglycemic values. PBMCs were 
stimulated with the TLR4 agonist LPS, the TLR2 agonist Pam3Cys, C. Albicans, or lysate of M. 
tuberculosis. Data are mean (continuous lines) ± SEMv(dotted lines). * P < 0.05, ** P < 0.01. HC, 
healthy control; T1DM, type 1 diabetes mellitus.
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Hypoglycemia does not affect glycolytic metabolism of PBMCs
We then investigated whether hypoglycemia affected glycolytic metabolism 
of PBMCs. As expected, stimulation with LPS significantly increased glucose 
consumption and lactate production of PBMCs in all groups (Fig. 3A and B). 
However, no difference was found in either glucose consumption or lactate 
production between cells exposed to hypoglycemic versus euglycemic 
conditions, regardless of whether stimulated with LPS. 
Figure 3: No differences in glycolytic 
metabolism of PBMCs isolated from 
hypoglycemia vs. euglycemia. Glucose 
consumption (A) and lactate secretion (B) 
measured in the supernatants of PBMCs 
isolated from euglycemic or hypoglycemic 
conditions and cultured for 24 h with or 
without stimulation with LPS. * P < 0.05, 
** P < 0.01. HC, healthy control; T1DM, 
type 1 diabetes mellitus.
Hypoglycemia generally increases expression of markers for 
demargination and cells with cytotoxic effector potential 
Because adrenaline levels increased markedly in response to hypoglycemia and 
because adrenaline drives demargination of leukocytes (20), we investigated 
whether hypoglycemia altered gene expression levels of demargination markers 
in isolated PBMCs. Hypoglycemia increased the expression of the integrin CD11a 
in PBMCs of healthy control participants and patients with NAH but not in patients 
with IAH (Fig. 4A). Hypoglycemia also increased the expression of the chemokine 
receptor CX3CR1 in PBMCs of healthy control participants (Fig. 4B). 
Next, we assessed the expression of marker genes of various immune cell types 
in PBMCs exposed to hypoglycemia or euglycemia (Fig. 4C-G). Hypoglycemia 
increased the expression of CD8 but not of CD4 or CD56 in PBMCs in all groups. 
A
B
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Figure 4: Increased expression of markers for demargination and cells with cytotoxic effector 
potential after hypoglycemia as assessed by qRT-PCR in PBMCs exposed to euglycemia or 
hypoglycemia. Relative expression of CD11a (A), CX3CR1 (B), CD4 (C), CD8 (D), CD56 (E), CD14 
(F) and CD16 (G). * P < 0.05, ** P < 0.01. HC, healthy control; T1DM, type 1 diabetes mellitus.
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Figure 5: CD14+ monocytes isolated after hypoglycemia produce more proinflammatory 
cytokines than CD14+ cells isolated after euglycemia. A: Percentage of CD14+ cells isolated 
by MACS. B: Fold change in cytokine production (IL-6, IL-1β, TNF-α) by CD14+ cells isolated 
from hypoglycemic vs. euglycemic conditions. CD14+ cells were stimulated with the TLR4 
agonist LPS, the TLR2 agonist Pam3Cys, C. Albicans, or lysate of M. tuberculosis. Data are mean 
(continuous lines) ± SEM (dotted lines). HC, healthy control; T1DM, type 1 diabetes mellitus.
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Moreover, although hypoglycemia did not alter expression of CD14, it increased 
the expression of CD16, a marker for the nonclassical monocyte subset that 
produces more cytokines than the classical monocytes in response to certain 
stimulations (29).
Hypoglycemia increases ex vivo cytokine production of CD14+ cells 
Because monocytes are the major producers of proinflammatory cytokines 
within the heterogeneous PBMC cell population, we specifically investigated 
the effect of hypoglycemia on the inflammatory function of CD14+ monocytes. 
Hypoglycemia did not affect the percentage of isolated CD14+ monocytes within 
the PBMC fraction in any of the three groups (Fig. 5A). When stimulated ex vivo, 
CD14+ cells produced more proinflammatory cytokines, particularly TNFα, if 
isolated after hypoglycemia compared with euglycemia (Fig. 5B). Nevertheless, 
CD14+ cells did not have increased gene expression levels of surface markers 
characterizing proinflammatory monocytes (CD11a, CXRCR1, CCR5, CCR2) 
(Supplementary Fig. 3).
Discussion
The present study aimed to investigate the effect of acute hypoglycemia on 
the composition and inflammatory function of circulating immune cells. We 
demonstrate that exposure to hypoglycemia leads to demargination of specific 
immune cell subtypes and enhances the inflammatory response of PBMCs and 
CD14+ monocytes. Of note, the hypoglycemic response of PBMCs was partly 
blunted in patients with type 1 diabetes and IAH, highlighting the role of 
adrenaline in immune cell recruitment and in the acute inflammatory response 
to hypoglycemia. The data support the concept that hypoglycemia shifts 
circulating immune cells toward a more proinflammatory state. When sustained, 
such an enhanced inflammatory state could contribute to atherogenesis in 
people with diabetes.
In line with previous findings (15), the results demonstrate that hypoglycemia 
induces leukocytosis. The strong correlation with adrenaline responses to 
hypoglycemia suggests a role for adrenaline, which is supported by our 
observations in patients with type 1 and IAH who have blunted counterregulatory 
hormone responses to hypoglycemia. These studies now extend previous findings 
by investigating the inflammatory function of isolated immune cells ex vivo. 
We observed that TNFα production significantly increases in PBMCs exposed 
161
7
to hypoglycemia, independent of the pathogenic stimulus (LPS, Pam3Cys, C. 
albicans or M. tuberculosis), which strongly implies that the hypoglycemic event 
causes a universal potentiation of inflammatory function of the cells. Because 
equal numbers of PBMCs were used in stimulations to compare the two glycemic 
conditions, the increased levels of circulating proinflammatory cytokines found 
in previous studies (15; 17-19; 30) are not only due to the increase in the number 
of circulating immune cells in response to hypoglycemia but also likely reflect 
changes in the functional status of immune cells. 
In contrast to TNF-α responses, the effect of hypoglycemia on IL-6 and IL-1β 
production was less pronounced and more variable between the various stimuli, 
suggesting that changes in pathogen-specific signalling pathways are involved. 
Such changes could affect either the expression of pattern recognition receptors 
on the cell surface or expression of their downstream effectors. If intracellular 
signalling pathways are indeed affected by hypoglycemia, this could also prime 
the immune cells to respond differently to other stimuli, such as proatherogenic 
factors. 
PBMCs are a heterogeneous mix of cell populations, and changes in composition 
could also explain the increased cytokine production observed in response to 
hypoglycemia. However, measurements of the cellular composition of several 
PBMC samples did not reveal major changes (percentage of lymphocytes, 
monocytes, and granulocytes) after hypoglycemia. Of note, CD11a and CX3CR1 
gene expression levels were increased in PBMCs exposed to hypoglycemia, 
suggesting an increase in the number of demarginated cells (20). Recruitment 
of a distinct cell population with a different phenotype and function likely 
contributes to the observed change in inflammatory responses after exposure 
to hypoglycemia. Similar to leukocytosis experimentally induced by adrenaline 
(20), hypoglycemia increased the number of cells with cytotoxic effector 
potential, such as lymphocytes expressing CD8. Additionally, hypoglycemia 
increased levels of CD16, suggesting an increase in circulating CD16+ monocytes 
and natural killer cells, also secondary to adrenaline-mediated leukocytosis (20). 
Future studies applying flow cytometric analysis of circulating immune cells to 
provide additional information on the specific surface expression of selected 
proteins on certain cell populations would be of particular interest. 
Cytokine production was similarly altered in CD14+ cells and PBMCs exposed 
to hypoglycemia. Although we cannot distinguish between the different 
monocyte subsets (classical, intermediate, nonclassic) within the population of 
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isolated CD14+ cells, the increased cytokine response of PBMCs is likely based 
on the enhanced cytokine production capacity of CD14+ monocytes because the 
percentage of monocytes was similar at hypoglycemia and euglycemia. 
Another factor that may contribute to an altered inflammatory output of 
immune cells is a shift in cellular metabolism induced by changes in the 
metabolic environment. For instance,  a highly active glycolytic metabolism has 
been shown to drive proinflammatory cytokine production in M1 macrophages 
and is also important for activated effector T cells (31). However, similar glucose 
consumption and lactate production of cells isolated from hypoglycemic versus 
euglycemic conditions make it unlikely that changes in inflammatory responses 
are due to changes in glycolytic metabolism of immune cells. We cannot fully 
exclude an involvement of glycolytic metabolism because acute changes can 
occur in vivo, but might be masked at the time point that we measured lactate 
levels in vitro.
The results revealed abrogation of hypoglycemia-induced leukocytosis and 
an attenuated inflammatory response to hypoglycemia in patients with IAH, 
potentially as a consequence of extensive prior exposure to hypoglycemia. 
The attenuated inflammatory response in patients with IAH underscores 
the contribution of counterregulatory hormones, especially adrenaline, in 
hypoglycemia-induced proinflammatory effects. Of note, hypoglycemia 
increased CD8 and CD16 expression in PBMCs of patients with IAH, indicating 
an increase in circulating cells with cytotoxic effector potential in these patients 
even while total leukocyte count did not increase upon hypoglycemia. This might 
be explained by the minimal, albeit still significant, increase in adrenaline levels 
in response to hypoglycemia. Leukocyte numbers and cytokine responses during 
euglycemia appeared higher but were not significantly elevated in patients with 
IAH compared with healthy control participants or patients with NAH. Although 
attributing this trend to prior exposure to hypoglycemia is tempting, a larger 
sample size would be required to address this question. 
One could speculate that an attenuated proinflammatory response to acute 
hypoglycemia as observed in the patients with IAH might provide some 
protection against harmful effects of subsequent hypoglycemia. Frequent 
hypoglycemic events, typical for patients with type 1 diabetes, have been 
reported to protect against hypoglycemia-induced mortality (32) or neuronal 
damage (33) in rats. These adaptive effects of recurrent hypoglycemia appear 
to be in line with the reported absence of increased cardiovascular mortality 
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in patients with type 1 diabetes and IAH compared with those with NAH (10) 
but contrasts with studies focussing on vascular effects that reported higher 
rates of preclinical atherosclerosis in patients with repeated hypoglycemia (23) 
and greater proatherothrombotic responses and endothelial dysfunction after 
recurrent hypoglycemia (16). Studies are needed to determine the long-term 
consequences of repeated hypoglycemia and IAH on inflammation and immune 
cells, their inflammatory function, and their involvement in atherogenesis. 
The strengths of this study include the use of glucose clamps in three matched 
groups of participants under similar glycemic conditions, which enabled us to 
differentiate between the impact of diabetes and IAH. A larger sample size 
would have allowed us to differentiate better between patients with IAH and 
NAH, especially with regard to baseline values. Although we analyzed gene 
expression of demargination markers and of specific cell types, flow cytometric 
analysis would have provided a more detailed characterization of changes in 
composition and inflammatory status of leukocytes. Future studies should focus 
on mechanistic studies in lymphocytes and also look into the role of neutrophils 
to extend the current gene expression data. Another limitation of this study is 
that participants with and without diabetes were healthy and relatively young. 
Inflammatory responses to hypoglycemia might differ in older patients, in those 
with a history of cardiovascular disease, or in those with poor glycemic control. 
We conclude that hypoglycemia leads to demargination, an increase in 
circulating immune cells with cytotoxic effector potential, and an induction of 
proinflammatory functional changes in PBMCs and CD14+ monocytes. Acute 
inflammatory responses to hypoglycemia were partly blunted in patients with 
type 1 diabetes and impaired awareness of hypoglycemia, highlighting that 
counterregulatory hormone responses are key modulators of proinflammatory 
responses to hypoglycemia. These data indicate that hypoglycemia induces a 
shift in inflammatory function of immune cells, which could promote a sustained 
proinflammatory state in patients with diabetes.
Acknowledgments
We thank all the volunteers for their participation in this work. We are indebted 
to Evita Wiegers (Department of radiology and nuclear medicine, Radboud 
university medical center) for assistance during the glucose clamps. 
164
Pro-inflammatory effects of hypoglycemia
Funding
Research support from the Dutch Diabetes Research Foundation (DFN 
2012.00.1542) and the European Foundation for the Study of Diabetes is 
gratefully acknowledged. RS is supported by a VIDI-grant from the The 
Netherlands Organisation for Scientific Research (NWO). MGN is supported by 
an ERC Consolidator grant (310372).
Contributors
JR, HR, BdG and RS designed the study with input from MN and CT. JR, RS, AH 
and HR performed the experiments. JR and HR analyzed the data. All authors 
discussed the results and implications and commented on the manuscript at all 
stages. RS is the guarantor of this work and, as such, had full access to all the 
data in the study and takes responsibility for the integrity of the data and the 
accuracy of the data analysis.
165
7
References
1.  Cryer PE: Mechanisms of hypoglycemia-associated autonomic failure in diabetes. N Engl J Med 
2013;369:362-372
2.  Ostenson CG, Geelhoed-Duijvestijn P, Lahtela J, Weitgasser R, Markert Jensen M, Pedersen-
Bjergaard U: Self-reported non-severe hypoglycaemic events in Europe. Diabet Med 2014;31:92-
101
3.  Bonds DE, Miller ME, Bergenstal RM, Buse JB, Byington RP, Cutler JA, Dudl RJ, Ismail-Beigi F, 
Kimel AR, Hoogwerf B, Horowitz KR, Savage PJ, Seaquist ER, Simmons DL, Sivitz WI, Speril-
Hillen JM, Sweeney ME: The association between symptomatic, severe hypoglycaemia and 
mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ 
2010;340:b4909
4.  Zoungas S, Patel A, Chalmers J, de Galan BE, Li Q, Billot L, Woodward M, Ninomiya T, Neal B, 
MacMahon S, Grobbee DE, Kengne AP, Marre M, Heller S, Group AC: Severe hypoglycemia and 
risks of vascular events and death. N Engl J Med 2010;363:1410-1418
5.  Hsu PF, Sung SH, Cheng HM, Yeh JS, Liu WL, Chan WL, Chen CH, Chou P, Chuang SY: Association 
of clinical symptomatic hypoglycemia with cardiovascular events and total mortality in type 2 
diabetes: a nationwide population-based study. Diabetes care 2013;36:894-900
6.  Khunti K, Davies M, Majeed A, Thorsted BL, Wolden ML, Paul SK: Hypoglycemia and risk of 
cardiovascular disease and all-cause mortality in insulin-treated people with type 1 and type 2 
diabetes: a cohort study. Diabetes care 2015;38:316-322
7.  Gruden G, Barutta F, Chaturvedi N, Schalkwijk C, Stehouwer CD, Witte DR, Fuller JH, Perin PC, 
Bruno G: Severe hypoglycemia and cardiovascular disease incidence in type 1 diabetes: the 
EURODIAB Prospective Complications Study. Diabetes care 2012;35:1598-1604
8.  Writing Group for the DERG, Orchard TJ, Nathan DM, Zinman B, Cleary P, Brillon D, Backlund JY, 
Lachin JM: Association between 7 years of intensive treatment of type 1 diabetes and long-term 
mortality. Jama 2015;313:45-53
9.  Lu CL, Shen HN, Hu SC, Wang JD, Li CY: A Population-Based Study of All-Cause Mortality and 
Cardiovascular Disease in Association With Prior History of Hypoglycemia Among Patients With 
Type 1 Diabetes. Diabetes care 2016;
10.  Sejling AS, Schouwenberg B, Faerch LH, Thorsteinsson B, de Galan BE, Pedersen-Bjergaard U: 
Association between hypoglycaemia and impaired hypoglycaemia awareness and mortality in 
people with Type 1 diabetes mellitus. Diabet Med 2016;33:77-83
11.  Group UKHS: Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities 
and their duration. Diabetologia 2007;50:1140-1147
12.  Wright RJ, Frier BM: Vascular disease and diabetes: is hypoglycaemia an aggravating factor? 
Diabetes/metabolism research and reviews 2008;24:353-363
13.  Hanefeld M, Duetting E, Bramlage P: Cardiac implications of hypoglycaemia in patients with 
diabetes - a systematic review. Cardiovascular diabetology 2013;12:135
166
Pro-inflammatory effects of hypoglycemia
14.  Ceriello A, Novials A, Ortega E, Pujadas G, La Sala L, Testa R, Bonfigli AR, Genovese S: 
Hyperglycemia following recovery from hypoglycemia worsens endothelial damage and 
thrombosis activation in type 1 diabetes and in healthy controls. Nutr Metab Cardiovasc Dis 
2014;24:116-123
15.  Razavi Nematollahi L, Kitabchi AE, Stentz FB, Wan JY, Larijani BA, Tehrani MM, Gozashti MH, 
Omidfar K, Taheri E: Proinflammatory cytokines in response to insulin-induced hypoglycemic 
stress in healthy subjects. Metabolism 2009;58:443-448
16.  Joy NG, Tate DB, Younk LM, Davis SN: Effects of Acute and Antecedent Hypoglycemia on 
Endothelial Function and Markers of Atherothrombotic Balance in Healthy Humans. Diabetes 
2015;64:2571-2580
17.  Ceriello A, Novials A, Ortega E, La Sala L, Pujadas G, Testa R, Bonfigli AR, Esposito K, Giugliano 
D: Evidence that hyperglycemia after recovery from hypoglycemia worsens endothelial function 
and increases oxidative stress and inflammation in healthy control subjects and subjects with 
type 1 diabetes. Diabetes 2012;61:2993-2997
18.  Dotson S, Freeman R, Failing HJ, Adler GK: Hypoglycemia increases serum interleukin-6 levels in 
healthy men and women. Diabetes care 2008;31:1222-1223
19.  Gogitidze Joy N, Hedrington MS, Briscoe VJ, Tate DB, Ertl AC, Davis SN: Effects of acute 
hypoglycemia on inflammatory and pro-atherothrombotic biomarkers in individuals with type 1 
diabetes and healthy individuals. Diabetes care 2010;33:1529-1535
20.  Dimitrov S, Lange T, Born J: Selective mobilization of cytotoxic leukocytes by epinephrine. J 
Immunol 2010;184:503-511
21.  Geddes J, Schopman JE, Zammitt NN, Frier BM: Prevalence of impaired awareness of 
hypoglycaemia in adults with Type 1 diabetes. Diabet Med 2008;25:501-504
22.  Dagogo-Jack SE, Craft S, Cryer PE: Hypoglycemia-associated autonomic failure in insulin-
dependent diabetes mellitus. Recent antecedent hypoglycemia reduces autonomic responses 
to, symptoms of, and defense against subsequent hypoglycemia. The Journal of clinical 
investigation 1993;91:819-828
23.  Gimenez M, Gilabert R, Monteagudo J, Alonso A, Casamitjana R, Pare C, Conget I: Repeated 
episodes of hypoglycemia as a potential aggravating factor for preclinical atherosclerosis in 
subjects with type 1 diabetes. Diabetes care 2011;34:198-203
24.  Clarke WL, Cox DJ, Gonder-Frederick LA, Julian D, Schlundt D, Polonsky W: Reduced awareness 
of hypoglycemia in adults with IDDM. A prospective study of hypoglycemic frequency and 
associated symptoms. Diabetes care 1995;18:517-522
25.  Janssen MM, Snoek FJ, Heine RJ: Assessing impaired hypoglycemia awareness in type 1 diabetes: 
agreement of self-report but not of field study data with the autonomic symptom threshold 
during experimental hypoglycemia. Diabetes care 2000;23:529-532
26.  Abbink EJ, Walker AJ, van der Sluijs HA, Tack CJ, Smits P: No role of calcium- and ATP-dependent 
potassium channels in insulin-induced vasodilation in humans in vivo. Diabetes/metabolism 
research and reviews 2002;18:143-148
167
7
27.  Hendriks T: Radioimmunoassay of clinically meaningful components of circulating glucagon: 
removal of big plasma glucagon prior to assay. Clinica chimica acta; international journal of 
clinical chemistry 1984;140:301-307
28.  Willemsen JJ, Ross HA, Jacobs MC, Lenders JW, Thien T, Swinkels LM, Benraad TJ: Highly 
sensitive and specific HPLC with fluorometric detection for determination of plasma epinephrine 
and norepinephrine applied to kinetic studies in humans. Clin Chem 1995;41:1455-1460
29.  Wong KL, Tai JJ, Wong WC, Han H, Sem X, Yeap WH, Kourilsky P, Wong SC: Gene expression 
profiling reveals the defining features of the classical, intermediate, and nonclassical human 
monocyte subsets. Blood 2011;118:e16-31
30.  Wright RJ, Newby DE, Stirling D, Ludlam CA, Macdonald IA, Frier BM: Effects of acute insulin-
induced hypoglycemia on indices of inflammation: putative mechanism for aggravating vascular 
disease in diabetes. Diabetes care 2010;33:1591-1597
31.  O’Neill LA, Kishton RJ, Rathmell J: A guide to immunometabolism for immunologists. Nature 
reviews Immunology 2016;
32.  Reno CM, Daphna-Iken D, Chen YS, VanderWeele J, Jethi K, Fisher SJ: Severe hypoglycemia-
induced lethal cardiac arrhythmias are mediated by sympathoadrenal activation. Diabetes 
2013;62:3570-3581
33.  Puente EC, Silverstein J, Bree AJ, Musikantow DR, Wozniak DF, Maloney S, Daphna-Iken D, Fisher 
SJ: Recurrent moderate hypoglycemia ameliorates brain damage and cognitive dysfunction 
induced by severe hypoglycemia. Diabetes 2010;59:1055-1062
168
Pro-inflammatory effects of hypoglycemia
Supplementary material
Table S1: Hormonal responses to hypoglycemia 
Healthy controls T1DM-NAH T1DM-IAH
EU HYPO EU HYPO EU HYPO
Glucagon (pmol/L) 15.8 ± 0.8 33.0 ± 3.7* 13.4 ± 0.8 17.7 ± 2.6† 13.0 ± 0.9 16.1 ± 3.3†
Adrenaline (nmol/L) 0.11 ± 0.02 1.90 ± 0.46*‡ 0.10 ± 0.01 1.94 ± 0.29*‡ 0.12 ± 0.02 0.39 ± 0.07*
Noradrenaline (nmol/L) 1.19 ± 0.17 1.94 ± 0.20* 1.20 ± 0.08 1.46 ± 0.07* 1.33 ± 0.15 1.51 ± 0.20
Cortisol (µmol/L) 0.38 ± 0.06 0.51 ± 0.08* 0.48 ± 0.08 0.69 ± 0.10* 0.43 ± 0.10 0.41 ± 0.08
hGH (mU/L) 8.4 ± 3.8 32.2 ± 9.5* 5.7 ± 1.6 69.2 ± 14.8* 10.2 ± 5.2 52.0 ± 12.4*
Hormonal responses at euglycemia and after 60 minutes of hypoglycemia. Data are mean ± 
SEM, *P < 0.05 for euglycemia versus hypoglycemia, † P  <0.05 versus healthy controls, ‡ P 
<0.01 versus T1DM-IAH
Table S2: Primer sequences used to assess gene expression by qRT-PCR.
target gene forward primer reverse primer
B2M ATGAGTATGCCTGCCGTGTG CCAAATGCGGCATCTTCAAAC
CD11a CAGGCTATTTGGGTTACACCG CCATGTGCTGGTATCGAGGG
CX3CR1 ATATTGGGGACATCGTGGTCT TGGCAAAGATGACGGAGTAGA
CD4 AAGGGGATACAGTGGAACTGAC GGACCTTTAGTTAAGAAGGAGCC
CD8 GCAACCACAGGAACCGAAGA GTCTCCCGATTTGACCACAGG
CD56 TGTCCGATTCATAGTCCTGTCC CTCACAGCGATAAGTGCCCTC
CD14 ACGCCAGAACCTTGTGAGC GCATGGATCTCCACCTCTACTG
CD16 ATGTGTCTTCAGAGACTGTGAAC TTTATGGTCCTTCCAGTCTCTTG
CCR2 CCACATCTCGTTCTCGGTTTATC CAGGGAGCACCGTAATCATAATC
CCR5 CAAAAAGAAGGTCTTCATTACACC CCTGTGCCTCTTCTTCTCATTTCG
169
7
Figure S1: Correlation between the difference in lymphocyte (A), monocyte (B) and neutrophil 
(C) numbers during hypoglycemia versus euglycemia and the difference in adrenaline levels 
between hypoglycemia and euglycemia. Black circles, healthy controls; black squares, T1DM-
NAH patients; black triangles, T1DM-IAH patients.
Figure  S2: IL-6, IL-1β and TNF-α production of PBMCs isolated from euglycemic or 
hypoglycemic conditions and stimulated for 24 h with Pam3Cys (A-C), C. albicans (D-F) or lysate 
of M. tuberculosis (G-I). Open bars, euglycemic values; black bars, hypoglycemic values. * P 
<0.05, ** P <0.01.
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Figure S3: Relative expression of CD11a, CX3CR1, CCR5 and CCR2 assessed by qRT-PCR in CD14- 
(A-D) or CD14+ (E-H) cells exposed to euglycemia or hypoglycemia. Open circles, euglycemic 
values; black circles; hypoglycemic values. * P <0.05.
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Summary
One out of three patients with type 1 diabetes has a reduced ability to 
perceive the onset of hypoglycemia. This condition is referred to as impaired 
awareness of hypoglycemia (IAH) and is usually the consequence of a process 
of habituation to recurrent hypoglycemia. IAH and the associated increased 
risk for severe hypoglycemia constitute a major burden for patients with type 1 
diabetes and their relatives. Alterations in brain metabolism are most certainly 
involved in the pathogenesis of IAH, but the precise mechanisms underlying 
IAH have remained unclear. As a consequence, targeted treatment options that 
do not deteriorate glycemic control are lacking, and more detailed knowledge 
regarding the pathophysiology of IAH is urgently needed. We hypothesized that 
the brain of patients with IAH has been conditioned to use an alternative fuel 
when plasma glucose levels are low. The overall aim of this thesis was to explore 
the role of lactate as a non-glucose alternative fuel in the development of IAH. 
In Chapter 2, we explained which neuroimaging techniques can be used to 
study brain metabolism in humans in vivo and critically reviewed the results 
of studies that have used these techniques to asses cerebral metabolism in 
response to (recurrent) hypoglycemia in individuals with and without IAH. In 
short, neuroimaging studies have shown that recurrent hypoglycemia and IAH 
induce cerebral adaptations on many different levels, including alterations in 
regional cerebral blood flow, neuronal activation patterns, and in the handling 
of brain fuels. Overall, patients with IAH seem better able in preserving brain 
metabolism during hypoglycemia than healthy volunteers, probably as a 
result of these adaptations. Most neuroimaging studies found no evidence of 
altered brain glucose uptake and concentrations in these patients, suggesting 
a role for non-glucose alternative fuels, particularly lactate, in preserving brain 
metabolism. 
Brain lactate concentrations can be assessed and quantified in humans in vivo 
by using proton magnetic resonance spectroscopy (1H-MRS). Throughout this 
thesis we have employed this non-invasive, MRI-related method to quantify 
brain lactate concentrations. In a series of experiments, we combined 1H-MRS 
with the glucose clamp technique, a method that allows plasma glucose 
levels to be held at specific predetermined targets by using a constant insulin 
infusion and a variable glucose infusion. The results of the first set of these 
experiments are described in Chapter 3. Using 1H-MRS for lactate detection, 
we measured brain lactate concentrations during stepped hyperinsulinemic-
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euglycemic-hypoglycemic clamps in three groups of participants: patients with 
type 1 diabetes and IAH, patients with type 1 diabetes and normal awareness of 
hypoglycemia (NAH), and healthy participants without diabetes. Brain lactate 
concentrations dropped in response to acute hypoglycemia in patients with type 
1 diabetes and IAH, whereas concentrations remained unaltered in patients with 
NAH and in participants without diabetes. This effect could not be explained by 
differences in plasma lactate levels. We concluded that the fall in brain lactate 
in patients with IAH most likely reflects increased brain lactate oxidation during 
acute hypoglycemia, which may preserve brain metabolism and interfere with 
the brain’s capacity to detect hypoglycemia.
Next, we aimed to investigate the effect of elevated plasma lactate levels, 
and we studied both the effect of exogenous and endogenous plasma lactate 
elevations on brain lactate concentrations during hypoglycemia with 1H-MRS. 
In Chapter 4, we first demonstrate that the administration of exogenous lactate 
during hypoglycemia, compared with placebo infusion, considerably suppresses 
counterregulatory responses to hypoglycemia in patients with NAH. These data 
are in line with studies performed in the late 1990s that demonstrated blunted 
symptomatic and hormonal responses to hypoglycemia and reduced cognitive 
dysfunction when lactate was infused during hypoglycemia. While previous 
studies primarily focused on clinical effects, we also assessed changes in the 
brain. Lactate administration increased brain lactate levels modestly during 
both euglycemia and hypoglycemia in patients with NAH and IAH. Since cerebral 
lactate uptake is driven by a concentration gradient from blood to brain, elevated 
plasma lactate levels would have been expected to result in an increased brain 
lactate uptake. As the accumulation of lactate in the brain in response to lactate 
infusion was rather limited and less than expected, we hypothesized that lactate 
taken up by the brain is almost immediately oxidized. Such an increase in brain 
lactate oxidation during hypoglycemia could indeed explain the suppressive 
effects of lactate on awareness of hypoglycemia observed in patients with NAH. 
Next, we studied the effect of endogenous plasma lactate elevations on brain 
lactate concentrations during hypoglycemia, using high-intensity interval 
training (HIIT). This relatively new training modality has gained popularity and is 
increasingly advocated among patients with diabetes, but also markedly elevates 
plasma lactate levels. Since exercise may affect counterregulatory responses to 
subsequent hypoglycemia, it is also clinically relevant to examine the effect of 
HIIT. In Chapter 5, patients with IAH, patients with NAH, and healthy individuals 
underwent a hypoglycemic clamp after performing a 15 min HIIT-session on a 
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cycle ergometer. We measured brain lactate concentrations before HIIT and 
continuously during hypoglycemia after HIIT with 1H-MRS. Plasma lactate levels 
increased similarly in all groups in response to HIIT and resulted in increased 
brain lactate concentrations during hypoglycemia. However, the increase 
in brain lactate was most pronounced in patients with IAH. In addition, brain 
lactate levels decreased below baseline levels in this group during subsequent 
hypoglycemia, very similar to the observation described in chapter 3. These 
results further support the concept of increased brain lactate transport and 
increased brain lactate oxidation in patients with type 1 diabetes and IAH. 
Following on our demonstration that HIIT increases brain lactate concentrations, 
we investigated the clinical effects of HIIT on awareness of subsequent 
hypoglycemia. We hypothesized that elevated lactate levels in response to HIIT 
have similar suppressive effects on awareness of hypoglycemia as exogenously 
infused lactate. To address this question we performed a randomized crossover 
trial in which patients with NAH, patients with IAH, and healthy individuals 
underwent a hypoglycemic clamp, either after a HIIT-session as described 
above, or after seated rest. The results of this trial, reported in Chapter 6, 
confirmed our hypothesis and showed that a single, short HIIT-session leading to 
a markedly increased plasma lactate level, reduced symptoms of hypoglycemia 
in patients with NAH, compared with rest. Furthermore, HIIT attenuated the 
decline in cognitive function that normally occurs during hypoglycemia, again 
consistent with previous studies using exogenous lactate administration. In 
patients with IAH, HIIT had no effect on awareness of hypoglycemia, probably 
because symptom responses were already low in these patients and could not 
be suppressed any further. It is likely that elevated (brain) lactate levels after 
HIIT have mediated the suppressive effects of HIIT, by acting as an alternative 
brain fuel during hypoglycemia. Clinically, the reduced symptomatic responses 
may result in an increased risk of hypoglycemia after HIIT in patients with type 
1 diabetes. 
Hypoglycemia does not only affect the brain, but has also been associated 
with increased cardiovascular morbidity and mortality. Although hypoglycemia 
could simply be a marker of underlying vulnerability explaining this association, 
a direct contribution of hypoglycemia to cardiovascular complications seems 
likely. It has been hypothesized that inflammation explains this link, because 
hypoglycemia increases circulating proinflammatory cytokines and systemic 
inflammation increases the risk for cardiovascular complications. However, 
the mechanisms leading to increased cytokine production and the effects of 
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(recurrent) hypoglycemia on the inflammatory function of immune cells are 
unknown. In Chapter 7, the results of a study into the effect of hypoglycemia 
on the composition and inflammatory function of immune cells, using ex vivo 
stimulations of peripheral blood mononuclear cells (PBMCs) obtained during 
a euglycemic-hypoglycemic clamp in patients with IAH, NAH, and healthy 
volunteers, are described. We found that hypoglycemia promotes mobilization of 
specific (more inflammatory) leukocyte subsets and increases the inflammatory 
response of PBMCs. These data demonstrate that hypoglycemia is able to 
shift circulating immune cells toward a more proinflammatory profile, which 
(when sustained) may promote low-grade inflammation and may contribute 
to the development of atherosclerosis in patients with diabetes. However, 
acute inflammatory responses to hypoglycemia were related to the adrenaline 
responses and therefore partly blunted in patients with IAH. This observation 
highlights the role of counterregulatory hormones in immune cell recruitment 
and pro-inflammatory responses to hypoglycemia and raises the question as to 
whether IAH has protective effects against hypoglycemia-induced harm beyond 
that of the brain.
Discussion
Impaired awareness of hypoglycemia is a fairly prevalent syndrome that 
constitutes a major burden for patients with type 1 diabetes, but the underlying 
mechanisms remain insufficiently clarified. The studies described in the present 
thesis support a role for lactate in the development and persistence of IAH. 
This is supported by the fact that brain lactate concentrations behave quite 
comparably in patients with normal awareness of hypoglycemia (NAH) and 
healthy volunteers, whereas cerebral lactate handling is altered in patients with 
IAH. In patients with IAH, hypoglycemia decreases brain lactate, most likely 
due to increased lactate oxidation. After high-intensity interval training, brain 
lactate concentrations increase more pronounced in these patients, compatible 
with enhanced cerebral lactate transport into the brain. Both alterations in 
brain lactate handling may contribute to the preservation of brain metabolism 
during hypoglycemia that could interfere with the brain’s capacity to detect 
hypoglycemia, thus explaining the clinical picture of IAH. This concept is in 
line with our observation that both exogenous and endogenous plasma lactate 
elevations compromise awareness of subsequent hypoglycemia and reduce 
hypoglycemia-induced cognitive dysfunction. 
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Lactate as an alternative fuel
We provide further evidence that brain lactate plays an important role in IAH, 
presumably by acting as an alternative energy fuel for the brain. Measuring brain 
lactate during hypoglycemia is challenging, but with 1H-MRS we were able to 
quantify brain lactate concentrations in vivo in a non-invasive and direct manner. 
However, the current studies cannot fully prove that lactate is indeed oxidized. 
Although spectra were recorded over time, 1H-MRS was used to measure brain 
lactate levels and cannot provide information about brain lactate fluxes. Brain 
lactate concentrations depend on the rates of brain lactate uptake, production, 
oxidation and export. An decrease in brain lactate transport for example, may 
also decrease brain lactate concentrations during hypoglycemia as observed in 
patients with IAH, but we consider this less likely, as plasma lactate levels fall 
to a similar extent in patients with and without IAH during hypoglycemia, and 
because lactate transport capacity has been reported to be increased in patients 
with IAH. Future research, using 13C MRS in combination with infusion of 13C 
labeled compounds, may provide detailed information on lactate fluxes during 
hypoglycemia and could be used to confirm increased brain lactate oxidation 
in patients with IAH. It should be noted that 13C-MRS is technically challenging, 
involves expensive 13C labeled materials and needs mathematic modeling. Future 
studies should also address alterations in brain lactate in patients with type 1 
diabetes in a longitudinal study and before and after (successful) treatment of 
IAH. Reversibility of adaptations in brain lactate handling could substantiate a 
causative role for lactate in the development of IAH. 
The present work describes adaptations in brain lactate in a relatively large area 
in the periventricular region of the brain. Hypotheses that consider alterations 
in brain fuels as the cause of IAH are based on the premise that hypoglycemia 
causes a decrease in cerebral glucose metabolism, which in turn causes an 
increase in sympathoadrenal activity. Metabolism of the alternative fuel (i.e. 
lactate) needs to be sufficient to raise brain oxidative metabolism. A recent PET 
study challenges this view, as hormonal counterregulatory responses occurred 
at milder levels of hypoglycemia than those necessary to produce a reduction 
in cerebral glucose metabolism (1). While these data suggest that a reduction 
in global brain metabolism is not required for counterregulatory hormone 
responses, they do not exclude the possibility that such responses are triggered 
by local reductions in glucose metabolism in critical brain regions. Regarding 
lactate, this may implicate that metabolism only needs to be sufficient to 
increase brain oxidative metabolism in local brain areas. The most important 
region in the brain for the detection of hypoglycemia is the ventromedial 
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hypothalamus (VMH) and it would be interesting to asses changes in lactate 
handling in patients with IAH in this specific region in future studies.
Alternative roles for lactate
Recently, it has been suggested that lactate may exert other roles in the brain, 
in addition to being used as a fuel (2; 3). Lactate has the potential to act as an 
intercellular signaling molecule and metabolic regulator. Mechanistic evidence 
is limited to in vitro data, but may prove relevant in the pathogenesis of IAH. 
A few observations from hypoglycemia studies support such an additional 
role for lactate. In a rodent model of IAH, Herzog et al. demonstrated that 
elevating lactate levels during hypoglycemia resulted in maintenance of brain 
glucose metabolism rather than in an increase in lactate oxidation (4). A study 
that evaluated cross-brain arteriovenous concentration differences during 
hypoglycemia in humans calculated that the increase in brain lactate oxidation 
during hypoglycemia was able to account for a substantial part (~25%) of the 
brain glucose energy deficit, but did not completely offset the fuel deficit (5). 
The proportional contribution of lactate to overall brain energy consumption 
is likely higher in patients with IAH, due to an increased brain lactate transport 
capacity (6; 7), but still may not be sufficient to fully substitute glucose. 
Lactate may not only support brain metabolism by acting as an energy 
substrate, but may also act a ‘metabolic regulator’ through various mechanisms. 
Lactate is taken up by the brain through proton-linked facilitated diffusion 
by monocarboxylate transporters (8). Entry of large amounts of lactate and 
co-transported protons may alter intracellular pH, which affects the activity 
of important glycolytic enzymes, such as phosphofructokinase (9). Inside the 
brain cell, the enzyme lactate dehydrogenase (LDH) catalyzes the conversion of 
lactate to pyruvate and back, through a reversible oxidation-reduction (redox) 
reaction. Even relatively small increases in local brain lactate uptake can shift 
the LDH reaction toward pyruvate formation (10), which increases NADH/NAD+ 
ratios and triggers several intracellular responses (2). Lactate may also signal 
through a specific lactate receptor, the G-protein-coupled receptor 81 (GPR81), 
only discovered in the mammalian brain in 2013 (11), which affects metabolism 
via the cAMP pathway. Future studies focusing on lactate should further explore 
these alternative mechanisms. 
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Other cerebral adaptations in IAH
Given the complexity of the physiological response to hypoglycemia, it is likely that 
the brain adapts to recurrent hypoglycemia by more than one mechanism. Recent 
studies (12; 13) report alterations in global and regional cerebral blood flow responses 
to hypoglycemia in patients with IAH. For example, hypoglycemia increases global 
CBF in patients with IAH, but not in patients with NAH or healthy volunteers (13). 
Similar to adaptations in lactate handling, this may be an adaptive response aimed 
at neuroprotection that simultaneously suppresses counterregulatory responses. 
In addition, alterations in neutrotransmission, in particular increased output of 
the inhibitory neurotransmitter GABA in the VMH (14), may also contribute to 
defective counterregulatory responses. Of note, lactate is able to influence both 
cerebral blood flow and (15) and VMH GABA levels (16). 
Clinical implications and future perspectives
The work performed in this thesis contributes to a better understanding of the 
mechanisms involved in IAH, but also has some direct clinical implications. 
Antecedent low- and moderate-intensity exercise has previously been shown to 
suppress hormonal and symptomatic responses to next-day hypoglycemia (17). In 
chapter 6, we demonstrated that a more intensive, but shorter, exercise modality 
in the form of a single HIIT-session, is able to rapidly reduce symptomatic 
responses to a subsequent episode of hypoglycemia in patients with NAH. These 
results imply that patients with type 1 diabetes should closely monitor their blood 
glucose levels after high-intensity interval exercise, since this may increase the 
risk of postexercise hypoglycemia or prolong its duration. Because short-term 
increments in plasma glucose levels often occur after HIIT, patients may tend to 
correct this with insulin, but this should only be done with great care. 
The central role of lactate in the suppression of counterregulatory responses 
to hypoglycemia may eventually translate into clinical approaches. First and 
foremost, the mechanisms by which lactate affects awareness of hypoglycemia 
require further, detailed mechanistic studies. In animal models of IAH, lactate 
metabolism and its signaling pathways can be specifically assessed with blockers 
(e.g. using LDH-blockers, GPR81 antibodies etc.) or studied in rodents with 
genetically deleted or overexpressed enzymes. In animal models of epilepsy, 
LDH blockage has already been tested and successfully suppressed seizures 
(18). It will be challenging to develop targeted clinical interventions, aimed at 
reducing brain lactate transport or metabolism as lactate is such an important 
mediator in multiple pathways and interfering with its metabolism may result in 
untoward effects (19). 
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While many people with type 1 diabetes experience recurrent hypoglycemia, 
less than half of them develop IAH. Another future direction would be to 
investigate genetic variations in lactate receptors or transporters, which may 
affect susceptibility to develop IAH. It would also be interesting to look into 
changes in lactate transporters in the brain in response to various types of 
exercise. Acute exercise has been shown to increase region-specific expression 
of lactate transporters in rats (20), and this may be a mechanistic link between 
exercise and the development of counterregulatory defects.
IAH: the two sides of the coin
Maintaining a level of glucose control that both prevents complications 
associated with hyperglycemia and minimizes the problems associated with 
hypoglycemia is a continuous challenge for patients with type 1 diabetes and 
their health care providers. Our results contribute to a more balanced view on 
cerebral and inflammatory effects of hypoglycemia. Recurrent hypoglycemia 
is regarded by patients and caregivers as unfavorable, because of its potential 
harmful effects for the brain and the interference with daily life activities, 
occasionally leading to dangerous situations. Few may realize that recurrent 
hypoglycemia may also induce some beneficial adaptations that may (partly) 
protect against harm from subsequent hypoglycemia and perhaps dampen the 
systemic effects of hypoglycemia. Animal studies have shown that recurrent 
mild to moderate hypoglycemia protects against severe hypoglycemia-induced 
neuronal damage, cognitive impairment and death (21; 22). In analogy, the 
adaptations in brain lactate handling in patients with IAH are likely aimed at 
protecting the brain against harm from subsequent severe hypoglycemia, by 
preserving brain metabolism when glucose supply is limited. Paradoxically, 
these adaptations may simultaneously impair the detection of hypoglycemia 
by the brain and thus the initiation of protective counterregulatory responses. 
Altogether, it seems that recurrent episodes of hypoglycemia render a patient 
more prone to an episode of severe hypoglycemia, but somewhat less vulnerable 
to its harm. 
Hypoglycemia is a systemic stressor with effects beyond that affecting the brain. 
We found that hypoglycemia induces proinflammatory changes in circulating 
immune cells in healthy volunteers and patients with NAH, which may contribute 
to systemic inflammation and aggravate cardiovascular complications in patients 
with diabetes. In patients with IAH, however, we observed an attenuated 
proinflammatory response to acute hypoglycemia. Analogously to cerebral 
adaptations, this attenuated response may provide some protection against 
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harmful effects of subsequent hypoglycemia. This adaptive effect of recurrent 
hypoglycemia is in line with recent observations that IAH may not increase 
all-cause or cardiovascular mortality in patients with type 1 diabetes (23). In 
contrast, studies focusing on vascular effects report higher rates of preclinical 
atherosclerosis in patients who experienced recurrent hypoglycemia and greater 
proatherothrombotic responses after prior hypoglycemia in healthy individuals 
(24; 25). More research is needed to determine long-term consequences of 
recurrent hypoglycemia and IAH on inflammation and immune cells, and their 
role in atherogenesis.
Closing remarks
Impaired awareness of hypoglycemia is a prevalent and burdensome syndrome 
that limits optimal glucose control and substantially increases the risk for 
severe hypoglycemia in patients with type 1 diabetes. Our studies contribute to 
the unraveling of its pathophysiology and support an important role for brain 
lactate handling in the development of IAH. The results of our studies may add 
towards better understanding of IAH and in the end provide avenues towards 
therapeutic interventions for IAH. A joint effort of clinical and non-clinical 
researchers is needed to further disentangle the mechanisms of IAH in order 
to reduce the burden of severe hypoglycemia, maintain the benefits of good 
glycemic control, and improve the overall wellbeing of people suffering from 
type 1 diabetes. 
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Suikerziekte (diabetes mellitus) is een steeds vaker voorkomende ziekte. 
Alleen al in Nederland zijn er ruim een miljoen mensen met diabetes. Er zijn 
verschillende vormen van diabetes, waarvan de bekendste type 1 en 2 diabetes 
zijn. Dit proefschrift gaat over type 1 diabetes, de vorm die bij grofweg 10% van de 
diabetespatiënten voorkomt en vaak op jonge leeftijd ontstaat. Type 1 diabetes is 
een auto-immuunziekte, dat wil zeggen dat het eigen afweersysteem de insuline 
producerende cellen in de alvleesklier kapot maakt. Insuline zorgt ervoor dat 
suiker (glucose) uit het bloed wordt opgenomen in spieren en vet, waar het als 
brandstof gebruikt kan worden. Insuline verlaagt dus de bloedglucosespiegel. Bij 
patiënten met type 1 diabetes stijgt de bloedglucosespiegel door het gebrek aan 
insuline. Zonder toediening van insuline leidt dit op korte termijn tot overlijden. 
Een chronische, mildere, verhoging van de bloedglucosespiegel is ook gevaarlijk, 
want dit kan leiden tot ernstige complicaties, zoals hart- en vaatziekten, blindheid 
en zenuw- en nierschade. Om deze complicaties zoveel mogelijk te voorkomen 
wordt gestreefd naar een zo normaal mogelijke bloedglucosespiegel. Patiënten 
spuiten hiervoor dagelijks meerdere malen insuline. 
De afgelopen decennia zijn er veel ontwikkelingen geweest in de behandeling van 
diabetes, met verfijndere insulines en nieuwe toedieningsvormen. Desondanks 
blijft de behandeling met insuline in de praktijk verre van perfect. Bij te weinig 
spuiten van insuline blijft de bloedglucosespiegel te hoog en bij te veel spuiten 
van insuline daalt de glucosespiegel te sterk. Een te lage bloedglucosespiegel 
wordt een hypoglykemie (hypo) genoemd. Patiënten met type 1 diabetes 
ervaren gemiddeld twee hypo’s per week, wat neerkomt op vele duizenden 
hypo’s gedurende hun leven. Normaal gesproken zorgt een hypo ervoor dat 
bepaalde stresshormonen vrijkomen (zoals adrenaline), deze hormonen helpen 
het lichaam om de glucosespiegel te herstellen. Ook ontstaan er herkenbare 
klachten als zweten, trillen en honger. Echter, bij één op de drie patiënten treden 
de hormoonreactie en klachten van een hypo niet meer of in verminderde mate 
op. Dit verminderde gevoel om hypo’s op te merken wordt ‘impaired awareness 
of hypoglycemia’ (IAH) genoemd. Patiënten met deze aandoening lopen een 
zeer groot risico op ernstige hypo’s. De glucosespiegel is dan zo laag dat een 
verminderd bewustzijn of een coma optreedt. Patiënten zijn dan niet meer in 
staat om zelf de glucosespiegel te corrigeren, maar afhankelijk van anderen 
voor hulp. Ernstige hypo’s kunnen zo gevaarlijke situaties opleveren en leiden 
tot ongelukken en soms zelfs tot overlijden. 
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Hoe IAH ontstaat, is niet precies bekend. Men denkt dat oorzaak ergens in het 
brein ligt, omdat de hersenen een rol spelen in zowel het opmerken van een 
hypo als in het opstarten en regelen van de hormoon- en symptoomreactie 
op een hypo. Waarschijnlijk spelen veranderingen in de energiehuishouding 
van de hersenen, ten gevolge van het ervaren van eerdere hypo’s, een rol in 
IAH. Normaal gesproken is glucose de belangrijkste brandstof voor het brein, 
maar de hersenen kunnen ook andere, alternatieve brandstoffen gebruiken. 
Één van die brandstoffen is melkzuur (lactaat). Lactaat is het zuur wat het 
lichaam aanmaakt als de spieren ‘verzuren’ door intensief sporten, maar is ook 
in rust in kleine hoeveelheden in het bloed en brein aanwezig. Onze hypothese 
was dat de hersenen van patiënten met IAH als het ware zijn getraind om een 
alternatieve brandstof te gebruiken wanneer de bloedglucosespiegel laag is. In 
dit proefschrift onderzochten we de rol van lactaat, als alternatieve brandstof 
voor glucose, in het ontstaan van IAH. 
Hoofdstuk 1 geeft uitleg over de achtergrond van IAH, de gevolgen die deze 
aandoening heeft voor het dagelijks leven van patiënten en de huidige (beperkte) 
behandelopties. In hoofdstuk 2 bekeken we welke technieken het mogelijk 
maken om hersenmetabolisme in ‘real life’ (in vivo) te meten in mensen. Ook 
gaan we dieper in op de resultaten van eerdere studies die deze technieken 
hebben gebruikt om te kijken naar veranderingen in hersenmetabolisme tijdens 
een hypo of in reactie op een hypo. Samenvattend laten deze neuroimaging 
studies zien dat (herhaalde) hypo’s leiden tot aanpassingen in de hersenen 
op meerdere niveaus, waaronder veranderingen in regionale bloedtoevoer, 
patronen van hersenactivititeit en gebruik van brandstoffen. Patiënten met 
diabetes (met name patiënten met IAH) lijken beter in staat om hun stofwisseling 
(metabolisme) in de hersenen in stand te houden tijdens een hypo dan gezonde 
vrijwilligers, waarschijnlijk ten gevolge van deze aanpassingen. Opvallend 
is dat neuroimaging studies geen aanwijzingen hebben gevonden voor een 
verandering in de hoeveelheid glucose in het brein van deze patiënten. Dit 
suggereert een rol voor alternatieve brandstoffen, zoals lactaat, in het behoud 
van brein metabolisme tijdens een hypo.
In de experimenten beschreven in dit proefschrift hebben we gebruik gemaakt 
van proton (1H) magnetische resonantie spectroscopie (1H-MRS) als neuro-
imaging techniek. Dit is een niet-invasieve, aan MRI-gerelateerde techniek 
waarbij concentraties van metabolieten in het brein gemeten kunnen worden. 
Voor het verrichten van de studies in dit proefschrift werd deze techniek 
geoptimaliseerd voor het meten van de hoeveelheid lactaat in het brein. In 
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een serie van experimenten combineerden we 1H-MRS met de zogeheten 
‘glucose clamp’ methode. Middels deze methode is het mogelijk om de 
bloedglucosespiegel zeer precies te regelen. Met behulp van een insuline-infuus 
en variabel glucose-infuus wordt de bloedglucosespiegel als het ware ‘vastgezet’ 
op een vooraf bepaalde glucosewaarde. 
In hoofdstuk 3 worden de resultaten van het eerste onderzoek beschreven, 
waarin we 1H-MRS gebruikten voor het meten van lactaat in de hersenen tijdens 
normale bloedglucosewaardes (euglykemie) en tijdens hypoglykemie in drie 
groepen proefpersonen: 1) proefpersonen zonder diabetes, 2) patiënten met 
type 1 diabetes en een normale gevoeligheid voor hypo’s (normal awareness of 
hypoglycemia: NAH) en 3) patiënten met type 1 diabetes en IAH. De concentratie 
lactaat in het brein daalde gedurende de hypo bij patiënten met diabetes en 
IAH, maar bleef stabiel in zowel de patiënten met NAH als in de proefpersonen 
zonder diabetes. De hoeveelheid lactaat in het bloed was gelijk in de drie 
groepen. We concludeerden dat de daling in brein lactaat in de patiënten met 
IAH meest waarschijnlijk komt door meer verbruik van lactaat als brandstof 
(oxidatie) tijdens de hypo. Wanneer lactaat inderdaad als alternatieve brandstof 
wordt gebruikt, kan dit zorgen voor behoud van brein metabolisme tijdens 
een hypo en op deze manier verhinderen dat het brein het glucosegebrek 
detecteert. Wanneer het brein geen energiegebrek detecteert, zal het ook geen 
waarschuwingsignaal afgeven naar het lichaam en komt de lichamelijke reactie 
op de hypo niet op gang. 
Vervolgens hebben we gekeken naar het effect van verhoogde lactaatwaardes 
in het bloed. Er zijn twee manieren om dit te bereiken: door toediening van 
lactaat via een infuus (exogeen lactaat) of door het lichaam zelf meer lactaat te 
laten aanmaken (endogeen lactaat), bijvoorbeeld middels sport. In hoofdstuk 
4 laten we zien dat de toediening van exogeen lactaat tijdens hypoglykemie, 
in vergelijking met toediening van een niet werkzame stof (placebo), leidt tot 
een sterke vermindering van hypoklachten en van de hormonale reactie op 
een hypo bij patiënten met NAH, patiënten die normaal gesproken een goede 
gevoeligheid voor hypo’s hebben. In deze studie zagen we een duidelijk toename 
van lactaat in het bloed, maar de toename van lactaat in het brein was relatief 
gering. Het is bekend dat het transport van lactaat naar het brein toeneemt bij 
hogere lactaatwaardes in het bloed. Het ontbreken van een duidelijke stijging 
van lactaat in het brein bij deze hoge bloedwaardes zou kunnen beteken dat het 
extra getransporteerde lactaat in het brein direct wordt gebruikt als brandstof. 
Dit verhoogde gebruik van lactaat in het brein zou de verklaring kunnen zijn 
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voor de onderdrukkende effecten van lactaat op hypo symptomen en de 
hormoonreactie bij patiënten met NAH. 
Vervolgens hebben we gekeken naar het effect van een endogene verhoging 
van bloed lactaat op brein lactaat concentraties tijdens hypoglykemie. Het 
endogene lactaat werd verhoogd met een hoogintensieve interval training (high-
intensity interval training: HIIT). HIIT is een relatief nieuwe, steeds populairdere 
trainingsmodaliteit die toenemend wordt geadviseerd aan patiënten met 
diabetes en tevens zorgt voor een sterke stijging van lactaat in het bloed. In 
hoofdstuk 5 ondergingen vergelijkbare groepen proefpersonen (proefpersonen 
zonder diabetes, patiënten met diabetes en NAH, en patiënten met diabetes en 
IAH) een hypo nadat ze een vijftien minuten durende HIIT-training op een fiets 
hadden uitgevoerd. De bloedlactaatwaardes namen fors toe en waren gelijk in 
de groepen. Tevens was in iedere groep een toename in brein lactaat zichtbaar, 
maar deze toename was het grootst in patiënten met IAH. Daarnaast daalde 
de hoeveelheid brein lactaat gedurende de hypo tot onder de beginwaardes 
in patiënten met IAH, maar niet in de andere twee groepen. Deze bevindingen 
zijn vergelijkbaar met de resultaten beschreven in hoofdstuk 3 en ondersteunen 
het idee dat patiënten met IAH een verhoogde capaciteit hebben om lactaat 
te transporteren naar het brein en om brein lactaat te oxideren (gebruiken als 
brandstof) tijdens een hypo. 
Nadat we aan hadden getoond dat HIIT brein lactaat concentraties verhoogd, 
onderzochten we het klinische effect van HIIT op de gevoeligheid voor 
het bemerken van een hypo. Van andere sportmodaliteiten (zoals laag- en 
middelintensieve training) is bekend dat ze de gevoeligheid voor het bemerken 
van een hypo kunnen verminderen, maar van HIIT is dit nog niet eerder 
onderzocht. Onze hypothese was dat verhoogde bloed lactaatspiegels na HIIT 
vergelijkbare onderdrukkende effecten hebben op de hypo gevoeligheid als 
exogeen lactaat. Om deze vraag te beantwoorden voerden we een onderzoek 
uit waarin proefpersonen zonder diabetes, patiënten met NAH en patiënten met 
IAH op twee ochtenden een hypo ondergingen, op de ene ochtend na een korte 
HIIT-sessie en op de andere ochtend na een periode van rust (in willekeurige 
volgorde). Ook bekeken we hoe proefpersonen konden functioneren tijdens de 
hypo’s met onder andere reken- en geheugentests. De resultaten van de trial 
worden gepresenteerd in hoofdstuk 6 en bevestigden onze hypothese dat een 
HIIT-sessie, welke leidt tot hoge lactaatwaardes in het bloed, symptomen van 
een hypo vermindert in vergelijking met een periode van rust in patiënten met 
NAH. Daarnaast konden deelnemers beter blijven functioneren tijdens de hypo 
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na HIIT in vergelijking met de hypo na rust. In patiënten met IAH had HIIT geen 
effect op de gevoeligheid voor hypo’s, waarschijnlijk omdat de hyposymptomen 
al zeer laag waren in deze groep, zodat ze niet nog verder onderdrukt konden 
worden. Het is waarschijnlijk dat de verhoogde bloedlactaatspiegels na HIIT de 
onderdrukkende effecten op hypo gevoeligheid hebben veroorzaakt, doordat 
lactaat als een alternatieve brandstof functioneert voor het brein tijdens de 
hypo. Dit zou ook het betere functioneren na HIIT kunnen verklaren. In de 
praktijk kan de verminderde symptoom- en hormoonreactie op een hypo na 
HIIT ervoor zorgen dat patiënten met diabetes een groter risico lopen op hypo’s 
na dergelijke trainingen.  
Hypoglykemieën hebben niet alleen effect op het brein, maar zijn ook 
geassocieerd met een verhoogd risico op (overlijden aan) hart- en vaatziekten. 
Ontstekingstoffen in het bloed dragen waarschijnlijk bij aan schade aan bloedvaten 
bij patiënten met diabetes. Van hoge bloedglucose is bekend dat dit leidt tot meer 
ontstekingstoffen in het bloed, onder andere aangemaakt door bepaalde witte 
bloedcellen, die betrokken zijn bij de afweer tegen ziektes. Wij vroegen ons af of 
hypo’s op een vergelijkbare manier zouden kunnen bijdragen aan ontsteking. In 
hoofdstuk 7 presenteren we de resultaten van een onderzoek dat werd gedaan 
in dezelfde drie onderzoeksgroepen als in hoofdstuk 6. Voorafgaand en aan het 
einde van een hypo filterden we een deel van de witte bloedcellen uit het bloed van 
proefpersonen. We zagen dat de hoeveelheid witte bloedcellen bij proefpersonen 
zonder diabetes en bij patiënten met NAH sterk toenam tijdens de hypo. Dit betrof 
met name witte bloedcellen die geassocieerd zijn met ontsteking. Deze toename 
wordt waarschijnlijk veroorzaakt door het stresshormoon adrenaline dat vrijkomt 
tijdens een hypo. Bij patiënten met IAH, bij wie de stressrespons bijna niet 
aanwezig is gedurende de hypo, zagen we dan ook geen toename in de hoeveelheid 
cellen. Wel zagen we in alle deelnemende groepen in het laboratorium dat witte 
bloedcellen die aan een hypo zijn blootgesteld, meer ontstekingstoffen aanmaken 
wanneer ze een nieuwe stressvolle situatie meemaken dan witte bloedcellen die 
alleen zijn blootgesteld aan ‘normale’ suikers. Deze data laten zien dat een hypo 
zorgt voor een toename in het aantal witte bloedcellen dat zich in het bloed 
bevindt, en dat deze cellen ook meer actief zijn (meer ontstekingsstoffen maken). 
Dit zou het ontstaan van vaatschade kunnen promoten, met name wanneer het 
effect lang aan houdt. Echter, de inflammatoire reactie was minder uitgesproken 
in patiënten met IAH, mogelijk ten gevolge van het frequent ervaren van eerdere 
hypo’s. Voor het brein is het reeds aangetoond dat het herhaald ervaren van milde 
hypo’s beschermt tegen breinschade tijdens volgende hypo’s. Mogelijk geldt dit 
beschermende effect ook voor de bloedvaten. 
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Conclusie
Impaired awareness of hypoglycemia (IAH) is een vaak voorkomend syndroom dat 
belastend is voor patiënten met type 1 diabetes. Het onderliggende mechanisme 
blijft onvoldoende verklaard. De studies in dit proefschrift ondersteunen een rol 
voor lactaat in het ontstaan en persisteren van IAH. Onze bevindingen laten zien 
dat brein lactaat concentraties zich vergelijkbaar gedragen in proefpersonen 
zonder diabetes en patiënten met type 1 diabetes met een normale gevoeligheid 
voor hypo’s, maar dat er veranderingen optreden in brein lactaat concentraties 
in patiënten met IAH. In deze patiënten daalt de hoeveelheid lactaat in het 
brein tijdens hypoglykemie, waarschijnlijk ten gevolge van een toename in 
de capaciteit om brein lactaat te oxideren en gebruiken als brandstof. Na een 
hoogintensieve intervaltraining nemen brein lactaat concentraties meer toe in 
patiënten met IAH, wat past bij een verhoogde capaciteit om lactaat van het 
bloed te transporteren naar het brein. Beide aanpassingen in de verwerking van 
brein lactaat (meer oxidatie en meer transport) kunnen bijdragen aan behoud 
van brein metabolisme tijdens een hypoglykemie. Deze aanpassingen zijn 
waarschijnlijk gericht op bescherming van het brein tegen schade ten gevolge 
van een mogelijke volgende hypoglykemie, maar belemmeren tegelijkertijd de 
detectie van de hypo door het brein, waarmee ze bijdragen aan het klinische 
beeld van IAH. Er zijn in nieuwe laboratorium onderzoeken zelfs aanwijzingen 
dat lactaat niet alleen direct, maar ook indirect (als een soort van hormoon) 
invloed zou kunnen uitoefenen op het brein metabolisme. Een rol voor 
lactaat in het onderdrukken van de hypo reactie wordt bevestigd door onze 
bevindingen dat zowel een exogene als endogene verhoging van lactaat in het 
bloed de gevoeligheid voor het bemerken van een hypo vermindert en cognitief 
disfunctioneren tijdens de hypo beperkt. 
Daarnaast hebben we laten zien dat een hypo ook belangrijke effecten heeft 
buiten het brein. We ontdekten dat het aantal witte bloedcellen toeneemt na 
een hypo en dat deze cellen ook actiever zijn: ze maken meer ontstekingsstoffen 
aan bij stress. Het is mogelijk dat deze ontstekingsreactie na een hypo bijdraagt 
aan het ontstaan van vaatschade bij mensen met diabetes. 
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Dankwoord
De afgelopen jaren heb ik het geluk gehad te mogen werken en ontspannen met 
fantastische mensen. Op deze plek wil ik van de gelegenheid gebruik maken 
om een aantal van deze mensen te bedanken voor hun bewuste of onbewuste 
bijdrage aan dit proefschrift. 
Allereerst alle studiedeelnemers. Ik heb jullie niet bepaald de prettigste 
onderzoeken laten ondergaan en was vaak verwonderd over jullie bereid-
willigheid en enthousiasme voor (herhaaldelijke!) deelname. Bedankt voor 
de ongelofelijke inzet, het -dikwijls lachend- ondergaan van alle ontberingen 
en de persoonlijke, vaak indrukwekkende verhalen tijdens de soms lange 
onderzoeksdagen. In de toekomst hoop ik voor jullie op een langere ‘vakantie’ 
van de diabetes dan de paar uurtjes bij mij in het research centrum. 
Dr. de Galan, beste Bastiaan, onderzoek doen met jou ging als vanzelf. Dank 
voor het vertrouwen dat ik kreeg en voor het feit dat ik altijd bij je terecht kon 
met vragen, hoe druk het ook was. Van praktische vaardigheden als clampen 
tot kritisch schrijven, ik heb héél veel van je geleerd. Ik ken niemand die zo 
toegewijd is aan het onderzoek (die beurs is dubbel en dwars verdiend) en ben 
nog altijd blij dat je me aansprak daar in de gang bij EOV. Ik hoop in de toekomst 
nog lang met je te kunnen blijven samenwerken.  
Prof. dr. Tack, beste Cees, ondanks het feit dat onze karakters wat verschillen, 
of misschien juist dankzij dat verschil, heb ik de grootste (levens)lessen van jou 
geleerd. Voor mij de meest gehoorde van je vele oneliners: ‘You have to séll it!’ 
(je kan nog zo goed onderzoek doen, maar moet het ook kunnen verkopen). 
Ik wil je bedanken voor je directheid en eerlijkheid en vond het prettig dat je 
waakte over de grote lijnen van het onderzoek en waar nodig op kwam voor je 
promovendi. Jij en Bastiaan vormen een super team. En ja: ‘life is like a box of 
chocolates, ...’  
Dr. ir. van der Graaf, beste Marinette. Bedankt voor de technische adviezen en 
je altijd kritische blik op protocollen en artikelen. Dank ook voor de jaarlijkse 
etentjes, aandacht voor persoonlijke verhalen (tussen al dat mannengeweld) en 
voor de gezelligheid tijdens besprekingen en congressen.   
197
A
Prof. dr. Heerschap, beste Arend, hoewel je als tweede promotor wat minder 
intensief betrokken was bij het onderzoek, was je MR-kennis onmisbaar bij het 
tot stand komen van dit boekje. Ik wil je bedanken voor je scherpe blik en rake 
opmerkingen de afgelopen jaren. 
Dan, Evita, mijn technische wederhelft ofwel ‘partner in crime’. Wat ben ik blij 
dat we samen dit traject hebben mogen doorlopen, ik had me geen betere 
match kunnen voorstellen! Zonder jouw technische inzichten waren we niet tot 
dit eindresultaat gekomen. En minstens zo belangrijk: de jaren waren een stuk 
minder gezellig geweest. Ik vond het jammer dat ik zonder je verder moest in de 
kliniek en wens je alle goeds voor de toekomst. Waar je ook terecht komt later, 
ik vind je een hele sterke onderzoeker. Voor dat biertje of kopje koffie nu en dan 
is het overigens wel handig als je een beetje in de buurt blijft.  
Leden van de manuscriptcommissie, prof. dr. Brock, prof. dr. Hoekstra, prof 
dr. McCrimmon: hartelijk dank voor het lezen en kritisch beoordelen van mijn 
manuscript. 
De experimenten waren niet mogelijk geweest zonder praktische ondersteuning: 
Karin, Simone en Adrianne vanuit het CRCN (en overigens ook iedereen die een 
dagje in kon vallen) dank voor de hulp bij de eindeloze, ontzettend onpraktische 
bloedafnames in de MRI. Voor het halen van nieuwe of repareren van kapotte 
infuuspompen en voor morele ondersteuning als de onderzoeksochtend niet 
liep zoals gepland. De medisch studenten die hebben geholpen bij de metingen 
in de weekends en op vakantiedagen: Iris, Lisa en Nikki, dank voor jullie bijdrage. 
Kirsten, bedankt voor het mede opzetten van de ASL metingen. Medewerkers 
van het secretariaat interne, het research bureau van de radiologie en MR 
laboranten: bedankt voor de logistieke ondersteuning. 
Mijn dank gaat ook uit naar collega’s bij de radiologie. Een paar namen die ik eruit 
wil lichten: Mark, Sjaak en Bart. Bedankt voor jullie technische kennis en geduld. 
Of het nu ging om de MR sequentie of een ‘simpel’ computerprobleem, hulp was 
altijd beschikbaar. Ook dank voor het begrip dat ons project zoveel meettijd op 
de MRI in beslag nam, voor het warme welkom op radiologiebesprekingen of 
borrels en voor het aannemen (en aanhoren!) van al mijn telefoongesprekken 
met Evita. 
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Daarnaast wil ik alle coauteurs van de papers bedanken voor de prettige 
samenwerking en kritische input. In het bijzonder bedank ik Bregina en Dick 
van de afdeling fysiologie, voor praktische hulp en inhoudelijke adviezen. 
Collega’s van de nucleaire geneeskunde: Martin, Mijke, Marti en Maarten, waar 
ik de mogelijkheid kreeg om te leren clampen, en Roy Kessels van de medische 
psychologie voor statistisch advies. 
Dan wil ik graag alle (oud-)collega onderzoekers van de interne bedanken, 
van wie ik velen inmiddels ook regelmatig buiten het ziekenhuis tref. 
Elsemiek, dank dat je me voorging in het onderzoeksgebeuren, voor je 
nuchtere kijk op zaken en praktische oplossingen. Ik hoop dat we in de toekomst 
nog ergens samen in de kliniek mogen werken. In de tussentijd moeten we 
maar gewoon koffie- of thee dates plannen. Vanuit het lab: Jacqueline, werk 
uit handen geven en volledig op iemand anders vertrouwen vind ik normaal 
gesproken lastig. Bij jou had ik hier totaal geen last van. Je bent een super 
wetenschapper en ik vond het erg fijn om met je te kunnen samenwerken. 
Dank ook voor de heerlijke taartjes en relaxte pasta-avonden in het prachtige, 
verre buitenland. Lian, ik vond het tof om je te introduceren in het onderzoek 
en bovenal gezellig dat je ons bent komen versterken. Ik wens je veel succes met 
je overige studies. Cor en Anneke, bedankt voor jullie hulp en ondersteuning 
bij de cytokinestudie. De internisten/diabetologen en diabetesverpleeg-
kundigen van het Radboudumc, bedankt voor de welkome ontvangst en hulp 
bij het zoeken naar geschikte onderzoeksdeelnemers. 
Dan overige collega’s uit de buitenhoek. Mede door de vele kamerwisselingen 
en samenwerkingen zijn het er eigenlijk teveel om op te noemen. Met koffie 
of een biertje sparren over mislukte metingen, missende labuitslagen of 
onhandige databases, of juist eens niet over werk praten, was erg fijn. Een korte 
selectie: Janna en Sam, mijn ‘langdurigste’ roomies, dank voor de gezelligheid. 
Inge, bedankt voor je tips en voor je vertrouwen (waarbij je zelfs de eerste 
proefpersoon wilde zijn). Super dat we nu opnieuw collega’s zijn. Megan, dank 
voor alle gezellige kopjes koffie en etentjes binnen en buiten het ziekenhuis. 
Voor gezelligheid tijdens congressen in binnen- en buitenland: Kathrin, Janna, 
Heleen, Juliane, Thalijn, Steef, Rinke en Bas, bedankt! Wielren-fanatiekelingen: 
Mark, dank voor je wielrenlessen die met net zoveel precisie en enthousiasme 
werden uitgevoerd als menig onderzoek. Ook Lisa, dank voor je aanstekelijke 
enthousiasme hierin. Overige collega’s van het lab AIG, met wie ik wel eens (of 
wat vaker) een drankje heb gedronken en waar ik altijd welkom was om aan 
te haken voor gezelligheid, ook al zat ik zelf nooit in het lab: Charlotte, Ekta, 
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Anouk, Maartje, Simone, Arjan, Floor, Stephan, Andreea, Kiki, Lily, Inge, Jelmer, 
Katharina, Kathrin (2x), Marlies, Michelle, Rob (2x), Wouter, Martin, Ruud, 
Valerie, Jessica, Berenice, Vera en Viola (ik hoop zo dat ik niemand ben vergeten). 
Collega’s uit het CWZ, ik wil jullie bedanken voor het warme welkom en voor 
alle begrip en ondersteuning. Met veel plezier kijk ik uit naar de komende 
jaren bij jullie. 
Vrienden en familie die me hebben helpen ontspannen de afgelopen jaren en 
wie ik niet allemaal bij naam zal noemen. Dank voor de gezelligheid, wijntjes en 
biertjes, champagne en taxiritjes naar Nijmegen. Vrienden van de oude garde, 
van de tafel van vijf: Sanne (en Jaap) en Sabine (en Giel). Het lijkt nog zo kort 
geleden dat we in het tussenuur samen aan tafel zaten. Dank voor ontelbaar 
veel mooie herinneringen, steun wanneer dat nodig is en vele buikpijn- 
momenten van het lachen. Lieve Marlies, na al die jaren alsnog tegelijk de 
opleiding gestart in Nijmegen, wie had dat gedacht. Je had ook zo paranimf 
kunnen zijn, maar ik heb je graag op die andere belangrijke dag aan mijn 
zijde. Bedankt voor ontzettend veel gezellige momenten en voor het er zijn 
als er iets is. Dan kort nog dank aan iedereen met wie ik een rondje mocht 
wielrennen (Marjolein, ook dank voor de  fanatieke spinning-uurtjes) en voor 
degenen die me hielpen mijn brein alert en geprikkeld te houden met muzikale 
uitjes of mentale uitdagingen (Huub, Sylke: wanneer is de volgende escape?). 
Lieve schoonfamilie, met jullie heb ik ook al zo’n geluk gehad. Ton en Aagje, dank 
voor jullie support. Voor het in elkaar knutselen van kapstokken, voor financieel, 
tuinstoel- of willekeurig ander advies en voor prachtige wintersportvakanties. 
Ook mijn schoonbroers en zusje bedankt voor het geduld als er tijdens het eten 
wéér een medisch onderwerp werd aangehaald. Ik hoop op verbetering.
Lieve Lisa, liefste zusje. Jouw knuffels en bemoedigende, volgekladde, 
handgeschreven kaartjes zorgen altijd voor een instant lach. Ik ben trots op 
jou en je schrijftalent. Dank voor het feit dat je altijd voor me klaar staat en 
voor het keer op keer trotseren van je angst voor snelwandelende dokters en 
ziekenhuishectiek voor een gezamenlijk kopje koffie in de kantine. 
Lieve pap, bedankt voor je eeuwige vertrouwen in mijn kunnen, ook als ik zelf 
weer eens twijfel. Dank ook voor alle ont- (en in-)spannende wandel-, hardloop- 
en later wielrentochten. Vaak wist je beter dan ik dat ik daar echt aan toe was. 
Geef me nog een jaartje (oké, twee), dan fiets ik je er toch echt een keer uit!
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Lieve Job, waar te beginnen. Een hele pagina is het uiteindelijk niet geworden. 
Ik zou hem makkelijk vol krijgen overigens, maar soms schieten woorden tekort. 
Dank dat je er was al deze jaren, voor je vertrouwen en geduld. Voor je kritische 
kijk op de wereld, voor je relativeringsvermogen, alle flauwe pesterijen, je 
nooit eindigende redeneringen en voor het helpen bij het overkomen van 
mijn onzekerheden. Met jou is de wereld geen dag saai. Ik kijk er naar uit om 
in de toekomst nog vele obstakels (letterlijk en figuurlijk) met jou te mogen 
overwinnen. 
En tenslotte, lieve mama, de laatste woorden voor jou omdat ik anders wellicht 
een andere richting in was geslagen. Bedankt voor de onvoorwaardelijke steun 
de afgelopen jaren en in het bijzonder voor het me van jongs af aan laten zien 
wat er te bereiken en overwinnen is met écht doorzettingsvermogen.
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